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Angiogenesis
Angiogenesis, the formation of blood vessels from preexisting vessels, occurs
during embryonic as well as during some processes in adult life.1 This is different from
vasculogenesis, which is the development of blood vessels from in-situ differentiating
endothelial cells.  Increased scientific attention for angiogenesis over the past years
has yielded many promising new therapeutic approaches.2 Angiogenesis has been
shown to play a pivotal role in pathological conditions, such as primary and metastatic
tumor growth. Induction of angiogenesis precedes the formation of macroscopic
malignant tumors, and increased vessel density correlates with the invasive properties
of tumors. On the other hand, angiogenesis is likely to be essential for a variety of
physiological processes as well, including healing of anastomoses and wounds, liver
regeneration, and embryonic development. In this respect, cancer has frequently been
referred to as a never healing wound. 
Vascular structures undergo a so-called "angiogenic switch" when they change from
benign to malignant tumor vessels. This is characterized by upregulation of pro-angio-
genic regulators and/or downregulation of anti-angiogenic regulators. Hence, the
balance is tilted towards vessel proliferation, resulting in an angiogenic phenotype.  In
one of the current most sophisticated technical experiments, St Croix et al. compared
expression patterns of endothelial cells derived from blood vessels of normal and
malignant colorectal tissues. They showed that tumor endothelium is distinct from
physiological endothelium.3 As shown in figure 1, immunohistochemistry with a
monoclonal antibody against CD31 displays an example of differential expression of
vascular phenotypes. In the tumor vessels of a murine colorectal liver metastasis, as
well as in liver endothelium directly surrounding the tumor, CD31 is upregulated as
compared to the normal liver sinusoids. With another recently developed tool to study
tumor vessels, in vivo microscopy, Jain’s group found that tortuousness and increased
vascular permeability are characteristics of these new tumor vessels in vivo.4
Angiogenesis is a complicated multi-step process and depends on different tissue
components. Endothelial cell survival, migration, alignment, adhesion, proliferation,
and subsequent formation of new capillary-like sprouts are all required. In addition,
interaction of endothelial cells with basement membrane5, extracellular matrix (ECM)6,
matrix metalloproteases (MMP’s)7, tumor cells, inflammation, and growth factors play
an important role in angiogenesis. A pivotal growth factor is Vascular Endothelial
Growth Factor (VEGF) that induces angiogenesis and tumor growth.8 VEGF is upregu-
lated via Hypoxia Inducible Factor-1alpha (HIF-1α).9 HIF-1a is induced by hypoxia10 and
is involved in cancer progression in different organs11-15. 
MMP’s are enzymes that can degrade virtually any component of the ECM. They
are important for cell migration, invasion, proliferation, apoptosis and regulation of
remodeling of ECM, embryonic growth, wound healing as well as angiogenesis.7 In
addition, ECM degradation is a prerequisite for tumor growth and metastasis. During
tumor growth the regulation of MMP’s is disturbed, and most of the times the balance
between active MMP’s and their inhibitors is in favor of proteolysis. Over-expression
of MMP’s in tumors has often been associated with increased invasiveness and grade
of malignancy, corresponding with unfavorable prognosis.16;17
Anti-angiogenesis
Anti-angiogenic therapy is considered one of the most promising new develop-
ments in cancer treatment. By preventing tumor growth through inhibition of its
vascular supply, a state of tumor dormancy is induced.2 Small tumors and micro-
metastases (< 2 mm3) are diffusion limited for their metabolism. For growth beyond
this diffusion-limited volume, newly formed tumor vasculature is necessary. Tumor
formation involves cell proliferation, metastasis, adhesion, transendothelial migration,
and matrix degradation. All these mechanisms might be potential targets for anti-
tumor agents. For example, reducing tumor angiogenesis can lead to an inhibition of
hematogenous metastases. Promising results to inhibit tumor growth via anti-angio-
genic treatment have been achieved in animal models and many clinical trials have
been initiated since.18
The discovery of naturally occurring endogenous angiogenesis inhibitors was
based on the following observations. After the removal of a primary tumor its
metastases appeared to develop new vessels and displayed an increased growth rate.
Therefore, the primary tumor was suspected to inhibit its remote metastases. A circu-
lating angiogenesis inhibitor responsible for this control of distant tumor growth was
discovered in the presence of the primary tumor. In this way, angiostatin, a 38-kDa
internal proteolytically generated fragment of plasminogen was discovered in 1994 in
the serum and urine of tumor bearing mice.19;20 Indeed, serum and urine from tumor-
bearing mice, but not from controls, specifically inhibited endothelial cell proliferation.
Our group was able to generate this angiostatin from human plasma, and has demon-
Figure 1. Example of the “angiogenic switch”. (see color appendix)
Immunohistochemistry with a monoclonal antibody against CD31 displays a differential
expression of vascular phenotypes of normal and tumor vasculature. In the tumor vessels of a
murine colorectal liver metastasis, as well as in liver endothelium directly surrounding the
tumor, CD31 is upregulated as compared to the normal liver sinusoids.
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strated in mice that its anti-tumor effects may be maximized by using an osmotic
pump for continuous administration.21 An other naturally occurring angiogenesis
inhibitor, Endostatin, the 20kDa C-terminal fragment of collagen XVIII was originally
isolated from a hemangioendothelioma cell line by the group of Dr. Judah Folkman.22
Continuous administration of endostatin was also shown to be most effective in
mice.23 Since the discovery of angiostatin and endostatin, a multitude of anti-angio-
genic agents have been identified or developed. Antibodies against growth factors
(e.g. VEGF24) or their receptors, inhibitors of MMP’s, inhibitors of cell adhesion or
proliferation are now all promising drugs under investigation in pre-clinical studies
and clinical trials. 
Potential advantages of anti-angiogenic therapy include the fact that -in contrast
to conventional chemotherapy- development of resistance has as yet not been
observed25, indicating that long-term treatment with these drugs should be effective.
And, although the effects of anti-angiogenic therapy on physiological angiogenesis are
unknown, serious toxicity was generally assumed not to be anticipated, because of
the almost complete lack of angiogenesis in the healthy adult.20;22
Anti-angiogenesis and surgery
By blocking the formation of novel tumor-associated vessels, anti-angiogenic
therapy has been shown to be capable of inducing and maintaining a state of
dormancy. Therefore, the clinical application of such therapy will most likely involve
long-term and (neo) adjuvant treatment schedules to maintain tumor dormancy. This
implies that, in the clinical situation, patients will have to undergo treatment for
prolonged periods of time, preferably in the (neo) adjuvant setting when patients
have minimal residual tumor burden. Consequently, patients will be likely to undergo
extensive surgery for primary or metastatic disease during anti-angiogenic therapy.
Physiological processes such as wound healing, healing of intestinal anastomoses,
and liver regeneration might be angiogenesis-dependent as well. Therefore, one could
hypothesize that patients undergoing surgery and with subsequent wound healing
might encounter serious problems when treated with anti-angiogenic drugs. This
would increase the likelihood of serious complications during the peri-operative
course. Knowledge about the effects of anti-angiogenic therapy on physiological
angiogenesis is, therefore, essential.
In addition to wound healing, other interactions between surgery and anti-angio-
genic therapy can be of importance. Surgery causes mobilization of microscopic tumor
deposits, potentially leading to hematogenous metastases, circumstances during
which angiogenesis and anti-angiogenesis might play an important role. Even in no-
touch colorectal surgery with mesenteric vessel ligation, 12.5% of patients still have
tumor spill in the circulation26, which can eventually lead to tumor metastases.
Furthermore, surgery may cause selective tissue hypoxia, but it is not known whether
this hypoxia leads to subsequent tumor angiogenesis. No studies are currently
available that address these interactions between surgery and (anti-) angiogenesis.
Conventional phase I/II trials are unlikely to resolve these important issues, since
they are typically done in patients with advanced cancer stages who have bulky
disease and a limited life span. It is unlikely that such patients will be exposed to
any kind of (major) surgery while undergoing angiogenesis-inhibition. Some indica-
tions however, can be extrapolated from the early data now available from trials.
Phase II trials with endostatin were initiated in November 2001. In the clinical trials so
far, endostatin has shown no dose-limiting toxicity or significant side effects. Until
recently, clinical trials with broad-spectrum MMP inhibitors have yielded disappointing
results, and included the observation of considerable side effects on connective
tissue.27
Wound healing
Wound repair is a complex combination of events. Considering regular peri-
operative care and aseptic surgical conditions, the healing of patients’ wounds
depends mostly on the clinical condition of the individual patient and on his/her
inflammatory response. Irrespective of the wounded tissue type, the continuous
process from surgical injury to a healed wound can be divided into three phases:
inflammation, proliferation and maturation.28 Directly following wounding, the inflam-
mation phase starts. Intravascular platelet aggregation, formation of a fibrin clot,
growth factor release, in combination with increased vascular permeability cause
migration of attracted inflammatory cells. After the arrival of fibroblasts, the prolife-
ration phase starts. Endothelial cells are important in this phase, as they contribute to
angiogenesis. Secondary wound healing in unsutured wounds, as opposed to primary
wound healing in sutured wounds, involves the migration of cells towards the
opposite wound edges. The migration of cells, angiogenesis and formation of granu-
lation tissue are all dependent on the ECM remodeling during the maturation phase.
Plasmin and other components of the plasminogen activation system play an
important role in tissue repair by regulating ECM remodeling. Fibrin acts as a provi-
sional matrix for the formation of granulation tissue and re-epithelialization. Without a
correct balance between degradation and production of new ECM, impaired wound
healing is likely to occur. For example, ulcers result from excessive degradation and
hypertrophic scars from excessive formation of ECM. 
The parameters to differentiate between correct or impaired wound healing are
diverse. Healing is measured by mechanical, histological, and biochemical parameters,
the latter being mostly determination of hydroxyproline content in lysed tissue
samples. Furthermore, different experimental models of wound healing exist to
investigate differences between the aforementioned parameters. A form of wound
healing that can be life threatening if impaired, is the healing of colonic anastomoses,
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since anastomotic leakage in the week following surgery comprises a disastrous
event, leading to high morbidity and mortality29. In contrast to the healing of
cutaneous wounds, the healing of colonic anastomoses is considered more dependent
on angiogenesis, and less dependent on diffusion of oxygen through preexisting
vasculature30-32. Thus, we expected this model to be more sensitive to angiogenesis-
directed interventions. Hence, the healing of colonic anastomoses could serve as a
model for "physiologically critical" angiogenesis. Putative adverse effects of anti-
angiogenic agents might be more apparent in this model compared to cutaneous
wound healing. Parameters to determine the healing of colonic anastomoses are
mechanical (bursting strength, bursting pressure, or bursting wall tension), histological
examination and measuring of the hydroxyproline content. The hydroxyproline content
is an indirect reflection of ECM quality, since it only determines collagen quantity.
Besides, the strength and quality of the ECM is dependent on the balance between
MMP’s and their inhibitors (TIMP’s) instead of on collagen quantity only. Angiogenesis
in colonic tissue has been studied using microscopy32 or intravascular fluorescent,
radioactive or radiopaque labeled circulating substances. Dynamic flow studies have
been done with laser doppler velocity measurements. The use of in vivo microscopy
can be very useful in determining real-time intra-colonic blood flow and angiogenesis
and could replace most of the aforementioned experiments. However, its application
and feasibility are still limited, mostly due to technical restrictions. At this moment,
the determination of the mechanical bursting pressure is the most feasible and
reliable parameter.33 Genetically altered mice in whom specific components involved in
wound healing are absent i.e. knock-outs, or over-expressed, are being recently
developed to determine the exact contribution of that particular component after
wounding.
Anti-angiogenesis and wound healing
Cutaneous wound healing has been investigated in several knockout mice
deficient for components that regulate the formation and/or degradation of the ECM.
Wound healing in plasminogen knockout mice showed a decrease in migration of
keratinocytes to cover the wound, leading to a delay in re-epithelialization.34 When
these mice were additionally treated with a MMP-inhibitor, no wound healing was
observed at all, indicating an important role for MMP’s.35 Accordingly, MMP-3-deficient
mice lack wound contraction and consequently have delayed closure of the wound.36
In mice deficient for plasminogen activator inhibitor-1 (PAI-1), the rate of wound
closure was found to be accelerated.37 In mice lacking fibrinogen the re-epitheliali-
zation of keratinocytes was inappropriately organized, leading to wound healing
defects.38 Plasmin and other components of the plasminogen activation system play
an important role in tissue repair by regulating extracellular matrix remodeling,
including fibrin degradation. Consequently, other proteins that are important
regulators of the ECM might also be players in the wound healing process. TAFI is a
procarboxypeptidase that is synthesized in the liver and secreted into the circulation.
Increased levels of TAFI have been associated with an increased risk for venous
thrombosis. Activated TAFI can down regulate fibrinolysis and it has been hypothe-
sized that it forms a link between coagulation and fibrinolysis. However, no physiolo-
gical function of TAFI in vivo has been described so far. In addition to the contri-
bution of MMP’s and ECM proteins, VEGF is an important angiogenic growth factor in
skin wound healing, and defects in VEGF in mice might be associated with wound
healing disorders39.
Studies on the effects of anti-angiogenic interventions on wound healing are
scarce and incomprehensive and have provided contradictory results. Endostatin does
not appear to impair cutaneous wound healing40, but does affect the maturation of
the vessels in the granulation tissue41. Data concerning short-term administration of
two mildly angio-suppressive agents seem to suggest possible adverse effects during
the early phase of intestinal wound healing.42;43 No data exist on angiostatin in wound
healing assays.
Colorectal carcinoma and liver metastases
In the USA, the combined mortality rate for colon carcinoma for men and women
is 47.700 deaths annually (American Cancer Society, estimate for 2000), and hereby
represents the second most probable cause of cancer deaths for both sexes. The
prevalence of colorectal cancer is among the highest of malignancies in the Western
countries.44 In the Netherlands, annually, 4400 patients die of colon cancer, while
8600 new patients are registered (CBS).  In as many as 50-80% of these patients the
disease will metastasise to the liver45 which is the sole site of initial colorectal tumor
recurrence in approximately 30%46. Once colorectal liver metastases have developed,
the natural course of the disease is associated with poor survival.47 Surgical resection
of the liver metastases offers the only hope of cure for these patients48, but is, unfor-
tunately, restricted to few selected ones, many of whom will still relapse within the
liver or develop extrahepatic metastases after resection49. The majority of patients
with hepatic metastases are not eligible for surgical resection because of a tumor size
beyond resection limits, unfavorable location near intrahepatic blood vessels
precluding a margin-negative resection, presence of too many tumors, or inadequate
hepatic function prior or following resection. Radiofrequency ablation (RFA) is a
relatively new surgical technique that is used to locally destroy (secondary colorectal)
hepatic malignancies.50-55 It is restricted to those patients not eligible for standard
surgical resection, with metastases confined to the liver. However, these patients have
cancer in an advanced stage and are likely to have distant micrometastases.
Through the use of adjuvant chemotherapy survival rates of patients with
colorectal carcinoma have improved. As a consequence, adjuvant chemotherapy has
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become standard practice in high-risk patients following surgery. Studies of chemo-
therapy prior or post liver resection for secondary malignant disease, however, have
produced contradictory results.56;57 Nevertheless, responses in novel schemes including
oxaliplatin were recently shown to increase resectability rates of previously unresec-
table colorectal liver metastases.58 Clearly, these results indicate that there is room for
improvement, particularly regarding peri-operative systemic treatment. A search for
alternative treatment modalities for colorectal liver metastases is, therefore,
warranted.
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This thesis addresses three different aspects concerning the combination of
surgery and angiogenesis or anti-angiogenic therapy.
In the first part, the safety of the administration of anti-angiogenic therapy when
combined with surgery is investigated. The second part deals with the interaction
between surgery and angiogenesis. Studies on the optimal administration of anti-
angiogenic agents with respect to maximal anti-tumoral efficacy are described in the
last chapters. 
The following important topics are addressed: Is physiological angiogenesis
affected by anti-angiogenic therapy as well? Can we safely combine antiangiogenic
therapy with surgery? Is angiogenesis influenced by surgical procedures? Is optimal
anti-tumoral efficacy of anti-angiogenic agents to be improved, i.e. for example by
combining treatment strategies, or prophylaxis prior to surgery? What is the best
timing of administration?
Serious toxicity of anti-angiogenic agents is generally assumed not to be
problematic, because of the almost complete lack of angiogenesis in the adult.
However, the effects of anti-angiogenic therapy on physiological angiogenesis are
largely unknown, and the differences between physiological and pathological angioge-
nesis are unclear. Surgeons will encounter an increasing number of patients under-
going such therapy. Hence, knowledge about the effects of anti-angiogenic therapy on
physiological angiogenesis in wound healing is essential. Until now, studies on effects
of anti-angiogenic interventions on wound healing are scarce and incomprehensive
and have provided contradictory results. A form of wound healing that can be particu-
larly life threatening if impaired, is the healing of colonic anastomoses. Anastomotic
leakage in the week following surgery comprises a disastrous event, leading to high
morbidity and mortality. 
To test the hypothesis that anti-angiogenic therapy affects physiological angioge-
nesis, the effects of anti-angiogenic treatment with angiostatin on the healing of
colonic anastomoses is investigated in chapter 3. Here, direct measurements of end-
points of colonic healing are clinical appearance of the mice, and the mechanical
strength and histology of the resected colon. Consequently, in an attempt to elucidate
the underlying mechanisms of the observed effects of angiostatin treatment, the
anastomotic tissues were subjected to immunohistochemical staining with an
extensive panel of markers (chapter 4). Cutaneous wound healing was studied in
chapter 5. Cutaneous wound healing has been investigated in several knockout mice
deficient for components that regulate the formation and/or degradation of the ECM.
However, the physiological role in vivo of Thrombin-activatable fibrinolysis inhibitor
(TAFI), a protein that is able to attenuate plasmin-mediated fibrin degradation, is
currently unknown. In a knock-out mouse lacking TAFI tissue repair and regulation of
the ECM remodeling were studied.  
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Adverse ef fects of the antiangiogenic agent angiostatin
on the healing of experimental colonic anastomoses
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In the second part of this thesis, the interaction between surgery and angioge-
nesis is addressed. There is evidence that surgery causes selective tissue hypoxia, but
it is not known whether this hypoxia leads to subsequent tumor angiogenesis. No
studies are currently available that address this interaction between surgery and
(anti-)angiogenesis.
We hypothesized that clamping of the vascular inflow of the liver unfavorably
affects the prognosis of cancer patients, by inducing temporary hypoxia. This
hypothesis was tested in chapter 6, where levels of Hypoxia Inducible Factor-1alpha
(HIF1α), Vascular Endothelial Growth Factor (VEGF) were measured in livers of mice
and patients. In addition, tumor recurrence and survival was investigated in patients
after vascular clamping of the liver.
Surgical treatment is the only curative option for patients with colorectal liver
metastases. Studies on the treatment of patients pre- or post- liver resection for
secondary malignant disease with conventional chemotherapy, have produced contra-
dictory results. Occasionally, an increase in resectability rates of previously unresec-
table colorectal liver metastases was described. Nevertheless, a search for alternative
treatment modalities for colorectal liver metastases is warranted. This is investigated
in the latter part of this thesis.
Combining conventional chemotherapy with antiangiogenic compounds might lead
to improved anti tumor efficacy by targeting both tumor cell and endothelial cell
compartments. Strategies combining these two targets have not, however, been
investigated thoroughly in models of early widespread metastatic colorectal liver
disease. In chapter 7 the efficacy of combinations of conventional chemotherapy and
strong angiogenesis inhibitors was assessed in a murine model of early metastatic
colorectal cancer. The effects of the combination therapies were compared with those
of conventional and antiangiogenic agents alone.
Surgery causes mobilization of microscopic tumor deposits, potentially leading to
hematogenous metastases, circumstances during which angiogenesis and anti-angio-
genesis might play an important role. We hypothesized that a significant part of the
in vivo anti-tumor efficacy of endostatin could be achieved during that initial phase of
the metastasizing process of tumor cells. In chapter 8 we have investigated the
influence of endostatin on the early spatiotemporal fate of murine colon carcinoma
cells metastasizing to the liver.
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Abstract 
Background: Antiangiogenic cancer therapy is likely to be administered long term for
sustained suppression of tumor outgrowth. Surgeons will encounter more patients
undergoing such therapy. Therefore, it is essential to know the effects of anti-
angiogenic agents on physiological angiogenesis, as occurs during the healing of
colonic anastomoses.
Methods: Angiostatin was generated from human plasma and administered
continuously. In 38 mice, the right colon was anastomosed after transection: group 1
(n = 13), anastomotic healing under angiostatin treatment from surgery until death
(day 7); group 2 (n = 13), phosphate-buffered saline controls. For healing on dis-
continuation of treatment, group 3 (n = 6) received angiostatin treatment preceding
surgery during 4 days; group 4 (n = 6) included controls. On day 7, all mice were
inspected for signs of anastomotic leakage. Bursting pressure measurements were
performed to test anastomotic strength. Neovascularization was assessed semi-
quantitatively by immunohistochemistry.
Results: Mice treated with angiostatin postoperatively showed significantly more signs
of leakage, more adhesions, and peritonitis. One mouse died on day 5. Five mice had
paralytical ileus. The bursting pressure in group 1 was 135+/-20 mm Hg, versus 175 ±
12 mm Hg in group 2 (mean ± SEM). Significantly fewer new vessels were found
surrounding the anastomosis in the treated group (6.6 ± .9) versus controls (16 ± 1.6).
All controls, as well as those animals treated with angiostatin only until surgery
(group 3), displayed normal healing and showed no signs of peritonitis or ileus.
Conclusions: Angiostatin impairs anastomotic healing in mice. However, on dis-
continuation of antiangiogenic therapy, normal anastomotic healing is promptly
restored.
Introduction
Antiangiogenic therapy is a highly promising new strategy in the treatment of
cancer. Because the growth and metastasizing capacity of a tumor depend on the
formation of new blood vessels, many antiangiogenic agents have been developed that
are directed against the endothelial cells of the tumor vasculature.1 Potential advan-
tages of antiangiogenic therapy include that the development of drug resistance seems
unlikely2 and that serious toxicity is not anticipated3,4. 
Angiostatin, a fragment of plasminogen, is considered to be one of the most potent
inhibitors of angiogenesis.5 Experimental models have shown that, during long-term
antiangiogenic therapy with angiostatin, tumors remain in a state of dormancy.3
However, when antiangiogenic therapy is discontinued, the tumor or its metastases
resume their outgrowth.2 Accordingly, angiostatin recently proved to be more potent
when administered continuously, instead of twice daily.6 From a clinical point of view,
antiangiogenic therapy should preferably be administered during a prolonged period of
time, e.g., in an adjuvant or neoadjuvant setting, to maintain remission after surgery.
As a consequence, surgeons may increasingly be confronted with patients undergoing
antiangiogenic therapy. It is, therefore, of great importance to investigate any adverse
effects that antiangiogenic therapy might have on physiological angiogenesis, as occurs
during wound healing. 
A form of wound healing that can be lifethreatening if impaired is the healing of
intestinal anastomoses, because anastomotic leakage in the week after surgery is a
disastrous event that leads to high morbidity and mortality.7 Until now, the scarce
studies regarding the effects of antiangiogenic strategies on intestinal anastomotic
healing have not been comprehensive and have provided contradictory results. Recent
data concerning short-term administration of two mildly angiosuppressive agents
suggest possible adverse effects during the early phase of wound healing.8,9 In contrast,
endostatin does not seem to impair cutaneous wound healing.10 The influence of strong
and continuous inhibition of angiogenesis—as would be needed for sustained tumor
suppression—on intestinal healing has never been studied. Moreover, data on the
temporal aspects of the relationship between angiosuppressive treatment and its
discontinuation are currently lacking. Besides, the effects of angiostatin on physiolo-
gical angiogenesis are unknown. Such knowledge is of the utmost importance for the
design of clinical studies and administration schedules with antiangiogenic agents. 
This study was undertaken to evaluate the effects of strong antiangiogenic
treatment with angiostatin, with maximally suppressive conditions, on the healing of
colonic anastomoses. First, we evaluated anastomotic healing under angiostatin
treatment by treatment from day 0 to day 7 after surgery. In a second set of experi-
ments, we investigated the effects of discontinuation of angiostatin therapy directly
preceding colonic surgery. 
Our data provide strong evidence that angiostatin impairs anastomotic healing in
mice. However, on discontinuation of antiangiogenic therapy, normal anastomotic
healing is promptly restored.
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Materials and methods
Generation and Purification of Angiostatin
Human angiostatin was generated as described by O’Reilly et al,5 with minor
modifications.6 Outdated human plasma, heated (37°C) and filtered, was diluted 1/2
with distilled water, supplemented by 3 mM of EDTA, and applied to a lysine-
Sepharose™ column (Pharmacia, Uppsala, Sweden). All column purifications were
performed at room temperature. After washing the column with .5 M of phosphate
buffer, plasminogen was eluted with .2 M of ε-aminocaproic acid, pH 7.4. Sodium
dodecyl sulfate-polyacrylamide gel electrophoresis revealed one band of apparent
molecular weight (Mr ) 92.000, corresponding to plasminogen. The eluant was
dialyzed against distilled water (MWCO, 6– 8000 Spectra/Por; Spectrum Laboratories,
Inc., Rancho Dominguez, CA; 4 > 107 dilution; 4°C), buffered with 20 mM of Tris 7.6,
and followed by proteolytic digestion with .8 U/mg plasminogen porcine pancreatic
elastase (Calbiochem, San Diego, CA) (shaker overnight at 37°C; 120 rpm). The
solution was applied to the same column, which had been equilibrated with a salt
solution. After the column was washed, angiostatin was eluted with .2 M of ε-amino-
caproic acid while the flow-through was collected and treated as recently cleaved
plasminogen, to collect angiostatin fragments with low lysine affinity. The angiostatin
was dialyzed against distilled water (MWCO, 6– 8000 Spectra/Por; 4 > 107 dilution;
4°C) and freeze dried. After the angiostatin and its flow-through were combined,
sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed three distinct
bands of approximately Mr 40.000, Mr 42.000, and Mr 45.000, according to the triplet
described by O’Reilly et al.5 In all experiments (unless stated otherwise), the
administration of angiostatin was as follows. The mice received a dorsal osmotic
pump (Alzet™ pump, type 2001; Alza, Palo Alto, CA) subcutaneously (SC) for conti-
nuous administration of angiostatin in a dose of 100 mg/kg/day plus a single bolus
loading dose of 2.5 mg/ 200 mL SC. This dose of angiostatin proved to be the
optimal dose to elicit a maximal antitumor effect in the murine SC and liver
metastasis models.6 All controls received an identical pump filled with phosphate-
buffered saline (PBS). The bioactivity of the angiostatin was confirmed by the mouse
cornea neovascularization assay, as described elsewhere (data not shown).6 Briefly, a
corneal micro-pocket was created by a keratotomy. A micropellet (.4 x .4 x .2 mm)
containing approximately 100 ng of basic fibroblast growth factor (Life Technologies,
Inc., Rock-ville, MD) was inserted. The mice were divided into a treated group (which
received angiostatin) and a control group (which received PBS). The corneas were
examined daily by use of a microscope to determine the outgrowth of newly formed
vessels from the limbus toward the pellet. When the vessels in the eyes of the
controls had reached the pellet, the experiment was terminated. According to the
formula .2 x π x maximal vessel length x clock hours, the surface area of neo-
vascularization of both groups was determined and compared.11 At a dose of 100
mg/kg/day, continuous administration of human angiostatin consistently caused
virtually complete (~93%) inhibition of angiogenesis.
Animals
The animals studied were BALB/c male mice, aged 12 weeks and weighing 25 to
30 g, purchased from the General Animal Laboratory of the University Medical Center
Utrecht. They were allowed food and water ad libitum. All experiments were executed
according to the guidelines of the Animal Welfare Committee of the University Medical
Center Utrecht. 
Surgical Procedures
In all mice, the right colon was anastomosed after transection. The mice were
anesthetized intraperitoneally with fentanyl citrate/fluanisone (.3 mg per mouse; Jans-
sen- Cilag, Brussels, Belgium) and midazolam chloride (12.5 mg per mouse; Roche,
Brussels, Belgium). The mice were shaved and placed on a heated surgical mi-
croscopy table. A midline laparotomy was performed under aseptic conditions. The
cecum was identified and lifted from the abdominal area. The right colon was trans-
ected 1 cm distal to the cecum with microscopic scissors, taking care not to damage
the mesenteric vessels. The colon was anastomosed by single-layer 8-O nonabsor-
bable (Prolene™; Ethicon, Brussels, Belgium) inverted running sutures. The abdominal
wall was closed by two-layer 5-O absorbable (Vicryl™, Ethicon) running sutures. Next,
the osmotic pump for administration of angiostatin or its solvent was implanted SC
through a 1-cm dorsolateral incision.
Study Design
For each individual experiment, groups of three or four mice underwent trans-
ection of the right colon with anastomosis. They were randomly assigned to the
angiostatin- treated group or the control group.
A. In 38 Balb/C mice the
right colon was lifted from
the abdomen, transected and
microscopically anastomosed.
B . During the same
procedure an osmotic pump
was implanted for continuous
administration of angiostatin
or PBS.
C. After sacrifice, the ana-
stomosis was resected and
ligated on both sides. PBS
was volumetrically infused at
60 ml/hr, until rupture of the
intestinal segment.
Figure 1
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Anastomotic Healing Under Angiostatin Treatment The following groups were
identified: group 1 (n = 13), continuous angiostatin treatment from surgery until death
(day 7); and group 2 (n = 13), PBS controls. These two groups received the osmotic
pump during the surgical procedure of colonic anastomosis.
Anastomotic Healing After Discontinuation of Angiostatin Treatment In group 3 (n = 6),
angiostatin was administered for 4 days before surgery. Group 4 (n = 6) included PBS
controls. In the last two groups, pumps were implanted 4 days before surgery and
were removed during the surgical procedure of colonic anastomosis, to determine
whether any adverse effect on the healing of those anastomoses would persist on
discontinuation of the angiostatin therapy. 
Outcome Measures 
The observers were blinded to the treatment in all outcome measures.
Clinical Performance Two independent observers recorded the postoperative clinical
condition of the mice daily, according to a pre-determined clinical assessment score,
as listed in Table 1. For calculation of the percentage of postoperative weight loss,
body weights on day 7 after surgery were compared with those on day 0, i.e., before
surgery. 
Macroscopic Intra-Abdominal Analysis  On day 7, the abdomen was reopened and
inspected for anastomotic dehiscence, local peritonitis, ileus, and the formation of
adhesions. Peritonitis was defined as macroscopic signs of inflammation, fibrin
deposition, and hypervascularity. Mechanical ileus was defined as obstruction of the
intestine caused by the suture, with distention proximal to the anastomosis but not
distal to the anastomosis, and was considered a failure of the surgical procedure.
Paralytical ileus was defined as distention of atone intestine and colon, with paling
and swelling of the colonic wall, in conjunction with the absence of mechanical ileus.
In addition, intestinal diameters 2 cm distal and proximal from the anastomotic line
were measured with calipers to quantitatively confirm these macroscopic findings.
Adhesions involving the suture line were counted, because the presence of adhesions
surrounding the suture line is indicative of an inflammatory healing process, e.g., as
caused by intestinal spill. All surrounding structures adhesive to the anastomosis
(colon, intestine, omentum, and pelvic fatty tissue) were considered separate
adhesions and were counted as such. Bacterial growth of the abdominal cavity was
determined by cotton swab, seeded on agar and Schaedler plates, and incubated.
Mechanical Analysis To test the anastomotic strength, 3 cm of colon, including the
anastomotic line, was resected, while care was taken not do disturb the anastomosis
and adhesions. The resected segment was ligated on both sides and, ex vivo, was
connected via a cannula to a volume-directed infusion pump filled with PBS. A side
arm of the cannula was connected to a pressure transducer, which in turn was
connected to a recorder. The intestinal segment was gradually filled with PBS at a
constant rate of 60 ml/hour while the intraluminal pressure was monitored until burst
occurred, as indicated as an abrupt loss of pressure. The bursting pressure was
documented, and the site of bursting was noted as being either at the anastomotic
line or outside the anastomotic line.12
Score Category Description
0 Dead
1 Sick Lies in corner, curled up, fur raised and grayish, high 
respiratory frequency, eyes shut all the time, sticky feces
(does not wash itself )
2 Reasonable Low reactivity, eyes opened but not clear, color of fur 
not homogenously white
3 Fair Stands up straight, clear opened eyes, eats if disturbed 
in sleep, clear white fur
4 As before surgery
Immunohistochemistry Anastomotic lines were fixed in 4% formaldehyde and
embedded in paraffin. Serial sections of 4-µm thickness from each block were
mounted on poly-L lysine–coated slides, and hematoxylin and eosin–stained sections
were made of every 10th section to identify the newly formed granulation tissue
surrounding the suture and adjacent to the normal colon tissue (as judged by two
independent observers). Generally, this granulation tissue was easily discernible from
the surrounding tissue. The selected adjacent unstained slides containing granulation
tissue were deparaffinized, rehydrated, and incubated with hydrogen peroxide for 10
minutes. The slides were pre-treated with pepsin and preincubated with normal goat
serum for 15 minutes. The tissue was incubated with a polyclonal primary antibody
against factor VIII/von Willebrand factor (DAKO, Carpinteris, CA) (1:500 in PBS/ bovine
serum albumin) for 1 hour. Incubation with a biotinylated goat anti-polyvalent
secondary antibody and large-volume streptavidin peroxidase (Lab Vision, Fremont,
CA) was followed by 3,3'-diaminobenzide tetra-hydrochloride, as chromogen. Sections
were counter-stained with hematoxylin and dehydrated. Negative controls were
prepared by substituting the primary anti-body for PBS and were negative in all
cases.
Table 1. Postoperative clinical scores
Results
Anastomotic Healing Under Angiostatin Treatment
The clinical scores showed that the postoperative recovery of the mice treated
with angiostatin was worse than that of control mice (P = .001). As shown in Figure 2,
the control mice had almost completely recovered from surgery by day 7. In Table 2
the data on the clinical analysis and the intra-abdominal macroscopy are summarized.
One angiostatin-treated mouse died on day 5. The clinical scores of this particular
animal were 1 to 2 on days 1 to 4, indicating a particularly poor postoperative
recovery. In accordance with these findings, the angiostatin-treated group on day 7
had lost more weight than the controls: 8.3 ± 2% as compared with 3.6 ± 1%. No
mechanical ileus was observed, indicating anastomotic patency. Five mice that had
been treated with angiostatin developed paralytical ileus. The intestinal diameter 2 cm
distal to the anastomosis was significantly wider in the angiostatin-treated group,
whereas the proximal diameter did not differ between groups. Six angiostatin-treated
mice had clear macroscopic signs of local peritonitis, versus none in the control group 
(P = .02). In three cases, this was confirmed microbiologically with objective bacterial
growth. In the controls, neither peritonitis nor ileus was found. The number of
adhesions was significantly higher in the angiostatin-treated group. In all mice, all the
other organs had normal macroscopic appearance. In 7 of 12 angiostatin-treated mice
and in 1 of 13 controls, the rupture of the intestinal segment during measurement of
the bursting pressure occurred on the anastomotic line instead of in adjacent colon
tissue. As a consequence, the anastomosis was judged to be weaker than the
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Morphometric analysis was performed with a LEICA-Q- Prodit (Leica Microsystems BV,
Rijswijk, The Netherlands). The number of factor VIII–positive newly formed vessels
was counted in granulation tissue surrounding the anastomotic line. The morpho-
metric area of the granulation tissue and the relative area of the newly formed
vessels were determined in all slides (according to the following formula: area
vessels/area granulation tissue).
Statistical Analysis
Independent t tests (equal variances not assumed) were performed to determine
statistical differences between the treated and nontreated groups, and Fisher’s exact
test was performed for the presence of peritonitis. For the difference in clinical scores
over time, repeated-measurements analysis of variance was performed. Results are
presented as mean ± SEM. Data were considered significant when P < .05.
Figure 2.
Clinical appearance after colonic anastomosis on day 0. (   ) Scores of mice treated continu-
ously with angiostatin; (  ) control group (phosphate-buffered saline).
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surrounding tissue in these animals. In the controls, all but one mouse had an
anastomotic line that had become at least as strong as the surrounding tissue 1 week
after surgery, with bursting occurring in the normal intestinal tissue. The bursting
pressure in the angiostatin-treated group was 135 ± 20 mm Hg, versus 175 ± 12 mm
Hg in the controls. On immunohistochemical analysis, 16 ± 2 newly formed vessels
were counted in the granulation tissue adjacent to the suture in the controls. In
contrast, the granulation tissue of the mice that were treated with angiostatin
contained significantly fewer new vessels (6.6 ± 1; P = .001). In addition, the area of
granulation tissue occupied by new vessels was significantly decreased in the mice
that were treated with angiostatin (.5 ± .1% vs. 2.2 ± .7%; P = .005) (Figure 3). The
administration of angiostatin itself, in animals without an intestinal anastomosis, did
not affect mouse body weight (as shown in our previous experiments with
angiostatin6), intestinal diameter, or histology (data not shown). 
revealed that all mice in groups 3 and 4 had bursting pressures above 130 mm Hg
(control animals, 164.5 ± 7 mm Hg versus angiostatin-treated animals, 151.6  ± 6 mm
Hg; not significant). Also, the anastomotic lines of these mice had become at least as
strong as the adjacent intestinal tissue.
Table 2. Anastomotic healing under angiostatin treatment
Table 3. Anastomotic healing directly after discontinuation of angiostatin administration
Variable Angiostatin PBS P value
N 13 13
Mortality 1 0 NS
Weight loss % (mean ± SEM) 8.3 ± 2 3.6 ± 1 NS
Parallytical ileus 5 0 NS
Diameter 2 cm distal (cm) 4.7 ± .3 3.1 ± .1 <.001
Local peritonitis 6 0 .02
Bacterial growth 3 0
Adhesions 3.25 ± .3 1.08 ± .14 <.001
PBS, phosphate-buffered saline; NS, not significant. Data were pooled from seven independent
experiments with identical design; angiostatin was administered from the time of operation until
the day of termination of the experiment (day 7 after surgery).
Anastomotic Healing on Discontinuation of Angiostatin Treatment
The clinical scores of the angiostatin-treated mice (group 3) were comparable to
those of the controls (group 4) during postoperative recovery (P = .93). None of the
mice died. Weight loss in the angiostatin-treated group was 2.5 ± .3% vs. 3.0 ± .4% 
(P = .4) (Table 3). None of the mice showed signs of peritonitis, ileus, or intestinal
distention. The number of adhesions did not differ between the two groups (P = .08).
The intestinal diameter 2 cm distal to the anastomosis was 3.1 ± .06 cm in the angio-
statin-treated group, compared with 3.1 ± .05 in the control group (P = .8). Again, no
macroscopic abnormalities were found in the other organs. Mechanical analysis
Figure 3. (see color appendix)
Anastomotic healing on day 7 after surgery. (A) Group 1; (B) group 2. A decreased number of
newly formed vessels alongside the anastomosis in the granulation tissue were found in the
angiostatin-treated mice (6.6 ± 1 vs. 16 ± 2). Also, the relative area of the newly formed vessels
in the granulation tissue was less in those mice (.5 ± .1% vs. 2.2 ± .7%). Factor VIII immuno-
histochemistry visualized the vessels (brown staining; some representative examples indicated
by arrows). S, suture; Gr, granulation tissue (delineated by arrowheads); N, normal adjacent
intestinal tissue.
Variable Angiostatin before PBS P value
N 6 6
Mortality 0 0 NS
Weight loss % (mean  SEM) 2.5 ± .3 3.0 ± .4 .4
Parallytical ileus 0 0 NS
Diameter 2 cm distal (cm) 3.1 ± .06  3.1 ± .05 .8
Local peritonitis 0 0 NS
Adhesions 1.5 ± .2 1.0 ± 0 .08
Data was pooled from four independent experiments with identical design; angiostatin was
administered from four days before surgery until the day of the surgical procedure. PBS,
phosphate-buffered saline; NS, not significant.
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Discussion
Our data provide strong evidence that angiostatin impaired anastomotic healing in
mice when administered continuously during the phase of postoperative repair. Until
now, it has been generally assumed that antiangiogenic agents specifically affect
activated, proliferating, and migrating endothelial cells and thus would lack any major
side effects during treatment.3,4 In concordance with this assumption, endostatin,
another strong inhibitor of angiogenesis, was recently reported to have no adverse
effects on physiological angiogenesis in cutaneous wound healing,10 whereas no data
exist on angiostatin in wound healing assays. But, in contrast to the healing of
cutaneous wounds, the healing of colonic anastomoses is considered more dependent
on angiogenesis and less dependent on diffusion of oxygen through pre-existing
vasculature.13,14 Thus, our model might be more sensitive to angiogenesis-directed
interventions. This healing of colonic anastomoses could therefore serve as a model
for physiologically critical angiogenesis. Putative adverse effects of antiangiogenic
agents might be more apparent in this model compared with cutaneous wound
healing. Indeed, in two recent studies, the short-term administration of two mildly
angiosuppressive agents seemed to have adverse effects during the early phase of
intestinal healing.8,9 However, the adverse effects of suramin on rats’ anastomotic
healing did not include any clinical signs of dehiscence of the anastomotic sites, such
as abscess formation, and were not exclusively restricted to the intestine. Even at low
doses, suramin was toxic to other organs in all animals and caused intra-abdominal
bleeding and splenomegaly.9 In contrast, in this study, angiostatin did not impose
toxicity on any organ besides the anastomosis (data not shown). 
Furthermore, the other two studies mentioned do not provide temporal data. We
have examined the kinetics of the adverse effects of angiostatin on the healing of co-
lonic anastomoses. This was undertaken by administering the agent before surgery
and discontinuing the treatment on the same day as the surgical procedure.
Administration of angiostatin immediately before surgery had no negative effect on
the healing of the anastomoses. These results in mice suggest that surgical patients
who are treated with angiostatin can safely be operated on as soon as the treatment
is discontinued. 
Recently, angiostatin was shown by our group to be effective against experimental
colorectal liver metastases.6 Assuming that antiangiogenic treatment is used periopera-
tively in patients undergoing colonic resection, it should preferentially be discontinued
as briefly as possible, in an attempt to keep any metastatic tumor cell deposits in a
state of dormancy. This is based on the findings of recent studies that showed that,
after resection of the primary tumor, the levels of circulating endogenous antiangio-
genic agents produced by the primary tumor diminish, leading to accelerated
metastatic outgrowth.6,15 Considering the short half-life of angiostatin (4 to 6 hours),
one might speculate that brief discontinuation of angiostatin treatment and resuming
its administration shortly after anastomotic healing could circumvent the risk of
anastomotic leakage while still effectively suppressing metastatic outgrowth.
Although the exact working mechanism of angiostatin has not been elucidated, it
was recently shown to have a direct effect on endothelial cells.16 Our immunohistoche-
mical evaluation showed a reduction in the number of newly formed vessels in the
granulation tissue surrounding the anastomotic line. On the basis of these data, we
speculate that the formation of new vessels at the site of the anastomosis is impaired
by angiostatin. This in turn may lead to a decrease in delivery of oxygen and
nutrients to the healing colon. The adverse effects of angiostatin on physiological
angiogenesis suggest mutual underlying mechanisms for tumor-induced and physiolo-
gical angiogenesis. This assumption is supported by the knowledge that many other
factors involved in angiogenesis, such as vascular endothelial growth factor, do
indeed affect both physiological and pathologic angiogenesis.17 It could well be that
the antitumor effect and the effects on physiological angiogenesis of angiostatin are
both mediated through a direct effect on endothelial cells.
We conclude from these results in mice that the healing of experimental colonic
anastomoses is impaired by angiostatin when it is administered during the post-
operative repair. However, on discontinuation of angiostatin therapy, normal anasto-
motic healing is promptly restored.
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Introduction
Antiangiogenic therapy is a highly promising new strategy in the treatment of
cancer. Since the growth and metastasizing capacity of a tumor depend on the
formation of new blood vessels, many antiangiogenic agents have been developed
that are directed against the endothelial cells of the tumor vasculature. One of the
first angiogenesis inhibitors described was angiostatin, a 38-kDa internal proteolyti-
cally generated fragment of plasminogen. It was discovered in the serum and urine
of tumor bearing mice.1 Gelatinase A (matrix metalloproteinase-2, MMP-2), produced
directly by those tumor cells, was found to be responsible for the production of the
angiostatin.2 Other MMP’s (matrilysin (MMP-7) and gelatinase B/type IV collagenase
(MMP-9)) were also shown to produce angiostatin.3 Its anti-tumor activity has been
proven in many experimental models as a single agent4,5 as well as in combination
with conventional therapies6.
Still many questions concerning the working mechanism of angiostatin in anti-
tumor efficacy remain to be elucidated.7 Thus far, those studies have resulted in the
identification of angiostatin-specific receptors, its role in cell migration through the
extracellular matrix and its effects on endothelial cell death or apoptosis. The earliest
studies showed that the antiangiogenic properties of angiostatin are caused by
blocking endothelial cell migration and proliferation.8-9 One of the identified receptors
through which angiostatin was shown to act was ATP-synthase. Angiostatin was
demonstrated to suppresses endothelial-surface ATP metabolism.10,11 Another predom-
inant receptor for angiostatin was found to be αvβ3.12 In addition, a third receptor
was identified in a yeast two-hybrid screen using a placenta cDNA library investi-
gating the angiostatin-binding peptides, resulting in the identification of angiomotin.13
Angiostatin inhibited cell motility and migration by interfering with angiomotin
activity in endothelial cells. It is localized to the lamellipodia at the leading edge of
migrating endothelial cells. In vivo, angiomotin is expressed in the endothelial cells
of capillaries as well as larger vessels of the human placenta.  All the aforemen-
tioned receptors could act independently or in combination with each other. 
Neutrophils were shown to express both mRNAs for the angiostatin receptors ATP
synthase and angiomotin. As shown by Benelli et al. angiostatin directly inhibited
neutrophil migration and neutrophil-mediated angiogenesis, suggesting that angio-
statin might inhibit inflammation as well as angiogenesis.14
In addition to inhibition of tumor angiogenesis, we showed in a previous study
that angiostatin also influenced physiological angiogenesis in vivo. We evaluated the
effects of angiostatin treatment during anastomotic healing.15 Even though serious
toxicity was not anticipated5,16 we found that angiostatin impaired healing when
administered during tissue repair, as reflected by a decrease in mechanical strength.
On histology, we observed a decrease in factor VIII stained vessel amount and -
volume in angiostatin treated colonic anastomosis.15 Since no other reports on angio-
statin and physiological angiogenesis have been published so far, the working
Abstract 
Antiangiogenic therapy is a highly promising new strategy in the treatment of
cancer. One of the first angiogenesis inhibitors described was angiostatin, a 38-kDa
internal proteolytically generated fragment of plasminogen. In a previous study we
found that angiostatin affected physiological angiogenesis as well as tumor angioge-
nesis. It impaired healing when administered during repair of experimental colonic
anastomoses, as reflected by a decrease in mechanical strength. On histology, we
observed a decrease in factor VIII stained vessel amount and -volume in angiostatin
treated colonic anastomoses. The exact working mechanism of angiostatin has not
been elucidated. Based on the available studies on proposed working mechanisms of
angiostatin, we have attempted to address histological differences in physiological
angiogenesis between the tissues of colonic anastomoses of mice with impaired
healing and control mice. After angiostatin treatment there was more inflammatory
tissue as a result of impaired healing. Furthermore, we found fewer vessels in the
granulation tissue after angiostatin treatment. However, especially with respect to
ECM, endothelial cell apoptosis, proliferation, or neutrophil influx, no gross differences
were discerned one week following surgery, using histology and immunohistoche-
mistry techniques.
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mechanism of angiostatin under those circumstances are not known.  
The purpose of the present study was to attempt to further investigate colonic
anastomoses for effects of angiostatin treatment in physiological angiogenesis by use
of histology. Specimens of the two groups of mice (angiostatin treated vs. controls)
were compared for additional immunohistochemical and histological markers. The
selection of the markers was based on the presumed working mechanisms of angio-
statin in tumor angiogenesis, as suggested by literature. 
Materials and methods
The mouse tissue under investigation was derived from a previous study.15 In
short, groups of 3-4 Balb-c male mice underwent transection of the right colon with
anastomosis. Human angiostatin was generated as described8 using minor modifica-
tions.4,15 The mice had been randomly assigned to angiostatin treatment (n=13), or the
PBS-control group (n=13). Angiostatin-treatment consisted of continuous
administration from surgery until sacrifice (7 days). Based on macroscopic, mechanical
as well as histological parameters, the anastomosis had been judged to be weaker in
animals receiving angiostatin. In the controls, all but one mouse had an anastomotic
line that had become at least as strong as the surrounding tissue one week after
surgery. 
The resected anastomotic lines were divided in two. One half was fixed in 4%
formaldehyde and imbedded in paraffin, whereas the other half was snap-frozen in
liquid nitrogen. Pending on antigen retrieval capacity of the epitopes frozen or
formalin fixed material was used. Serial sections of 4-µm thickness from each block
were mounted on poly-l-lysine-coated slides, and hematoxylin & eosin-stained
sections were made of every tenth section in order to identify the newly formed
granulation tissue surrounding the suture and adjacent to the normal colon tissue.
Generally, this granulation tissue was easily discernable from the surrounding tissue.
Differences in inflammation were assessed with H&E staining, anti-NIMP-R14, and
FA11. NIMP-R14 is a 25–30 kDa epitope mainly present on neutrophils. Rat
monoclonal antibody FA/11 (rat anti-mouse FA-11) identifies macrosialin, a heavily
glycosylated transmembrane sialoglycoprotein of 87-115 kDa, highly and specifically
expressed by mouse tissue macrophages. The ECM was investigated using polyclonal
anti-Laminin antibody (Dako, Glostrup, Denmark), serving as matrix for endothelial
migration. Conventional matrix staining for reticulin-elements (Laguesse) and Azan for
complete collagenous matrix staining were used in order to determine differences in
matrix components reflecting a mechanical tissue instability. Anti-murine CD31 (MEC
13.3; Pharmingen) and anti-murine CD34 (Hycult Biotechnology, Uden, The
Netherlands) identified the endothelial cells. In addition we stained MMP2 by rabbit
anti-MMP-2  (pAB809; Chemicon, California), and Vascular Endothelial growth factor
receptor flk-1 by rabbit anti-flk-1 (Santa Cruz Biotechnology, Santa Cruz, California). An
antibody against NG2-chondroitin-sulfateproteoglycan (pAB5320; Chemicon, California)
was used to study pericytes in pathological microvasculature and NG2-positive cells
that may bind, internalize, and co-immunoprecipitate with angiostatin. In addition,
proliferation of endothelial cells was assessed using double-staining of Ki67 by rabbit
anti-mouse Ki-67 (Dianova, Hamburg, Germany) and anti-CD31. Endothelial cell
apoptosis was investigated using rabbit anti-activated-caspase-3 (Pharmingen). For
architectural analysis of the specimen, 4 µm sections of formalin fixed and paraffin
embedded material were stained. Depending on the antibody, either frozen of paraffin
embedded material was used for staining. Frozen 4 µm sections were fixed in acetone
for 10 min, dried and incubated with primary Ab overnight at 4 °C temperature in
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phosphate-buffered saline containing 1% bovine serum albumin (PBS/BSA). After
washing with PBS, bound Abs were detected with a peroxidase-conjugated secondary
Ab (Vector, Burlingame, California) using the Vectastain elite ABC kit (Vector,
Burlingame, California). Sections were counterstained with hematoxylin.
Immunohistochemistry for formalin fixed and paraffin embedded material was carried
out using a similar protocol preceded by an antigen retrieval using microwave or
proteinase-K digestion after deparaffination. 
Results and discussion
The colonic anastomoses healed worse when treatment with angiostatin was
administered, and apart from more inflammatory tissue, a lower number of vessels in
the granulation tissue were discerned at histology (figure 1, CD31), in concordance
with factor VIII stainings in our previous work15. Angiostatin affects tumor angioge-
nesis, by causing a decreased number of tumor vessels o.a.4,5 Therefore, the demon-
strated difference in number of vessels is comparable between tumor- and physiolo-
gical angiogenesis. 
Figure 1 Comparison of granulation tissue in colonic wound healing in control mice and 
angiostatin treated mice. (see color appendix)
Azan staining shows comparable collagen deposition (blue matrix components) in both groups,
ruling out a lack of collagen deposition in angiostatin treated mice as reason for mechanical
instability of the wound tissue. CD31 staining highlights the vessels, There is an overall lower
vessel density in angiostatin treated mice, but no difference in vascular phenotype: capillaries
stain positive for VEGFR-2, characteristic for angiogenic blood vessels. Pericytes are positive for
NG2 in both groups, neither arguing for a functional angiostatin depletion, nor showing a lack
in normal microcapillary maturation. FA11 staining demonstrates the abundance of macrophages
(besides granulocytes, not shown) in the granulation tissue, more prominent in the angiostatin
treated group.
PBS Control Angiostatin
Azan
CD31
FA11
VEGFR-2
NG2
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This reduction of vessels in the granulation tissue of angiostatin-treated mice
could be a result of less endothelial cell production, or conversely, result from an
increase in endothelial cell destruction. Therefore, we investigated endothelial cell
proliferation (ki67) and endothelial cell apoptosis (caspase-3). Both ki67 and caspase-
3 stainings were similar in the tissues of mice that were treated with angiostatin (and
suffering from impaired healing), and the controls. Therefore, the observed differences
in angiogenesis could not be explained by immunohistochemical decrease in
endothelial cell proliferation or increase in endothelial cell apoptosis. This was,
however, only investigated on day seven following colonic anastomosis. We could
speculate angiostatin to affect either apoptosis or proliferation in the week following
the surgical procedure, resulting in fewer vessels later, at sacrifice. Indeed, in both
groups the vasculature in the granulation tissue expressed VEGFR-2 (figure 1), thus
representing an angiogenic phenotype17. In concordance, it has been speculated that
the in vivo target of angiostatin is not the mature endothelial cell, but the circulating
endothelial progenitor cells (EPCs) that contribute to the neovascularization.18 In that
study, EPCs were isolated from human subjects and was demonstrated that, in
contrast to that of mature endothelial cells, the growth of EPCs is exquisitely sensitive
to angiostatin. These results suggest that angiostatin works through inhibition of the
contribution of EPCs to angiogenesis in an early phase, and not by altering the
growth of mature endothelial cells later. If angiostatin indeed is most effective in early
angiogenesis, then this could be similar for physiological and tumor angiogenesis.
In order to examine the gross morphological background of the low mechanical
resistance present in the angiostatin treated mice, we investigated the ECM-formation
in the granulation tissue. The reticulin and azan staining (figure 1) demonstrated
matrix deposition in angiostatin treated mice that was comparable to the controls.
Staining for laminin revealed that this matrix component was expressed in the granu-
lation tissue (not shown) of both groups, especially located in basement membranes
of micro capillaries. Therefore, it seems that the architectural pattern of the ECM
deposition does not predict mechanical resistance. In a study on the interaction
between angiostatin and the ECM, matrix angiostatin functioned as a non-competitive
inhibitor of the ECM-enhanced, t-PA-catalyzed plasminogen activation.19 Angiostatin in
the cellular microenvironment could inhibit matrix-enhanced plasminogen activation,
resulting in reduced invasive activity. This study suggested a biochemical mechanism
whereby angiostatin-mediated regulation of plasmin formation could influence cellular
migration and invasion. However, investigating this mechanism requires functional
assays instead of immunohistochemical staining procedures. 
More inflammatory tissue was present in the mice that were treated with angio-
statin. H&E staining already showed a prominent granulocyte influx at this site,
confirmed by NIMP-R14 and FA11 staining (figure 1). Therefore, we could not substan-
tiate the findings that angiostatin directly inhibits neutrophil migration and neutrophil-
mediated angiogenesis14. The increase in inflammation with recruitment of neutrophils
was most likely a direct effect of the impaired healing, with subsequent leakage and local
peritonitis, as was found more frequently in the angiostatin treated mice. We speculate
that proteases derived by the more prominent granulocyte influx into the granulation
tissue in angiostatin treated animals may have caused a weakness of ECM-fibrils in the
tissue.
NG2 was located in vascular structures and abundantly stained pericytal cells in both
groups (figure 1). NG2 -proteoglycan was known to be expressed by pericytes in patholo-
gical microvasculature.20 In addition, NG2 is up-regulated in the adult brain during neovas-
cularization in granulating tissue of healing wounds21,22, which support a role for NG2
during vascular proliferation and morphogenesis. On the other hand, NG2-positive cells
bind, internalize, and co-immunoprecipitate with angiostatin.23 Immature vessels contain
NG2-positive pericytes, suggesting a role for this cell population in modulating
endothelial cell proliferation by blocking the inhibitory effects of angiostatin during vessel
development.  In this study, however, we could not observe immunohistochemical diffe-
rences in NG2-positive cells between the angiostatin treated mice and their controls.
In conclusion, adverse effects of angiostatin on experimental colonic healing coincide
with fewer vessels and increased inflammatory tissue one week after surgery.  Especially
with respect to ECM, endothelial cell apoptosis, proliferation, or neutrophil influx, no
gross differences were discerned one week following surgery, using histology and
immunohistochemistry techniques.
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Abstract
Plasmin and other components of the plasminogen activation system play an
important role in tissue repair by regulating extracellular matrix remodeling, including
fibrin degradation. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a procarboxy-
peptidase that, after activation, can attenuate plasmin-mediated fibrin degradation by
removing C-terminal lysine residues from fibrin. These C-terminal lysines play a role in
the binding and activation of plasminogen. To test the hypothesis that TAFI is an
important determinant in the control of tissue repair we investigated the effect of TAFI
deficiency on the healing of cutaneous wounds and colonic anastomoses. Histological
examination revealed inappropriate organization of skin wound closure in the TAFI
knockout mice, including an altered pattern of epithelial migration. The time required
to overall heal the cutaneous wounds was slightly delayed in TAFI deficient mice.
Healing of colonic anastomoses was also impaired, as was reflected by a decreased
strength of the tissue at the site of the suture as well as by bleeding complications in
3 out of 14 animals. Together these abnormalities resulted in increased mortality in
TAFI deficient mice after colonic anastomoses. Although our study shows that tissue
repair, including re-epithelialization and scar formation can ultimately proceed in some
TAFI deficient mice, TAFI appears to be important for appropriate organization of the
healing process.
Introduction
Wound healing is a complex process involving formation of a provisional matrix,
cell infiltration and subsequent tissue remodeling. Intravascular platelet aggregation,
formation of a fibrin clot, growth factor release, in combination with increased
vascular permeability cause migration of attracted inflammatory cells. Blood vessel
disruption caused by tissue injury leads to extravasation of plasma proteins, platelet
aggregation and activation of the coagulation system. Macrophages, as well as
platelets, are activated and produce growth factors for the initiation of granulation
tissue formation. After the arrival of fibroblasts, the proliferation phase starts.
Endothelial cells are important in this phase, as they contribute to angiogenesis.
Secondary wound healing in unsutured wounds, as opposed to primary wound
healing in sutured wounds, involves the migration of epithelial cells towards their
opposite wound edges while they cover the wound. The migration of cells, angioge-
nesis and formation of granulation tissue are all dependent on the extracellular
matrix (ECM) remodeling during the maturation phase. Plasmin and other compo-
nents of the plasminogen activation system play an important role in tissue repair by
regulating ECM remodeling. Furthermore, activated platelets greatly facilitate the
coagulation cascade and secrete several adhesive proteins, including fibrinogen,
fibronectin and collagen type V. Fibrin acts as a provisional matrix for the formation
of granulation tissue and re-epithelialization. Without a correct balance between
degradation and production of new ECM, impaired wound healing is likely to occur.
Ultimately, the provisional matrix is degraded as the wound contracts, leaving a
collagen scar. Both the coagulation and fibrinolytic systems play a fundamental role
in the formation and subsequent removal of a blood clot. The removal of the haemo-
static plug during the process of wound healing occurs by the fibrinolytic system in
which plasminogen is converted into plasmin, resulting in proteolysis of the fibrin
clot into soluble fibrin degradation products.
Cutaneous wound healing has been investigated in several knockout mice
deficient for components that regulate the formation and/or degradation of the provi-
sional matrix. Wound healing in plasminogen knockout mice is impaired.1 In these
mice migration of keratinocytes is decreased, leading to a delay in re-epitheliali-
sation. A double knockout model that is deficient in plasminogen and fibrinogen
showed a correction of the healing time to normal, implicating that an essential role
for plasminogen is fibrinolysis.2 On the other hand, in a wound-healing model of the
skin in mice lacking fibrinogen the re-epithelialization of keratinocytes was inappro-
priately organized, leading to wound healing defects.3 In mice deficient for plasmi-
nogen activator inhibitor-1 (PAI-1), the rate of skin wound closure was found to be
accelerated.4 Another form of wound healing is the healing of colonic anastomoses.
Since anastomotic leakage in the week following surgery comprises a disastrous
event, leading to high morbidity and mortality5 this form of wound healing can be
life threatening if impaired. We have recently investigated colonic healing in a mouse
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model6, and proved this model to be useful in investigating delicate effects of
impaired healing.
TAFI is a procarboxypeptidase that is synthesized in the liver as a prepropeptide
and secreted into the circulation as a 55 kDa glycoprotein, both in man and in
mice.7,8 Activated TAFI (TAFIa) can down regulate fibrinolysis by removing carboxy-
terminal lysines from fibrin, which act as binding sites for plasminogen and tissue-
type plasminogen activator. In vitro TAFIa is rapidly (t1/2 ~ 10 min) inactivated by
thrombin and/or by temperature-dependent instability.9-11 TAFI can be activated by
thrombin, both in the presence or absence of its cofactor thrombomodulin, plasmin,
trypsin and meizothrombin. In the absence of thrombomodulin, high levels of
thrombin are required for the activation of TAFI. Based on in vitro and in vivo studies
it has been hypothesized that thrombin-activatable fibrinolysis inhibitor (TAFI) forms
a link between coagulation and fibrinolysis.12,13 No physiological function of TAFI in
vivo has been described so far, although increased levels of TAFI have been
associated with an increased risk for venous thrombosis.14-16
To study the biological function of TAFI in blood coagulation, fibrinolysis and
wound healing, we generated genetically modified mice in which the endogenous
TAFI gene is disrupted. We here show that mice lacking TAFI have impaired healing
of colonic anastomoses and cutaneous wounds.
Materials and methods
CNBr-activated Sepharose and RediprimeTMII were from Amersham Pharmacia
Biotech (Uppsala, Sweden), bovine serum albumin (BSA, fraction V), L-α-phoshatidyl-
choline, dioleoyl (PC), L-α-phoshatidylserine, dioleoyl (PS), L-α-phoshatidylethano-
lamine, dioleoyl (PE) and proteinase K were from Sigma (St Louis, MO, USA). Tissue-
type plasminogen activator (tPA, 531,000 IU/mg) was obtained from Chromogenix
(Mölndal, Sweden). Hippuryl-arginine and H-D-Phe-Pro-Arg-chloromethylketone (PPACK)
were obtained from Bachem (Bubendorf, Switzerland) and potato carboxypeptidase
inhibitor (CPI) from Calbiochem (La Jolla, CA, USA). Human thrombin was a generous
gift from Dr. W. Kisiel (University of New Mexico, Albuquerque, NM, USA).
Thrombomodulin was from American Diagnostica (Greenwich, CT, USA). RNAzolTM was
from Campro Scientific (Veenendaal, The Netherlands). T4 DNA ligase, G418 and PCR
primers were from Life Sciences (Paisley, UK). AmpliTaq GoldTM DNA polymerase and
gancyclovir were obtained from Roche (Almere, The Netherlands). Peroxidase-conju-
gated swine antibody against rabbit IgG (SWARPO) was from DAKO (Glostrup,
Denmark). ImmobilonTM–P PVDF membrane was from Millipore (Bedford, MA, USA). ECL
Renaissance Western blot chemiluminescence reagent plus was from NEN Life Science
Products (Boston, MA, USA).
Animals
Mice were kept in a controlled dark/light cycle and had access to pellet food and
water ad libitum. Animal welfare was in accordance with institutional guidelines of the
University of Utrecht. Mice were killed by cardiac puncture under ether anaesthesia.
Blood was collected into citrate (3.8% weight/volume, 9:1 volume/volume) containing
tubes and centrifuged for 15 min at 3000 rpm in an Eppendorf centrifuge. Plasma was
collected, frozen immediately in 100 µl aliquots in liquid nitrogen and stored at
–70 °C until use. Organs were removed immediately after decapitation after ether
anaesthesia, frozen in liquid nitrogen and stored at –70 °C until use for Northern blot
analysis or fixed overnight in a freshly prepared formaldehyde solution (4% parafor-
maldehyde (weight/volume) in PBS, pH (7.4) at 4 °C for histological examination.
Generation of the targeting vector for homologous recombination in ES cells A 200
kb genomic DNA clone (BacM-13908, nr 18412, Genome Systems, USA) was obtained
after screening of a mouse (129/Ola) genomic library with PCR primers (forward
primer: 5’-GAG GCA CGT GGA TTT CTA CAT CAT-3’; reversed primer: 5’-GCA GCG GTT
GTT CTT GTG AG-3’ corresponding to nt 716-830 of mouse TAFI cDNA (Genbank AF
164524). Restriction fragment analysis and Southern blotting with a 300 bp XhoI-
EcoR1 mouse TAFI cDNA probe, containing part of exon 1 and 2, revealed a 4.0 kb
EcoR1 DNA fragment that was cloned in pBR-GEM11 and was used for the generation
of the mouse TAFI knockout construct, and a 2.5 kb SacI DNA fragment that was used
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for the generation of a 500 bp EcoRI-SacI DNA probe for Southern analysis. Please
note that the 3’ SacI site in the 2.5 kb SacI DNA fragment was derived from the
cloning vector and was therefore absent in the genomic mouse TAFI DNA sequence.
The targeting vector was constructed by inserting a 1.6 kb phosphoglycerate kinase
(PGK) neomycin (neo) cassette in exon 2 in the opposite transcriptional orientation to
the TAFI gene (Figure 1A). Two PCR fragments were generated in which unique
restriction sites were added to facilitate cloning of the neo cassette in exon 2: PCR1
(forward primer: 5’-GTA ATA CGA CTC ACT ATA GGG C-3’ (T7); reversed primer: 5’-CTT
ATC GAT ACA GAA TCT TAC TAC AAC G-3’, ClaI restriction site is bold) and PCR 2
(forward primer: 5’ CCC CTC GAG GTT GAA CTT GCC TGG AGG-3’, XhoI restriction site is
bold; reversed primer: 5’-GCC TGA CTG CGT TAG CAA TTT AAC-3’ (pBR-GEM11rev) and
cloned via the TOPO vector into pBluescript-SK. Flanking the neo cassette the 2.4 kb
EcoR1-Xho1 PCR 2 fragment and the 1.6 kb Cla1-EcoR1 PCR 1 fragment were included
at the 5’ and 3’ ends, respectively. This approach resulted in the deletion of 11 nucle-
otides in exon 2. At the 5’ end a 3.0 kb PGK thymidine kinase cassette was included
in the opposite transcriptional orientation to the TAFI gene. The final 8.6 kb construct
was cloned in pBluescript-SK, linearized with NotI and introduced into E14 embryonic
stem (ES) cells by electroporation (800 V, 3 µF, 0.1 ms). Targeted ES cells were
selected after culturing in the presence of 200 µg/ml G418 and 5 µM gancyclovir.
Individual ES cell clones were screened for homologous recombination by Southern
blot analysis using a 500 bp EcoRI-SacI genomic fragment downstream of the
targeting construct. Targeted ES cells of 2 out of 56 individual ES cell clones were
microinjected into the blastocoele cavity of C57BL/6J blastocysts and were implanted
into pseudopregnant females. Three chimeric males of both targeted ES cell lines thus
generated were bred to C57BL/6J females to produce heterozygous TAFI± offspring.
Genotypes of mice were obtained by Southern blot or PCR by using tail tip DNA.
TAFI± mice were backcrossed with C57Bl/6J mice. For experiments mice with a mixed
background (75% C57Bl/6J and 25% 129/Ola) were used.
Southern blot analysis of genomic DNA
Genomic DNA was isolated from ES cell clones or mouse tail tips. The DNA was
digested with SacI and homologous recombination was analysed by hybridization with
a 500 bp EcoRI-SacI genomic DNA fragment localized at the 3’ end outside the
targeting vector. The probe detects a 7.4 kb wild type and a 8.8 kb mutant fragment.
PCR analysis of genomic DNA
For the PCR reactions 1 µl of 250-fold diluted DNA in sterile water was used. Each
sample was subjected to two separate PCR reactions. The reaction containing a neo-
specific primer set (forward primer: 5’-ACA AGA TGG ATT GCA CGC AGG-3’ corre-
sponding to nt 750-770 of PGK-Neo; reverse primer: 5’-GAA TGG GCA GGT AGC CGG
ATC-3’ corresponding to nt 1099-1199 of PGK-Neo) revealed the presence of a 350 bp
neo-specific product in TAFI± and TAFI-/- samples. The PCR reaction containing primers
annealing in exon 2 (forward primer) and intron 2 (reverse primer) of mouse TAFI
(forward primer: 5’-TGG CCA GGT TTT ATC TGC -3’ corresponding to nt 155-172
(Genbank AF 164524) and reverse primer 5’-CCA CTT GTC ATG AAT TAC-3’ revealed the
presence of a 1300 bp amplification product in TAFI+/+ and TAFI± samples.
Northern blot analysis
Total RNA was extracted from tissue homogenates using the RNAzolTM B method as
described by the manufacturer. Total RNA samples (10-30 µg) were electrophoretically
fractionated on denaturating 1% agarose gels, blotted onto nylon filters and UV-
crosslinked. The probe was the 0.8 Kb HindIII-HindIII mouse TAFI cDNA fragment
(Genbank AF 164524).17 After hybridisation, the blots were washed and exposed to
Kodak X-Omat Blue XB-1 film with intensifying screens.
Detection of TAFI in mouse plasma
Mouse TAFI protein was immunoprecipitated from fresh frozen citrated plasma
using a polyclonal rabbit anti-human TAFI antibody18 coupled to activated CNBr-
Sepharose (4 mg antibody to 1 g Sepharose). 45 µl mouse plasma was added to
385 µl Tris buffer (50 mM Tris, 150 mM NaCl; pH 7.4), containing 100 µl polyclonal
antibody coupled Sepharose (diluted 1:1 in Tris buffer) and PPACK (15 µM). Binding
was allowed for 90 min at room temperature on a top over top shaker. Samples were
washed 4 times in buffer (50 mM Tris, 500 mM NaCl, pH 7.4), eluted with 0.1 M
glycine (pH 2.7) and neutralized in 0.1 M Tris, pH 9.0. Samples were subjected to
SDS-PAGE under reducing conditions. Proteins were blotted on PVDF membranes,
detected with a rabbit anti-human TAFI polyclonal antibody and SWARPO, and
visualized with ECL followed by exposure to Kodak X-Omat Blue XB-1 film.
TAFI activity assay
TAFI activity was measured as described previously.19 In this assay, plasma is
treated with thrombin-thrombomodulin, and the carboxypeptidase activity generated is
determined with the substrate hippuryl-arginine. The assay is performed both in the
presence and absence of CPI, to be able to correct for the constitutively active
carboxypeptidase N present in plasma.
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Clot lysis assay
The clot lysis assay was performed essentially as described previously.18
Experiments were performed with plasmas of at least 5 mice per experimental group.
Cutaneous wound healing
Mice were anaesthetized intraperitoneally with fentanyl citrate/fluanisone (0.3
mg/mouse; Janssen-Cilag, Brussels, Belgium) and midazolam chloride (12.5 mg/mouse;
Roche, Brussels, Belgium). The dorsal skin was shaved and disinfected by alcohol 80%.
Excisional wounds were inflicted by a full thickness 3 mm disposable punch biopsy
(Stiefel Laboratories Inc, Florida, USA). Full thickness 1-cm incisional wounds were
created by surgical blade. The incisional as well as the excisional wounds were created
lateral to the dorsal midline. In the first set of experiments, the incisional and
excisional wounds were created on either side of the dorsal midline, 2 cm apart, in the
same animal. In a second set of experiments, only excisional wounds were studied and
all wounds were uniquely inflicted by 3-mm punch biopsies, one per animal. Surgery
was carried out blinded to the genotypes of the mice. All wounds were left unsutured
and undressed, in order to study secondary wound healing. The mice were housed
individually for the duration of the study and allowed food and water ad libitum.
Postoperatively, mice of each genotype were divided into three different groups,
consisting of 4-5 mice per group. Wounds were examined and photographed on days
4, 7 and 15 to follow progression of healing of the wounds. On days 4, 7 and 15
respectively, one group of each genotype was sacrificed. At sacrifice, the wounded
tissue was excised, formalin fixed, sectioned into half and completely embedded in
paraffin. Per wound serial 4-µm slides, perpendicular to the original wound incisions,
were stained with hematoxylin and eosin and analyzed blinded to the genotypes of the
mice, by two independent observers. Complete reepithelialization was defined as 100%
approximation of the keratinocyte layer covering the wound.
Colonic anastomosis
28 animals were subjected to surgery; 14 knockout and 14 wild-type animals.
Surgery was performed blinded to the genotype in 7 independent experiments. The
right colon was anastomosed following transection, as described previously.6 Briefly,
anesthetized mice were shaved and placed on a heated surgical microscopy table. A
midline laparotomy was performed under aseptic conditions. The right colon was trans-
ected one cm distal to the coecum by microscopical scissors, taking care not to
damage the mesenteric vessels. The colon was anastomosed by a single-layer 8.0 non-
absorbable (ProleneTM, Ethicon, Brussels, Belgium) inverted running suture. 
Two independent observers recorded the postoperative clinical condition of the
mice daily, according to a predetermined clinical assessment score as described in
table 1. For calculation of the percentage of postoperative weight loss, body weights
on day 7 postoperatively were compared to those on day 0, i.e. prior to surgery. All
mice that had died prior to sacrifice on day 7 were subjected to autopsy by the veteri-
narian of the animal housing facility. On day 7 the abdomen was reopened and
inspected for anastomotic dehiscence, local peritonitis, ileus, and the formation of
adhesions. Peritonitis was defined as macroscopic signs of inflammation, fibrin
deposition and hypervascularity. Mechanical ileus was defined as obstruction of the
intestine caused by the suture, with distention proximal to the anastomosis but not
distal to the anastomosis, and was considered a failure of the surgical procedure.
Paralytical ileus was defined as distention of atone intestine and colon, with paling
and swelling of the colonic wall, in conjunction with the absence of mechanical ileus.
Adhesions involving the suture line were counted, because the presence of adhesions
surrounding the suture line is indicative of an inflammatory process, e.g., as caused by
intestinal spill. All surrounding structures adhesive to the anastomosis (colon, intestine,
omemtum, and pelvic fatty tissue) were considered separate adhesions and were
counted as such.
Table 1. Clinical appearance scoring system
Appearance
0 = normal
1 = fur untreated
2 = 1 + red spots surrounding eyes
3 = 2 + abnormal posture
Behaviour
0 = normal
1 = minor changes
2 = decreased activity
3 = immobility
Reactivity
0 = normal
1 = increased or less 
2 = 1 but increased
3 = 2 but even more increased
Body weight
0 = normal
1 = <10% weight loss
2 = 10-20% weight loss
3 = >20% weight loss
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To test the anastomotic strength, 3 cm of colon, including the anastomotic line was
resected, while care was taken not to disturb the anastomosis and adhesions. The
resected segment was ligated on both sides and, ex vivo, was connected via a cannula
to a volume-directed infusion pump filled with PBS. A side arm of the canulla was
connected to a pressure transducer, which in turn was connected to a recorder. The
intestinal segment was gradually filled with PBS at a constant rate of 60 ml/hour while
the intraluminal pressure was monitored until burst occurred, as indicated as an abrupt
loss of pressure. The bursting pressure was documented, and the site of the bursting
was noted as being either at the anastomotic line or outside the anastomotic line. 
Anastomotic lesions were fixed in 4% formaldehyde and imbedded in paraffin.
Serial sections of 4-µm thickness from each block were mounted on poly-L-lysine-
coated slides, and hematoxylin & eosin-stained sections were made of every tenth
section in order to identify the newly formed granulation tissue surrounding the suture
and adjacent to the normal colon tissue (as judged by two independent observers).
Generally, this granulation tissue was easily discernable from the surrounding tissue.
The selected adjacent unstained slides containing granulation tissue were analyzed.
All animal experiments were executed according to the guidelines of the Animal
Welfare Committee of the University Medical Center Utrecht.
Statistical analysis
Independent t tests (equal variances not assumed) were performed to determine
statistical differences between the treated and non-treated groups for the wound
healing experiments. Results are presented as mean ± SEM. Data was considered
significant when p <0.05.
Figure 1.  TAFI gene inactivation. 
(A) Structure of the mouse TAFI gene, the targeting vector and the predicted disrupted gene.
The probe used for Southern blotting as well as the detected fragments are indicated. The PCR
primers used for genotyping are indicated with arrowheads. E, EcoRI; S, SacI. (B) Northern blot
analysis of total liver RNA from PCR genotyped animals. The loading of the gels was confirmed
by ethidium bromide staining of ribosomal RNA (lower part). (C) Western blot analysis of
plasma from PCR genotyped animals. 
Results
Targeted inactivation of the mouse TAFI gene was achieved by homologous recom-
bination in embryonic stem cells using a targeting construct, including part of intron
1, exon 2 and part of intron 2, in which a neomycin cassette was introduced in exon
2 (Figure 1A). A thymidine kinase cassette was introduced at the 5’ end of the
targeting construct. Two independent, correctly targeted ES cell clones were obtained,
which gave rise to chimeric mice after blastocyst injection. Germline transmission of
the inactivated TAFI gene was detected by PCR analysis of tail tip DNA. Intercrossing
of these heterozygous TAFI-deficient mice yielded homozygous TAFI-deficient offspring.
The absence of TAFI mRNA in livers of TAFI-/- offspring was demonstrated by Northern
blotting (Figure 1B). In addition, no TAFI protein could be detected by Western
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blotting of plasma of TAFI-/- mice (Figure 1C) or by ELISA (2.1 + 0.5 µg/ml in TAFI+/+,
1.7 + 0.4 µg/ml in TAFI±, and 0 µg/ml in TAFI-/- (mean + SD; n=14, 45 and 65, respec-
tively; detection limit of assay < 0.02 µg/ml)). TAFI deficient mice were fertile and
produced offspring according to Mendelian ratios. TAFI-/- mice produced similar sizes
and numbers of litter as TAFI+/+ mice. No signs of spontaneous bleeding or (develop-
mental) abnormalities were observed in TAFI-/- mice. The oldest TAFI-/- mice are more
than 1 year old and still appear healthy. 
We evaluated the consequences of the absence of TAFI on clot lysis in vitro. In
TAFI+/+ plasma (Figure 2A), the clot is protected from lysis, which can be reversed by
the specific TAFI inhibitor CPI (potato carboxypeptidase inhibitor). In contrast, in
plasma from TAFI-/- mice, the clot is lysed rapidly, and addition of CPI to the plasma
did not result in enhanced lysis (Figure 2A). This was confirmed by the absence of
TAFI activity in plasma of TAFI-/- mice (data not shown). TAFI deficiency could not
protect the animals from LPS-induced disseminated intravascular coagulation in a
lethal endotoxemia model (data not shown).
Figure 3.  Macroscopical appearance of skin wounds. (see color appendix)
Representative examples of excisional (A-D) and incisional (E-H) wounds at 4 days (A,B,E,F) and
7 days (C,D,G,H) postoperatively. The left panels show the wildtype mice (A,C,E,G) and the right
panel show the TAFI-/- mice (B,D,F,H). No gross differences were found in macroscopical appea-
rance of excisional wounds on either days (A-D). However, following incisional wounds TAFI-/-
mice (F,H) showed a subjective larger wound as well as scar and the wounds appeared to be
more red due to protruding tissue, as compared to wildtype mice (E-G).
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Figure 2.  Clot lysis assay in plasma of wild-type and TAFI-deficient mice. 
(A) Wild-type mice. (B) TAFI deficient mice. Plasma was mixed with potato carboxypeptidase
inhibitor (closed circles) or buffer (open circles). Coagulation and fibrinolysis were initiated by
addition of thrombin and tPA, respectively. Clotting and fibrinolysis were followed in time as the
change in turbidity at 405 nm. 
Histological examination of all wounds revealed that re-epithelialization in TAFI
deficient mice was different from that in control mice (Figure 4). Although keratino-
cytes seem to proliferate and migrate in both genotypes, the direction of migration in
TAFI deficient mice (5/8 at day 4, 1/8 at day 7) was different from wild type animals.
Keratinocytes migrated as usual between scar and granulation tissue from one wound
edge towards the opposing edge in wild-type animals (Figure 4A,C). In TAFI deficient
mice, however, keratinocytes followed an abnormal pattern in another direction,
mostly down into the dermal layer (Figure 4B,D). Furthermore, the edges of these
layers of keratinocytes were blunt and thickened (Figure 4B,D). Sinuses (Figure 4E)
were formed and keratinocyte inclusions (Figure 4F) were observed in the TAFI
deficient mice only. The aberrant epithelial cell migration resulted in prolonged wound
healing in TAFI-/- mice (Figure 5). Complete re-epithelialization in control mice on day
Cutaneous wound healing
To explore the role for TAFI in secondary cutaneous wound repair we have
generated incisional and excisional dorsal skin wounds. Within two days both control
and TAFI deficient mice developed a similar fibrotic scar over the wound area
(Figure 3). Daily examination of the excisional wounds revealed no gross differences
between the healing of control and TAFI deficient mice (Figure 3A-D). The incisional
wounds of TAFI deficient mice showed a larger wound area as well as scar and
appeared to be more red due to protruding tissue (Figure 3E-H). 
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4 and 7 occurred in 89% and 100% respectively, whereas 38% and 63% of the
wounds in the TAFI deficient mice were closed at these time points, respectively. All
mice had completed re-epithelialization by day 15 (using Fisher Exact-test comparing
wild-type and knockout animals on day 4, p=0.043, and on day 7, p=0.082).
Cohesive provisional matrix had developed normally in the wounds and the formation
of abundant and highly vascularized granulation tissue closed the wound gap in both
genotypes.
Healing of colonic anastomosis
We have examined the consequences of TAFI defiency on colonic anastomotic
healing, a sensitive model of wound healing that, if impaired, can have life threa-
tening consequences.5 
The clinical scores showed that the postoperative recovery of the TAFI-/- mice was
worse than control mice, as shown in Figure 6. In accordance with these findings, the
TAFI-/- mice on day 7 had lost more weight than the controls, 8.2 ± 1.6% as
compared to 4.2 ± 0.5% in the wild-type controls (p=0.015). In table 2 data on the
clinical analysis as well as the intra-abdominal microscopy are summarized. Four of
the knockout mice died, one each on days 1 and 5, and two on day 7. Autopsy
revealed peritonitis caused by impaired anastomotic healing in two cases (died on
day 5 and day 7). One mouse had a mesenterial thrombosis on day 7 and conse-
quently widespread intestinal and colonic ischemia. The mouse autopsied on the first
day postoperatively showed severe hemorrhage of the inner layer of the dorsal skin,
at the sites of inflicted wounds by littermates’ bites. In all the dead knockout mice,
we found bleeding and ecchymoses at places of mechanical trauma, such as the
injection site in the subcutaneous layer of the abdominal wall. Those signs of
bleeding were not found in dead wild-type littermates, nor in sacrificed wild-type
controls. One of the wild-type control littermates died on day 7 of unknown cause.
The abdominal cavity as well as the anastomotic line had normal appearances, and
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Figure 5.  Quantification of skin wound healing. 
The histological slides were H&E stained and analysed for re-epithelialisation. The aberrant
epithelial cell migration resulted in prolonged wound healing in TAFI-/- mice. On day 4 postoper-
atively complete re-epithelialisation in the wild types was 89% vs. 38% (p=0.043) in the TAFI
deficient mice. On day 7 postoperatively 100 % of control vs. 63% (p=0.082) in the TAFI
deficient mice had healed. On day 15, all mice in both genotypes had complete re-epitheliali-
zation. 
Figure 4.  Microscopic appearance of skin wounds. (see color appendix)
Cutaneous wounds of TAFI+/+ (A,C) and TAFI-/- (B,D,E,F) mice. Sections were prepared from
isolated skin tissue and stained with H&E. The images are shown perpendicular to the longitu-
dinal direction of the wounds. (A) A normal epithelial migration of a TAFI+/+ mouse on day 4
postoperatively. (B) A representative example of an altered pattern re-epithelialisation of a TAFI
deficient mouse on the same day as the control, day 4 postoperatively. The keratinocytes seem
to migrate into the dermal layer (as indicated by the arrow), with blunt edges of the keratino-
cytes’ layer. (C) Normal healing of a TAFI+/+ mouse on day 7 postoperatively, with complete re-
epithelialisation. (D) A TAFI-/- mouse on day 7; Non-complete healing, with the layer of keratino-
cytes ending blunt into the dermis (arrow). (E) A keratinocytes-inclusion in the dermal layer of a
TAFI deficient mouse (arrowhead). (F) A wound sinus in a TAFI-/- mouse, paved with keratino-
cytes. 
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no bleeding or coagulation complication could be discerned. In none of the mice
mechanical ileus was observed, indicating anastomotic patency in all cases. At
sacrifice, 4 knockout mice had clear macroscopic signs of local peritonitis vs. none in
the control group. The number of adhesions was not significantly different in the
knockout group (2.8 ± 0.8 vs. 1.6 ± 0.4 in the wild-types, p=0.15). In 4/14 knockout
mice the rupture of the intestinal segment occurred on the anastomotic line, instead
of in adjacent colon tissue. As a consequence, the anastomosis was judged to be
weaker than the surrounding tissue in these animals. In the controls, all had an
anastomotic line that had become at least as strong as the surrounding tissue one
week after surgery, with bursting occurring in the normal intestinal tissue. The
bursting pressure in the knockout mice was significantly lower (142.6 ± 19.9 mm Hg
vs. 193.2 ± 7.1 in the controls (p=0.015). Histological analysis revealed no gross diffe-
rences in granulation tissue between genotypes. Increased inflammation was found in
cases of intestinal leakage in those animals with bursting pressure measurements
corresponding to impaired healing.
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Figure 6.  Clinical appearance of mice following colonic anastomosis.
Course of clinical appearance from the day of surgery (day 0) until the day of sacrifice (day 7).
The appearance of each individual mouse was scored by two independent observers, in a semi-
quantitative manner. The scoring system used is depicted in table 1; note that the lower the
score, the healthier the animal (a normal mouse has a cumulative score of 0). Scores are
plotted per genotype and presented as mean ± SEM.
Table 2.  Parameters of the anastomotic healing in TAFI-/- mice
TAFI+/+ TAFI-/- p
N 14 14
Mortality 1 4
Bleeding 0 3
Mesent thrombosis 0 1
Dehiscence 0 2
Weight loss % (mean ± SEM) 4.2 (0.5) 8.2 (1.6) 0.015
Local peritonitis 0 4
Adhesions 1.6 (0.4) 2.8 (0.8) 0.15
Bursting pressure 193.2 (7.1) 142.6 (19.9) 0.015
On suture 0 4
E. A. te Velde, G.T.M. Wagenaar,  A. Reijerkerk, et al. · Woundhealing in TAFI -/- mice 6766 Woundhealing in TAFI -/- mice · E. A. te Velde, G.T.M. Wagenaar, A. Reijerkerk, et al.
Discussion
There is considerable evidence that TAFI is important for hemostasis and links the
coagulation and fibrinolytic systems7,12. To study the biological function of TAFI in
blood coagulation, fibrinolysis and wound healing, we generated genetically modified
mice in which the endogenous TAFI gene is disrupted. In this study, we found that
lack of TAFI is compatible with murine life and describe a novel physiological function
for TAFI in vivo. 
Nagashima et al.20 studied TAFI deficient mice with respect to coagulation and
fibrinolysis, and they did not find any effects on tail bleeding time, venous or arterial
thrombosis, thrombin-induced pulmonary embolism, factor X coagulant protein-
induced thrombosis, or endotoxin-induced disseminated intravascular coagulation.
Swaisgood et al.15 have recently determined the role of TAFI defiency in modulating
the functions of plasminogen. The TAFI knockout mice were tested in a compromised
plasminogen background (plasminogen ± mice). This compromised background made
the effects of TAFI apparent. It was demonstrated in a pulmonary clot lysis model that
fibrinolysis was significantly increased in TAFI knockout mice. Also, in a model of
peritoneal inflammation, the leukocyte migration in knockout mice was significantly
increased.14,21-23
Here we show that mice lacking TAFI have impaired wound healing in two different
models of tissue repair. First, skin wound healing was different in TAFI deficient mice.
The re-epithelialization by keratinocytes in TAFI-/- mice was delayed and did not
follow the normal pattern of migration. In normal secondary wound healing keratino-
cytes migrate from one wound edge towards the opposing edge. For undisturbed
migration the cells need contact with intact ECM over which they migrate. However, in
TAFI -/- mice the direction of keratinocyte migration was mostly directed down into
the dermal layer, indicating a disruption of functioning ECM. Nevertheless, in both
control and TAFI-/- mice cutaneous wound closure had ultimately been completed in
all mice within 15 days. Interestingly, fibrinogen deficient mice showed a remarkably
similar pattern of cutaneous wound healing3 as compared with the TAFI deficient mice.
We could speculate that, since activated TAFI inhibits fibrin stimulated tPA-mediated
plasmin formation, the absence of TAFI can presumably lead to uncontrolled plasmin
activation resulting in unbalanced matrix degradation. This may then result in the
excessive removal of fibrin and in the observed aberrant effects on keratinocyte
migration in the TAFI knockout mice that show similarities to the defects in the fibri-
nogen deficient mice. In contrast however, PAI-1 deficiency accelerates cutaneous
wound healing.4 PAI-1 does not only regulate plasmin formation, but also inhibits cell
migration by blocking the vitronectin receptor αvβ3 interaction with vitronectin.24 The
interaction of PAI-1 with plasminogen activators results in this setting in a loss of
affinity for vitronectin, which restores cell migration. In this respect it is interesting to
note that thrombomodulin, a cofactor for thrombin-mediated TAFI activation,25 is
weakly expressed in normal epidermis but markedly upregulated in keratinocytes
during cutaneous wound healing. Thrombomodulin is expressed in keratinocytes in
areas of stratification within the neoepidermis whereas thrombomodulin is absent in
keratinocytes at the margins of the neoepidermis.26 However, mice deficient in thromb-
omodulin did not show apparent defects in cutaneous wound healing.26 This may
suggest that other mechanisms, not involving thrombin-thrombomodulin mediated
activation of TAFI can occur in vivo. It also indicates a role for other proteases, such
as plasmin, in the in vivo activation of TAFI and that TAFI activation might not
necessarily be restricted to areas where thrombomodulin is present. 
Subsequently, we have shown that end-to-end anastomosis of the ascending colon
in those mice resulted in a decreased strength of the anastomosis at sacrifice at day
seven postoperatively as compared with the wild-type controls. The healing of colonic
anastomoses is a model of wound healing independent of keratinocyte migration but
dependent on matrix remodeling and angiogenesis,27 whereas cutaneous wound
healing benefits from diffusion of oxygen through preexisting vasculature28,29. Thus, in
agreement with Swaisgood et al.15 it seems that TAFI plays a role in modulating cell
migration and/or invasion independent of the cell type.
Proper control of proteolytic degradation of the ECM and ECM remodeling is
necessary for secondary wound healing, as well as for anastomotic healing. The
number of adhesions surrounding the anastomosis was not significantly different in
the knockout group (2.8 ± 0.8 vs. 1.6 ± 0.4 in the wild-types, p=0.15). The presence
of adhesions surrounding the suture line is indicative of an inflammatory process,
e.g., as caused by intestinal spill and prevents diffuse spreading of inflammation in
the abdomen. In addition, based on previous observations we had expected to
observe an increase in the number of adhesion as a response to the leakage6.
Apparently TAFI-/- mice did not form more adhesions in reaction to the observed intra-
abdominal leakage. 
Another remarkable result of our study, was that in some critically ill mice from
impaired colonic healing with dehiscence and subsequent peritoneal leakage, at
autopsy a mesenterial thrombosis was suspected in combination with diffuse bleeding
from inflicted littermate's bites. In all the dead knockout mice, we found bleeding and
ecchymoses at places of mechanical trauma, such as the injection site in the subcuta-
neous layer of the abdominal wall. This clinical manifestation in the TAFI deficient
mice could very well be a result of diffuse intravascular coagulation (DIC). In contrast,
mice in whom other components of the fibrinolytic system were disrupted, e.g.
antiplasmin32, PAI-133 and PAI-234, had normal bleeding phenotypes. Probably, the
coagulation system adequately functions under circumstances where the fibrinolytic
system is not dramatically challenged. The suspected DIC in the TAFI deficient mice
after impaired colonic anastomotic healing might be a result of a critically challenged
fibrinolytic system, where other mechanisms insufficiently compensate for the lack of
TAFI. 
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Based on the impaired healing in two wound healing models in mice lacking TAFI,
i.e. the alteration in keratinocyte migration, decreased anastomotic strength of the
healed colon, the presence of severe hematological complications in TAFI-/- with
peritonitis after impaired colonic healing, and a diminished induction of reactive
adhesion formation we could speculate that TAFI might be a player in this delicately
regulated process. 
In conclusion, our results provide direct evidence for a role for the hemostatic
factor TAFI in cellular processes in vivo. Although unchallenged TAFI-/- mice showed
no phenotype, we showed that TAFI is involved in tissue repair. Studies to investigate
the mechanisms underlying the etiology of the wound healing defect in TAFI
deficiency are now warranted. 
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Abstract
Background   Surgical treatment of colorectal liver metastases (CLM) is becoming
increasingly important. Routinely, temporary occlusion of the inflow of the liver, i.e.
Pringle maneuver (PM), is performed a.o. to reduce peri-operative blood loss. We
hypothesized that PM unfavorably affects the prognosis of cancer patients, by
inducing temporary hypoxia with upregulation of Hypoxia Inducible Factor-1alpha
(HIF1α), increase in Vascular Endothelial Growth Factor (VEGF) levels, and subsequent
angiogenesis and growth of residual tumor. We evaluated the effects of PM on 1)
tumor recurrence in patients following resection of CLM; 2) intrahepatic HIF1α
expression and systemic VEGF-levels in patients undergoing Radiofrequency Ablation,
and 3) outgrowth of experimental CLM.
Methods  1) All consecutive patients who underwent hepatectomy for CLM between
1991 and 2000, with or without PM were analyzed for tumor recurrence, disease
specific survival (DSS) and disease free survival (DFS); 2) In 10 patients scheduled for
Radiofrequency ablation a standard PM of 20 minutes was performed. Intrahepatic
HIF1α (immunohistochemistry) and circulating VEGF (ELISA) were measured before and
after PM; 3) In 16 mice the growth of CLM was calculated following PM or sham
operation. 
Findings   1) In the 63 patients analyzed, tumor recurrence was 80 % after PM, vs.
26.3 % in the non-PM group (p=0.000). Logistic regression analysis showed an
independent correlation between PM and tumor recurrence (p=0.000). DSS and DFS
were significantly worse in the PM group; 2) Directly after PM, intra-hepatic HIF-1α
was over-expressed in 8/10 patients and plasma VEGF was increased (p=0.002); 3) PM
resulted in a > 2-fold increase in experimental intrahepatic tumor volume (p=0.000).
Interpretation   Vascular clamping of the liver’s inflow during hepatic surgery for CLM
is associated with increased expression of HIF1α and VEGF, increased residual tumor
growth and decreased survival, and should therefore be avoided.
Introduction
One of the most common cancers in the Western countries is colorectal cancer.1
Unfortunately, in almost 75% of patients the cancer will eventually spread to the liver.2 In
the treatment of these metastases, surgery is becoming increasingly important. Despite
recent advances in systemic therapies3-5, partial liver resection for secondary colorectal
malignancies still offers the only hope for cure6. A novel surgical method of local
destruction of liver tumors, Radio Frequency Ablation (RFA), is increasingly performed in
those patients with colorectal liver metastases that are irresectable, but confined to the
liver.7-9
Pringle maneuver, i.e. temporary obstruction of the vascular inflow to the liver by
clamping of the portal triad, is routinely applied worldwide.10 It is predominantly used to
reduce intra-operative blood loss, because blood transfusions are known to be associated
with poor prognosis.11 In case of RFA, the additive purpose of Pringle maneuver -or
pharmacological reduction of blood flow12- is an increase in destructed tumor volume,
resulting in larger lesions.13;14
Remarkably, although many studies have used Pringle maneuver as an experimental
model for ischemia and reperfusion, none have addressed the consequences of Pringle
maneuver on tumor growth and recurrence. Authors have reported transiently elevated
AST/ALT levels, as well as an increase in the sticking of leucocytes15, cytokine release16,
and nitric oxide17. In addition, ischemia-induced hepatic injury was successfully reduced
by endothelin-converting enzyme15 , antioxidants18, enhancement of glycolytic activity by
Insulin19,  as well as L-arginine20. Taken together, these studies point towards a direct
correlation between Pringle maneuver and intrahepatic hypoxia.
Hypoxia induces the expression of Hypoxia Inducible Factor-1alpha (HIF-1α).21 HIF-1α
is involved in cancer progression in different organs.22-26 Under physiological circum-
stances, HIF-1α is rapidly degraded through ubiquitination. However, under hypoxic condi-
tions, the protein is stabilized and transported into the nucleus where it activates a
number of genes. One of the most important down stream effects of HIF-1α activation is
up-regulation of Vascular Endothelial Growth Factor (VEGF) gene transcription27, that
subsequently gives rise to increased plasma VEGF protein levels. VEGF is a pivotal growth
factor that induces angiogenesis28, which stimulates tumor growth. Indeed, VEGF receptors
are expressed in cancers from many organs.29 A positive relationship between VEGF over-
expression in colorectal cancer and the occurrence of liver metastases has been reported.
30;31;32. 
All patients undergoing resection or RFA of hepatic metastases have cancer in an
advanced stage. As a consequence, they are likely to have micro-metastases in the liver
and elsewhere. We therefore hypothesized that Pringle maneuver unfavorably affects the
prognosis of cancer patients, by inducing temporary hypoxia with up-regulation of HIF-1α,
an increase in circulating levels of VEGF, and subsequent outgrowth of micro-metastases. 
The present study was undertaken to evaluate the effect of Pringle maneuver on 1)
tumor recurrence in patients following resection of liver metastases, 2) the up-regulation
of HIF-1α and VEGF plasma levels in patients undergoing RFA, as well as 3) the
outgrowth of experimental intrahepatic metastases.
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Materials and Methods
Effects of Pringle maneuver on tumor recurrence 
Retrospectively, records were analyzed of consecutive patients that underwent
potentially curative partial hepatectomy for isolated colorectal liver metastases (1991-
2000), at the University Medical Center Utrecht, the Netherlands. Patient’s characte-
ristics included gender, age, the disease free interval between primary tumor and liver
metastases, if the liver metastases was (were) detected at the time of resection of the
primary (synchronous) or developed during follow up (metachronous), the number of
metastases, and uni- or bilobular distribution. Intra-operative parameters documented
were: extent of resection (major defined as three segments or more), duration of
surgery, blood loss (units of transfused blood), prolonged periods (> 10 minutes) of
hypotension (<95 mmHg systolic) and application of Pringle maneuver or no vascular
exclusion. Postoperatively, histological examination of the resection margins was
recorded. The duration of the follow-up and the time between hepatectomy and recur-
rence were registered, as well as the site of recurrence, where recurrence was defined
as development of cancer at any site from the same colorectal primary. In addition,
survival data were retrieved.
Retrospective anonymous retrieval of patient data and left over tissue material is
allowed according to local ethics, and was approved by the Institutional Review
Board.
Statistical analysis was used to determine whether the groups with and without
Pringle maneuver were comparable for different variables using Chi-square tests,
Mann-Whitney test, Fisher Exact-test, as well as independent sample T-tests. Pearson’s
correlation was determined to identify correlating variables. Logistic regression
analysis was used to determine the independence of the different variables on recur-
rence and survival. For multivariate survival analysis, disease specific survival (DSS,
censoring deaths unrelated to the metastases) and disease free survival (DFS) Kaplan-
Meijer curves were plotted and differences between the curves were analyzed with the
Mantel-Cox test. Data is presented as Mean ± SEM and considered significant when
p<0.05.
Effects of Pringle maneuver on HIF-1α and VEGF expression in
liver tissue
To prospectively assess the effects of Pringle maneuver on intrahepatic HIF-1α and
VEGF expression, a clinical study was performed that allowed sequential liver biopsies
during radiofrequency ablation. Patients with liver metastases from colorectal adeno-
carcinoma -confined to the liver- scheduled for local tumor destruction by
Radiofrequency ablation (RFA) were included, after written informed consent. Exclusion
criteria were documented extra-hepatic disease, >10 liver metastases, total metastatic
involvement of the liver of more than 50%, poor performance status (WHO grade >1),
uncontrolled congestive heart failure or angina pectoris, significant neurological or
psychiatric disorders, active infection, or major hepatic insufficiency.
RFA consisted of laparotomy, followed by exposure of the entire liver. After intrao-
perative ultrasound had revealed all detectable lesions, the RFA electrode was
positioned under ultrasound guidance. RFA was executed according to the manufactu-
rer’s instructions (Surgical Company, Amersfoort, The Netherlands, standard roll on/roll
off protocol)   
A standard Pringle maneuver was applied in all patients (n=10) by clamping the
hepatoduodenal ligament with an atraumatic vascular clamp for 20 minutes. A small
surgical liver biopsy (~1cm3) was taken for histological analysis before clamping and
5 min after unclamping. Liver biopsies were divided in two, one part snap frozen in
liquid nitrogen, and the other fixed in neutral buffered formaldehyde and paraffin
embedded. Blood samples were drawn at the same time points, as well as before
incision, one hour post-pringle, and one hour as well as 24 hours postoperatively. 
HIF-1α immunohistochemistry We examined liver biopsies before and after Pringle
maneuver for nuclear HIF-1α upregulation. Immunohistochemical staining was
performed on paraffin embedded samples, as described elsewhere.24;33 4-µm-Slides
were deparaffinized and rehydrated. Endogenous peroxidase was blocked by
Methanol-0.3% H2O2. After antigen retrieval (water bath; 45 min in Target Retrieval
Solution (DAKO A/S, Copenhagen, Denmark)) the primary antibody (anti-HIF-1α mouse
monoclonal, BD Transduction laboratories, Mississauga, ON, Canada) was applied in a
1:500 dilution for 30 min at room temperature. The signal was amplified with the
Catalyzed Signal Amplification System (DAKO) and developed with diaminobenzidine,
followed by haematoxylin counterstaining. Between steps, slides were washed in Tris
buffered saline, and appropriate positive and negative controls were used throughout. 
The slides were scored by two different observers, blinded to the procedure. The
percentage of the positive hepatocytes was estimated per specimen. Because the
number of unstained endothelial and Kupffer cells is not detectable, the intensity of
their staining was semi-quantitatively assessed, as negative (0) to strongly positive
(+++). 
HIF-1α Western blotting  Western blotting was done by standard SDS-polyacrylamide
gel electrophoresis. Of each frozen liver specimen 10 5µm slides were sectioned.
Tissue was lysed in lysis buffer (1% NP40, 50 mM Tris HCl pH 8.0, 150 mM NaCl, 5
mM EDTA, protease inhibitor cocktail) for 30 min at 4°C followed by 20 min centrifu-
gation. The protein concentration in the supernatant was determined using the BCA
protein assay (Pierce, Rockford, IL, USA). A maximum of 300 mg protein in loading
buffer was loaded to an 8% SDS-PAGE gel. As a positive control a lysate of MCF7
cells incubated at 1% oxygen was used. Proteins were transferred to nitrocellulose
membranes (Hybond, Amersham, Arlington Heights, Illinois, USA). Membranes were
blocked in 3% nonfat milk powder dissolved in Phosphate buffered saline with Tween-
20 (PBS-T) and incubated for 1 hour with a mouse monoclonal antibody against HIF-
1α (BD Transduction laboratories). After washing, the membranes were incubated with
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a secondary antibody conjugated with Horseradish-peroxidase. Chemoluminescent
detection of the antibody binding was performed using the super-ECL system
(Amersham Biosciences, Piscataway, NJ, USA). 
VEGF plasma levels To determine whether the upregulation of HIF-1α in the liver
translated to a systemic increase in one of the most important down stream effects of
HIF-1α activation, i.e. Vascular Endothelial Growth Factor (VEGF), we measured plasma
levels at different time-points after Pringle maneuver. VEGF was measured using a
commercially available ELISA kit (R&D Systems Inc, Minneapolis, MN, USA) with
duplicate ELISA readings, according to the manufacturer’s protocol. The patients’
individual VEGF level before Pringle maneuver was set at 100%. Relative VEGF levels
for the whole group at the aforementioned different time-points were calculated
(mean ± SEM).   
Effects of Pringle maneuver on experimental hepatic tumor
growth 
The murine colon carcinoma cell line C26 was routinely cultured in DMEM supple-
mented with 10 % heat-inactivated FCS, 100 units/ml penicillin and 100 micrograms/ml
streptomycin in a 10% C02 environment. Cell viability was determined by trypan blue
staining. Confluent cultures were harvested by brief trypsinisation (0.05 trypsin in
0.02% EDTA), to a final concentration of 1x105 cells/100 microliters PBS. Sixteen Balb/C
male mice, aged 12 weeks, purchased from Harlan (Leicestershire, England), were
housed under standard conditions and allowed food and water ad libitum. Colorectal
liver metastases were induced in all mice as follows.34 Mice were anaesthetized intra-
peritoneally with fentanyl citrate/fluanisone (0.3 mg/mouse; Janssen-Cilag, Brussels,
Belgium) and midazolamchloride (12.5 mg/mouse; Roche, Brussels, Belgium). Through
a left lateral flank incision 1x 105 C26 colorectal carcinoma cells / 100µl were injected
into the spleen parenchyma. After 10 minutes, the spleen was removed to prevent
intrasplenic tumor growth. 
On day 5, all mice underwent surgery with intravenous injection of heparin
(2U/200µl) and half of them underwent 2 x 5 minutes of Pringle maneuver. In a pilot
experiment, the maximal tolerable duration of clamping was assessed. The portal vein
and hepatic artery were clamped by microscopical vessels clamp. The clamp was
released after 5 minutes for 1 minute, to allow recirculation of the congested portal
blood from the intestine. Thereafter, the clamp was reapplied for another 5 minutes,
hereby resembling the clinical practice of intermitted clamping.
On day 12, the livers were harvested, formaldehyde fixed, and embedded in
paraffin. Intrahepatic tumor load was scored as the hepatic replacement area (HRA),
the percentage of hepatic tissue having been taken up by metastatic tumor cells. HRA
was assessed on non-sequential haematoxylin and eosin stained sections by semi-
automated stereology (Leica-Q-Prodit system, Leica Microsystems, Rijswijk, The
Netherlands) using a four points grid overlaid on 100 fields per slide at a magnifi-
cation of 40x. 
Data is a result of two independent experiments. All experiments were performed
in accordance with the guidelines of the Animal Welfare Committee of the UMC
Utrecht, The Netherlands.
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Results
Effects of Pringle maneuver on tumor recurrence 
Sixty-three patients underwent resection of colorectal liver metastases during the
studied period. Pringle maneuver was used in 25 of the 63 procedures (36,2 %),
whereas the remaining patients had no vascular occlusion. Both patient groups were
comparable, except for an age difference of 5 years (p=0.017), as shown in table 1.
Peroperatively, in both groups an equal amount of patients (n=3) experienced a
period of hypotension. All resected specimens had negative resection margins on
histology. The median follow-up was 36 months.
Overall, metastatic recurrence developed in 30 patients. The recurrence was solely
intrahepatic in 10 patients (in additional 8 in combination with other sites), solely
intrapulmonary in 2 patients (in 12 in combination with other sites) and elsewhere in
11 patients (in five patients without liver or lung involvement). The percentage of
patients that developed recurrence in the group that underwent Pringle maneuver,
was 80.0 %, vs. 26.3 % in the group that did not undergo Pringle maneuver
(p=0.000, Chi square test). Using Pearson’s correlation analysis, there was no signi-
ficant correlation between any of the other variables listed in table 1 and recurrence,
independent of whether patients had undergone Pringle maneuver. Logistic regression
analysis revealed a significant association between Pringle maneuver and recurrence,
(p=0.000). All other variables per group from table 1 showed no association with
recurrence.
Univariate survival analysis for Disease Specific Survival and Disease Free Survival,
revealed Pringle maneuver as the only significant variable (p=0.0421, p= 0.0013 resp.
log rank test). Multivariate survival analysis (correction for age, 61.0 yr.) showed a
significant decrease in DSS (p=0.029) (figure 1a), as well as DFS (p=0.002) (figure 1b)
after hepatectomy including Pringle maneuver compared to no Pringle maneuver.
Table 1. Pringle maneuver and tumor recurrence 
Characteristics of patients undergoing partial hepatectomy for colorectal liver metastases
combined with Pringle maneuver (Pringle) and without Pringle maneuver (No Pringle). All
variables were comparable (NS), except for age (5 years, p=0.017)
Pringle (n=25) No Pringle (n=38) p
Female 9 (36%) 13 (34%) 
Male 16 (64%) 25 (66%) 1.000
Age 58.0 ± 1.9 63.8 ± 1.4 0.017
Disease free interval 
primary-liver 14.5 ± 5 19.7 ± 3 0.085
metastases (months)
Metachronous 14 29
Synchronous 11 9 0.105
Number of metastases 1.8 ± 0.2 1.8 ± 0.2 0.485
Lobes involved 
One 15 (79%) 30 (60%)
Two 10 (21%) 8  (40%) 0.154
Number of segments 3.2 ± 0.2 3.0  ± 0.2 0.676
Resection 
Minor 6 (24%) 14 (37%)
Major  19 (76%) 24 (63%) 0.408
Duration of surgery (minutes) 266 ± 17.5 241 ± 13.3 0.27
Units of blood 3.8 ± 0.9 2.9 ± 0.5 0.903
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Figure 1. Survival analysis
(a) Disease specific survival (DSS) and (b) Disease free survival (DFS) curves for all 63 patients
after partial liver resection for colorectal liver metastases, as a function of Pringle maneuver.
Yes represents patients who underwent hepatectomy including Pringle maneuver, and No repre-
sents patients who did not. Both DSS and DFS were significantly lower after Pringle maneuver
(p=0.029 and p=0.002, resp, multivariate survival analysis using Cox regression).
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Effects of Pringle maneuver on HIF-1α expression 
Immunohistochemically, HIF-1α was not detectable before Pringle maneuver in the
nuclei of the liver cells of any of the 10 patients (figure 2a). Following 20 minutes of
Pringle maneuver and 5 minutes of reperfusion, HIF-1α was clearly over-expressed in
8/10 patients (figure 2b), as was evident from diffuse nuclear staining in hepatocytes
(on average 2% of the cells), endothelial cells (++ to +++) and Kupffer cells (++ to
+++), and occasionally in the bile-duct epithelium (figure 2c). Of all cells displaying
up-regulation of HIF-1α, approximately 10% were hepatocytes, the rest (90%)
consisted of endothelial and Kupffer cells. By Western analysis HIF-1α expression was
compared between cell lysates of MCF7 cells incubated at 1% oxygen (positive
control) and liver biopsies before and after Pringle maneuver. No HIF-1a could be
detected in any of the samples either before or after Pringle maneuver. The positive
control clearly showed the expected band at 120 kDa.
Effects of Pringle maneuver on experimental hepatic tumor
growth 
One mouse had died from the procedure, due to cardiopulmonary consequences
of Pringle maneuver in combination with spontaneous breathing anesthesia. In the
remaining mice (n=15) that underwent Pringle maneuver on day 5 after tumor
injection, a significant increase in macroscopic intrahepatic tumor load was seen
(figure 4). Correspondingly, the HRA was also significantly increased upon sacrifice
one week after Pringle maneuver (67.9 ± 6.4%) compared to control animals that did
not undergo Pringle maneuver (31.1 ± 3.5%)(p=0.000)(figure 5).
Figure 2. Effects of Pringle maneuver on intrahepatic HIF1α expression. (see color appendix)
Immunohistochemical staining for anti-HIF-1α showed up-regulation of the protein in the nucleus
(in brown). (a) In none of the 10 patients, nuclear HIF-1a was detectable before Pringle
maneuver. (b) Following 20 minutes of Pringle maneuver and 5 minutes of reperfusion, HIF-1α
was clearly over-expressed in 8/10 patients in the nuclei of hepatocytes (on average 2% of the
cells), endothelial cells (++ to +++) and Kupffer cells (++ to +++). (c) Occasional nuclear HIF-1α
upregulation was found in the bileduct epithelium.
Effects of Pringle maneuver on VEGF plasma levels
The mean relative VEGF levels before incision (125.4 ± 32 %) did not differ from
the levels before Pringle maneuver (p=0.5)(figure 3). VEGF levels were significantly
elevated directly after Pringle maneuver -allowing 5 minutes of reperfusion- (174.1 ±
24 %, p=0.002). One hour after Pringle maneuver, the mean levels were 388.1 ± 98 %
(p=0.002). One hour post-operatively, the levels were increased to a mean of 605.8 ±
310 %. After 24 hours, the mean circulating VEGF levels were 177.9 ± 34 percent of
the patient’s individual levels before Pringle maneuver (p=0.147).   
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Figure 3. Effects of Pringle maneuver on VEGF expression, as measured by plasma VEGF levels
using ELISA. 
Each patient’s individual VEGF level before Pringle maneuver was set at 100%. Relative VEGF
levels for the whole group at different time-points are given (mean ± SEM) The mean relative
VEGF levels before surgical trauma, i.e. prior to incision (125.4 ± 32.2 %) did not significantly
differ from those before Pringle maneuver (100%) (p=0.5). The VEGF levels were significantly
elevated following Pringle maneuver. Directly after Pringle maneuver – and subsequent 5
minutes of reperfusion-, the mean relative plasma VEGF levels (174,1 ± 23.6 %) were elevated in
all patients (p=0.002). One hour after Pringle maneuver, the mean levels were 388.1 ± 97.5 %
(p=0.002). One hour post-operatively, the levels had increased to a mean of 605.8 ± 309.6 %.
After 24 hours, the mean circulating VEGF levels had nearly normalized (177.9 ± 33.7 % of the
patient’s individual levels before Pringle maneuver, p=0.147).
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Discussion
Temporary occlusion of the liver’s inflow, i.e. Pringle maneuver, is applied
worldwide as a routine procedure during liver surgery and RFA.10;13;14 Here we show that
Pringle maneuver is associated with increased metastatic recurrence and decreased
survival. Further, we provide evidence that this is likely due to "Pringle-induced"
hepatic hypoxia that results in upregulation of HIF-1α in different types of liver cells.
This is the only plausible explanation for the observed increase in plasma VEGF levels
and outgrowth of micrometastases through induction of angiogenesis. Although we
investigated only a relatively small number of patients in a retrospective study
comparing two groups of patients with and without Pringle maneuver, the groups
were comparable (table 1) and multivariate analysis revealed Pringle maneuver as the
only significant prognostic variable, even when patients were matched (data not
shown). Based on these considerations and results, we suggest that Pringle maneuver
should be omitted in patients where it is not obligatory. Also, we believe that it
should be included as an independent prognostic factor in the design of future
clinical trials. In addition, the outcome of the retrospective study warrants a
prospective study on this matter.
Although we provide the first firm evidence for the disadvantageous effects of
Pringle-induced hypoxia, other studies have reported indirect clues to support this. In
a retrospective study comparing various forms of vascular clamping, Buell et al found
the lowest rate of recurrence in patients undergoing hepatic resection for metastatic
cancer when no form of vascular clamping was applied.35 In ventricular biopsies from
patients with coronary ischemia, angiogenic factors such as HIF-1α and VEGF were
shown to be increased, as a first adaptation mechanism of human myocardium to
deprivation of blood.36 However, no correlation between (surgery-induced) hypoxia,
angiogenic growth factors and tumor growth has been described so far.
The mechanism behind the described sequence of events is probably HIF-1α
driven. We have shown an increase in HIF-1α in the major cell types in liver biopsies
taken after Pringle maneuver, as proven by immunohistochemistry. Previous studies
on the expression of HIF-1α in hepatocytes provided contradictory results, as
measured by either mRNA levels or immunohistochemistry.37;38 However, since hypoxia
does not increase HIF-1α mRNA levels, studying hypoxia-induced upregulation of HIF-
1α on nuclear protein levels by immunohistochemistry, as opposed to mRNA levels, is
more appropriate. In concordance with our findings, the sole study on immunohisto-
chemical staining of nuclear HIF-1 in mouse tissue showed an increase in nuclear
staining of hepatocytes after a severe hypoxic stimulus.39 The high HIF-1α expression
we found in Kupffer cells -and bile epithelium- has not been demonstrated before,
although macrophages were recently shown to express HIF-1α40. Since macrophages
are known to produce VEGF41, our findings suggest that the Kupffer cells contribute to
the described VEGF production. However, hepatic HIF-1α levels were too low to be
detected by Western blotting, although technically well performed. This can be
Figure 4. Effects of Pringle maneuver on macroscopic intrahepatic tumorload. (see color appendix)
Effects of Pringle maneuver on experimental hepatic tumor growth as shown by macroscopical
appearance of mouse livers of one experiment. In the mice that underwent Pringle maneuver on
day 5 after tumor injection, a significant increase in tumor load was observed (B) as compared to
the mice that did not (A).
Figure 5. Effects of Pringle maneuver on experimental hepatic tumor growth. 
Hepatic replacement area (HRA) of the mouse livers represents the percentage of hepatic tissue
having been taken up by metastatic tumor cells. HRA was assessed on H&E stained sections by
semi-automated stereology. In the mice that underwent Pringle maneuver on day 5 after tumor
injection, a significant increase was observed in microscopical tumor load (67.9 ± 6.4%) as
compared to control animals that did not undergo Pringle maneuver (31.1 ± 3.5%) (p=0.000).
Data is a result of two independent experiments.
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explained by the fact that HIF-1α nuclear upregulation was restricted to a small
percentage of hepatic cells, and could be detected by enhanced immunohistochemical
staining only. Nonetheless, it has been convincingly shown that even limited upregu-
lation of HIF-1α can result in significant downstream effects42, and this is underlined
by the results of our experimental study with significant increase of hepatic tumor
volume after Pringle maneuver (figures 4,5).
The elevated plasma levels of VEGF are indicative of a direct effect of HIF-1α
upregulation on VEGF production43. Although liver endothelial and Kupffer cells
showed the most outspoken HIF-1α upregulation, circulating platelets, activated as a
result of the stasis induced by Pringle maneuver, may also contribute to the VEGF
release44. Laparotomy per se was eliminated as a confounding stimulator of VEGF
levels, since we found no significant difference between VEGF levels before surgery
and those before Pringle maneuver (figure 3).
Studies on spatiotemporal aspects of HIF-1α and/or VEGF upregulation have not
revealed for how long these factors must be upregulated before a pro-angiogenic
effect is achieved. We found systemic outgrowth of experimental micro-metastases
(figures 4,5), even though the plasma VEGF levels were only elevated for several
hours (figure 3). Others indeed, gave support for the findings that VEGF has a very
early metastatic potential.45 Furthermore, HIF-1α was shown to prolong the half-life of
VEGF in vitro, up to 3 hours, through the stabilization of VEGF mRNA.46 Therefore, the
timing of expression encountered in our studies seems to be of patho-physiological
relevance.
It is tempting to speculate that other surgical interventions that hamper oxygen
distribution can provide a similar physiologically relevant HIF-1α upregulation and
subsequent pro-angiogenic response. For instance, partial bladder outlet obstruction
increased angiogenic response in bladder tissue in rats.47 In addition, a decrease in
microcirculation is observed during pneumoperitoneum48-50, and is evident during
vascular surgery. The adverse effects of "surgery-induced" hypoxia on tumor growth,
recurrence and survival, as observed in this study, might theoretically be overcome if
HIF-1α is blocked completely. Studies using VEGF-antibodies or receptor-blockers or
antibodies directed against HIF-1α peri-operatively are warranted. 
In conclusion, vascular clamping of the liver’s inflow during hepatic surgery for
colorectal liver metastases is associated with increased tumor growth, metastatic
recurrence and decreased survival. The mechanism behind this is probably HIF-1α
driven due to its hypoxia induced up-regulation, leading to increased plasma VEGF
levels, which in turn stimulate outgrowth of micro-metastases through induction of
angiogenesis. 
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Abstract
Background: Tumor-induced microvascular networks have become attractive targets in
cancer therapy. Strategies that target both tumor cells and vasculature have not been
investigated in models of early metastatic colorectal disease. The efficacy of a combi-
nation of conventional chemotherapy with a potent angiogenesis inhibitor (endostatin
or angiostatin) in a murine model of early colorectal liver metastasis was studied.
Methods:  Sixty-six mice were subjected to intrasplenic injection of C26 tumor cells to
induce colorectal liver metastases. Control animals received phosphate-buffered saline
(n = 8) or citrate buffer (n = 8). Treatment included conventional chemotherapy 
(n = 9), endostatin (n = 8), high-dose (n = 5)or low-dose (one-tenth of optimal dose;
n = 10) angiostatin, as well as the combination of either of these drugs with chemo-
therapy (n > 5). Clinical appearance was scored daily using a semiquantitative scale.
Liver weight, macroscopic and histological tumor involvement (hepatic replacement
area; HRA) were measured upon death at day 12.
Results: Treated mice displayed significantly better clinical scores than controls,
except for those animals treated with low-dose angiostatin with or without chemo-
therapy. Treatment with conventional chemotherapy resulted in a decrease in HRA
from 42 ± 3 to 29 ± 1 per cent (P < 0.001). The addition of angiostatin or endostatin
to conventional chemotherapy improved antitumoral efficacy, in a multiplicative
manner, resulting in a HRA of approximately 3.5 per cent (P < 0.001).
Conclusion: The addition of angiostatin or endostatin to conventional chemotherapy
enhanced antitumoral efficacy in a murine model of early colorectal liver metastasis.
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Introduction
Colorectal cancer is one the most prevalent malignancies in developed countries.1
Secondary malignant hepatic disease will develop in as many as 50-80 percent of
these patients2, and is the sole site of initial recurrence in approximately 30 percent3.
Once colorectal liver metastases have developed, the natural course of the disease is
associated with a poor survival rate.4 Partial liver resection offers the only hope of
cure for these patients5, but is, unfortunately, restricted to selected patients, many of
whom will still have recurrence within the liver or develop extrahepatic metastases. 
As a result of the use of adjuvant chemotherapy, survival rates of patients with
colorectal carcinoma have improved. As a consequence, adjuvant chemotherapy has
become standard practice in high-risk patients after operation. Studies of chemo-
therapy before or after liver resection for secondary malignant disease, however,
have been contradictory,6-8 although responses to schemes including oxaliplatin have
recently been shown to increase the resectability rate of liver metastases7. These
results indicate that there is room for improvement, particularly regarding periope-
rative systemic treatment. A search for alternative treatment modalities for colorectal
liver metastases is therefore warranted. 
One promising antitumor strategy involves antiangiogenic treatment. This
approach aims to suppress metastatic outgrowth by inhibiting the formation of a
tumor-induced vascular network. Many antiangiogenic agents are being tested in
preclinical studies and clinical trials.9 Experimental models have shown that when
tumors are deprived of new blood vessels they remain in a microscopic state of
dormancy.10 As antiangiogenic drugs are directed against components of developing
vasculature, they may be expected to lead to stable disease, rather than complete
remission, and may have little or no effect on gross or bulky (metastatic) disease.
Moreover, discontinuation of antiangiogenic therapy may allow the tumor or its
metastases to resume growth.10,12 Hence, patients most suitable for long-term antian-
giogenic treatment may be those with `early metastatic' or `minimal residual'
disease.
Combining conventional chemotherapy with antiangiogenic compounds might lead
to improved antitumor efficacy by targeting both tumor cell and endothelial cell
compartments.13-18 Strategies combining these two targets have not, however, been
investigated thoroughly in models of early widespread metastatic colorectal liver
disease19-24.
In this study, the efficacy of combinations of conventional chemotherapy and
strong angiogenesis inhibitors was assessed in a murine model of early metastatic
colorectal cancer. The effects of the combination therapies were compared with those
of conventional and antiangiogenic agents alone.
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Drugs
Angiostatin  Human angiostatin was purified as described by O'Reilly et al.25, with
minor modifications12. Outdated human plasma was applied to a lysine-Sepharose
column (Pharmacia, Uppsala, Sweden). Plasminogen was eluted with e-aminocaproic
acid 0.2 mol/l and dialysed against distilled water (molecular weight cut-off: 6-8000
Spectra/Por (Spectrum Laboratories, Rancho Dominguez, California, USA); dilution
greater than 4x107; 4°C), buffered with Tris 7.6 20 mmol/l, followed by proteolytic
digestion with plasminogen porcine pancreatic elastase (Calbiochem, San Diego,
California, USA) 0.8 units/mg (shaken overnight at 37°C; 120 r.p.m.). The solution was
applied to the same column and eluted with ε-aminocaproicacid 0.2 mol/l, while the
flow-through was collected and treated as recently cleaved plasminogen, in order to
collect angiostatin fragments with low lysine affinity. The angiostatin was dialysed and
freeze-dried. The angiostatin and its flow-through were subsequently combined. The
bioactivity of the angiostatin was confirmed by means of the mouse cornea neovascu-
larization assay, as described elsewhere12.
In all experiments the administration of angiostatin was as follows. Mice were given a
dorsal osmotic pump (AlzetTM pump, type 2001; Alza, Palo Alto, California, USA)sub-
cutaneously for continuous administration of angiostatin in a dose of 100 mg/kg daily.
In previous work this dose was shown to elicit maximal antitumor effects12. This
concentration is subsequently referred to as ‘high dose’. In addition, one-tenth of this
dose (10 mg/kg daily) was used to study any additional effect over conventional
chemotherapy of low amounts of angiostatin.
Endostatin Human recombinant endostatinTM produced in Pichia pastoris (Entremed,
Rockville, Maryland, USA) was administered by daily subcutaneous injection of 100 ml
in a dose of 500 µg/day. Control animals received the solvent citrate buffer (17 mmol/l
citric acid, 59 mmol/l sodium chloride, 66 mmol/l sodium phosphate, pH 6.2) 100
µl/day subcutaneously.
Chemotherapy Doxorubicin® (Pharmacia and Upjohn, Woerden, TheNetherlands), in a
dose of 10 mg/kg body-weight, was administered intravenously by tail vein injection
once on postoperative day 326. Controls received an equal volume of PBS intra-
venously.
Tumor cell line
The murine colonic carcinoma cell line C26 was cultured in Dulbecco's modified
Eagle's medium supplemented with 10 percent heat-inactivated fetal calf serum,
penicillin 100 units/ml and streptomycin 100 µg/ml in a 10 per cent carbon dioxide
Materials and methods
E. A. te Velde, J. M. Vogten, M. F. G. B. Gebbink et al. Multidrug treatment of liver metastases 93
environment. Cell viability was determinedby trypan blue staining. Confluent cultures
were harvested by brief trypsinization (0.05 trypsin in 0.02 per cent ethylenediamine
tetra-aceticacid), to a final concentration of 1 x 105 cells per 100 µl PBS.
Animals
The animals studied were male Balb/c mice, aged 10 weeks, purchased from the
General Animal Laboratory of the University Medical Center Utrecht. They were housed
under standard conditions and allowed food and water adlibitum. All experiments
were carried out according to the guidelines of the Animal Welfare Committee of the
University Medical Center Utrecht. Mice were anaesthetized intraperitoneally with
fentanylcitrate fluanisone (0.3 mg per mouse; Janssen-Cilag,Brussels, Belgium) and
midazolam chloride (12.5 mg per mouse; Roche, Brussels, Belgium). The spleen was
exteriorized through a left lateral flank incision. Some 1 x 105  C26 colorectal carcinoma
cells per 100 ml were injected into the spleen parenchyma using a 27-G needle. After
10 min, the spleen was removed to prevent intrasplenic tumor growth. The
peritoneum and skin were closed in two layers with 5-0 polyglactin.
Study design
Mice were subsequently divided into the following groups: controls received PBS
(n = 8) or citrate buffer (n = 8). Conventional chemotherapy alone consisted of
doxorubicin (n = 9). Single-agent antiangiogenic therapy included high-dose angio-
statin (n = 5), low-dose angiostatin (n = 10) or endostatin (n = 8). Combination
therapies included treatment with high- or low-dose angiostatin combined with
doxorubicin (n = 4 and n = 9, respectively) or endostatin combined with doxorubicin
(n = 5). The treatment was initiated 6 h after tumor cell injection based on calcula-
tions for tumor cell arrest and extravasation27.  The clinical appearance of the mice
was scored daily by two independent observers blinded to the treatment, according
to the scoring system provided by the animal facility (Table 1).
All mice were killed on day 12 after tumor implantation. Livers were collected for
the analysis of wet liver weight and hepatic replacement areas (HRAs).
Histological analysis
Formalin-fixed livers were sectioned into 4-µm slices and embedded completely in
paraffin. For each liver, four non- sequential 4-µm slides were stained with haema-
toxylin and eosin, and analysed. The HRA was defined as the percentage of normal
hepatic tissue that had been taken up by metastatic tumor cells, and assessed
morphometrically in a semi-quantitative manner (Leica-Q-Prodit, Leica Microsystems,
Ryswyk, The Netherlands). A four- grid analysis was used to determine the area ratio
in 100 fields per slide.  According to this protocol, a 5 per cent confidence interval
can be achieved.28
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Statistical analysis
For differences in clinical scores, the post hoc test of repeated measurements
analysis of variance (ANOVA) was performed. The independent t test was used to
compare the various treatment groups. The interaction effects between the different
antiangiogenic drugs in combination with conventional chemotherapy were tested with
ANOVA. A multiplicative effect was defined as an enhanced effect of antiangiogenic
therapy in the presence of chemotherapy, or vice versa. Intrahepatic tumor load (HRA)
was expressed as a percentage of the total liver area. Relative HRA was defined as the
HRA resulting from a particular treatment modality in relation to the HRA following
conventional chemotherapy alone (100 per cent). Results are presented as mean ± SEM.
Differences were considered significant when P < 0.003 for t test calculations (Bonferroni
correction for high number of tests) and when P < 0.05 for ANOVA.
Table 1  Clinical appearance scoring system
Score
Appearance
Normal 0
Fur untreated 1
As above + red spots around eyes 2
As above + abnormal posture 3
Behaviour
Normal 0
Minor changes 1
Decreased activity 2
Immobility 3
Reactivity
Normal 0
Increased or reduced 1
As above but more so 2
As above but even more so 3
Body-weight
Normal 0
Approx. 10 per cent weight loss 1
Approx. 20 per cent weight loss 2
More than 20 per cent weight loss 3
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Results
Clinical appearance
Mice treated with either drug displayed a significantly better clinical score than the
(citrate) control animals, except for those treated with low-dose angiostatin or its
combination with chemotherapy. The clinical appearance scores showed an increase on
days 3-5 for all mice treated with chemotherapy, indicating a transient adverse effect
on clinical condition on the days immediately after intravenous injection (Figure 1).
Figure 1 Course of clinical appearance 
From the day of operation (day 0) until the day of death (day 12). The appearance of
each mouse was scored by two independent observers in a semi-quantitative manner.
The scoring system used is depicted in Table 1; note that the lower the score, the
healthier the animal (a normal mouse has a cumulative score of 0). Scores are plotted
per treatment group; mean values are given. PBS, phosphate-buffered saline
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Macroscopic appearance and liver weight
The macroscopic appearance of tumor-bearing control livers was distinctive from
that of treated livers (Figure 2). Livers of untreated animals were enlarged, showing
an irregular liver surface caused by extensive tumor growth, whereas those of treated
animals were smaller in size, having a macroscopically normal appearance with
smoother, elastic, normal texture. The mean(±SEM) liver weight of mice treated with
endostatin (1.4(0.1) g) or with endostatin in combination with chemotherapy (1.2(0.1)
g) was significantly decreased compared with that in untreated tumor-bearing livers
(2.5(0.2) g) (P = 0.002 and P < 0.001 respectively). Non-tumor-bearing control age-
matched mice had a mean liver weight of 1.2(0.1) g (data not shown). 
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Antitumor effect
Table 2 and Figure 3 summarize the results of the histological analysis of the
HRAs in the various groups. Respective P values for comparisons between individual
treatment groups are outlined in Table 3. All single-agent drugs gave superior results
with regard to antitumor efficacy compared with no treatment (P < 0.001).
Chemotherapy monotreatment  In a pilot experiment, the optimal antitumor dose
(HRA 25-30 per cent) resulted in a high clinical score (greater than 6), indicating a
toxic response to chemotherapy (data not shown). A suboptimal antitumor dose,
resulting in a significant antitumor effect but with diminished, moderate toxicity, was
determined, as judged by a clinical score below 4 (Figure 1). All experiments were
carried out with this suboptimal reduced-toxicity dose of chemotherapy. The treatment
of liver metastases with this dose of doxorubicin monotherapy (n = 5) resulted in a
Figure 2. The macroscopic and histological appearance of resected livers. (see color appendix)
A. The irregular white surface of the liver is due to excessive tumor growth  B. This is signifi-
cantly reduced by endostatin and chemotherapy. A’. Normal liver architecture is highly disturbed
by tumor (hepatic replacement area (HRA) 53 per cent)(stained with haematoxylin and eosin).
B’. After combination treatment infiltration by tumor is significantly less (HRA 5 per cent).
Arrows indicate metastatic lesions.
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decrease in mean ± SEM HRA, from 42.3(2.0) (95 per cent confidence interval (c.i.)
37.5 to 47.0) per cent in non-treated controls to 29.1(0.9) (95 per cent c.i. 27.2 to
31.1) per cent (P < 0.001) (Tables 2 and 3; Figure 3).
Angiostatin  As shown in Tables 2 and 3, and in Figure 3, high-dose treatment (n = 5)
resulted in a mean(s.e.m.) HRA of 8.6(2.6) (95 per cent c.i. 1.4 to 15.8) per cent (P <
0.001). Low-dose angiostatin (n = 10) resulted in a HRA of 27.2(1.0) (95 per cent c.i.
25.0 to 29.4) per cent (P < 0.001). The addition of high- and low-dose angiostatin to
the conventional chemotherapy improved antitumor efficacy, resulting in HRAs of
3.3(1.4) (95 per cent c.i. 1.1 to 7.6) and 8.7(0.7) (95 per cent c.i. 7.1 to 10.2) per cent
respectively. High-dose angiostatin added to conventional chemotherapy was not
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Figure 3. Results of tumor hepatic replacement area (HRA).
Each treatment group on day 12 after C26 intrasplenic tumor injection to induce liver
metastases. PBS, phosphate-buffered saline
Hepatic replacement area (%)
No chemotherapy Chemotherapy
Controls 42.3(2.0) 29.1(0.9)
High-dose angiostatin 8.6 (2.6) 3.3(1.4)
Low-dose angiostatin 27.2(1.0) 8.7(0.7)
Endostatin 12.4(1.4) 3.8(1.1)
Citrate 42.1(5.9)
Table 2. Tumor hepatic replacement area 
Per treatment group on day 12 after C26 intrasplenic tumor injection to induce liver metastases.
Values are mean ± SEM
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Agents P*
Controls versus all agents < 0.001
Citrate versus endostatin 0.001
Citrate versus endostatin + chemotherapy < 0.001
Chemotherapy versus high-dose angiostatin + < 0.001
chemotherapy
Chemotherapy versus low-dose angiostatin + < 0.001
chemotherapy
Chemotherapy versus endostatin + chemotherapy < 0.001
High-dose angiostatin versus high-dose angiostatin + 0.135
chemotherapy
Low-dose angiostatin versus low-dose angiostatin + < 0.001
chemotherapy
Endostatin versus endostatin + chemotherapy 0.001
Table 3. Statistical analysis of hepatic replacement area per treatment group on day 12 after C26
intrasplenic tumor injection to induce liver metastases
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Figure 4. Results of the univariate analysis of variance. 
Calculation of the interaction effect of low-dose angiostatin (10 mg per kg per day, continuously)
in combination with conventional chemotherapy (doxorubicin). The solid line represents the
effect of chemotherapy alone on the hepatic tumor load (hepatic replacement area; HRA) and the
dashed line shows the effect of low-dose angiostatin in combination with chemotherapy on the
HRA. The multiplicative effect of the combination was significant (P = 0.029, univariate analysis
of variance).
significantly more effective than high-dose angiostatin monotherapy (P = 0.135).
However, low-dose angiostatin combined with conventional chemotherapy significantly
enhanced antitumor efficacy when compared with low- dose angiostatin alone (P <
0.001). When compared with chemotherapy alone, the effect of addition of angiostatin
to chemotherapy was multiplicative for both high-dose (P = 0.047) and low-dose (P =
0.029) angiostatin, as shown in Figure 4. The effect of the addition of low-dose angio-
statin to chemotherapy on the relative HRA was also multiplicative (P < 0.001).
Endostatin  Endostatin monotherapy resulted in a mean(s.e.m.) HRA of 12.4(1.4) (95
per cent c.i. 9.1 to 15.7) per cent (P < 0´001) (Tables 2 and 3; Figure 3). Addition to
the conventional chemotherapy regimen further reduced the hepatic tumor load to a
HRA of 3.8(1.1) (95 per cent c.i. 0.7 to 6.9) per cent (P < 0.001). Again, co-
administration of the antiangiogenic agent and conventional chemotherapy was multi-
plicative with regard to the effect on the relative HRA (P = 0.017).
*Independent t test with Bonferroni correction
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Discussion
In this murine model of early colorectal liver metastases, the addition of angio-
statin or endostatin to a conventional chemotherapeutic agent improved antitumor
efficacy compared to chemotherapy alone. These results support the concept that
combined cytotoxic and antiangiogenic therapy may improve results in the treatment
of microscopic colorectal liver metastases. Compared with monotherapy chemo-
therapeutic regimens, the antitumor effect of combined chemotherapeutic and anti-
angiogenic agents was multiplicative (Fig. 4); the combination was more effective than
the sum of effects of either monotherapies, suggesting synergy between the agents.
Thus, the rationale of the combination strategy, i.e. targeting two separate cell
populations (tumor cells and endothelial cells), is supported by this study. In
apparent contrast to these findings, some authors have speculated that treatment
targeting the vasculature (vascular endothelial growth factor) could hamper other
blood-borne therapeutic agents from reaching tumor cells.29,30 A combination of tumor
necrosis factor alpha and melphalan, however, was shown to generate a higher intra-
tumoral concentration of the cytotoxic agent than chemotherapy alone.31 Recently,
Jain32 suggested that antiangiogenic therapy may lead to `normalization' of tumor
vasculature before its destruction. The effect of chemotherapy during the normali-
zation phase might be enhanced, rather than being inhibited at a later stage once
vasculature has been destroyed. Another advantage of combination strategies might
be a dose reduction of the individual drugs involved, without impairing antitumor
efficacy. Based on experimental data, antiangiogenic agents are believed generally to
be safe, although some caution should be exercised, because the authors' group
recently showed that angiostatin, administered in a high dose immediately after
primary colonic anastomosis, results in impaired healing.33 In the present experimental
study, treatment with low-dose angiostatin combined with relatively low doses of
conventional chemotherapy was effective, and the mice displayed only minor toxicity
throughout the treatment period. Antiangiogenic scheduling of treatment by lowering
the dose with increased frequency of administration, has also proved effective.34
This study employed an experimental model that resembles the most suitable
patient category (`early' metastatic disease). This is important because most angio-
genesis inhibitors that are currently in clinical trials are being administered to patients
with bulky end-stage tumors. This is also true for the combination strategies currently
under study.35 Only a few trials are evaluating the efficacy of the combination of
antiangiogenic and chemotherapeutic agents in an adjuvant setting.15,35 Based on the
action of ant angiogenic therapy, i.e. preventing outgrowth of microscopic tumor
deposits, few or no antitumor effects may be anticipated in bulky disease, and the
selection of suitable patient categories is required before efficacy can be established.
Although doxorubicin is not used conventionally in the treatment of human colorectal
cancer, there is a large body of literature confirming the biological relevance of this
murine model for colorectal metastatic disease26,36. The results of the present study on
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experimental early colorectal liver metastases indicate that antiangiogenic therapy
may be highly attractive for perioperative treatment schedules. Future clinical studies
evaluating the effectiveness of combination strategies should be undertaken in a
perioperative setting so that assessement can be made of antiangiogenic agents in
multidrug therapy of patients with `early' metastatic or `minimal residual' disease.
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Abstract
Endostatin (rh-E), a carboxyterminal fragment of collagen XVIII potently inhibits
angiogenesis and tumor growth, presumably through induction of apoptosis in
endothelial cells and/or inhibition of their migration. Here we show that the anti-
tumor activity of endostatin in a liver metastasis model of colorectal cancer cells
depends on the time of its administration. 
First, 500 µg/day rh-E was administered on different time-points to mice before
and/or after intrasplenic injection of C26 coloncarcinoma cells metastasizing to the
liver. Hepatic tumor volume replacement (HRA) was assessed on day 12 (n=24).
Quantitative analysis (t=15 and t=60 min) of intrahepatic fluorescent C26 cells by use
of in vivo microscopy (IVM) (n=20), as well as [125I]iododeoxyuridine-labeled C26 cells
(n=40) was performed, following rh-E treatment of the mice 2 hours before tumor cell
injection. In vitro, the effects of 100/200/400 µg/ml rh-E on C26 cell death and
migration, and effects of 2-hour pre-incubation with rh-E on the adhesion of C26
tumor cells to TNF-alpha stimulated HUVEC’s under flow conditions (n=15) were
assessed. 
rh-E was most effective when administered early, even if rh-E was only continued
until day 4 (HRA on day 12 was 15 ± 3.5 %, vs. 60 ± 2.9. in the controls, p=0.001).
Rh-E did not inhibit tumor growth when administered later than 4 days after tumor
injection. IVM and radioactive tumor cell labeling experiments revealed that the effect
of endostatin-pretreatment was mainly due to inhibition of tumor cell arrest in the
liver (IVM: 3.2 ± 0.5 cells / high power field vs. 7.3 ± 0.6 / high power field in the
citrate-controls, p<0.001; [125I]iododeoxyuridine-labeled C26 cells 34.4 ± 5.6 % vs.
57.44 ± 2.5 % in controls, p=0.001). These results are supported by in vitro perfusion
experiments showing that endostatin induced a two fold decrease of tumor cell
adhesion to endothelial cells under flow conditions (103 ± 18 vs. 180 ± 15 adhered
cells/mm2, p=0.007). 
Our results show that endostatin, in addition to its effects on the developing
tumor vasculature, also affects tumor cell adhesion in the very early phases of
metastasis formation. Possible mechanisms include inhibition of integrin dependent
adhesion of tumor cells to endothelial cells, in addition to inhibition of angiogenesis.
These data can be helpful in the design of trials to augment surgical treatment of
colorectal carcinoma and liver metastases. 
Introduction
Anti-angiogenic drugs are directed against components of the developing vascu-
lature. Based on the working mechanism of these drugs, i.e. preventing outgrowth of
microscopic tumor deposits, little or no anti-tumor effects might be anticipated in
gross or bulky (metastatic) disease.  In the case of established (unresectable) tumors,
treatment with anti-angiogenic agents will -at best- lead to disease stabilization,
rather than to complete tumor remission. Furthermore, discontinuation of therapy will
allow the tumor or its metastases to resume their outgrowth.1 Taken together, initi-
ation of the treatment already during the initial phase of tumor growth can be
essential in optimizing anti-angiogenic therapy.
Endostatin, a naturally occuring fragment of collagen XVIII, is one of the most
effective inhibitors of angiogenesis and dramatically reduced tumor growth in several
mouse models with no serious side effects observed.1-3 However, endostatin was
ineffective in other studies, and these data have prompted the discussion about the
efficacy of endostatin4. In a previous report by our group, endostatin resulted in signi-
ficant anti-tumor effects in a model of murine colorectal liver.5 These effects, as
measured 12 days following tumor cell injection by histology, were achieved with
administration of endostatin from day 0 until day 12. Others found that the efficacy of
endostatin improved when administered before tumor cell injection, as measured by
tumor load 21 days following tumor cell injection.6 In a pilot study, we have observed
different biological activities of endostatin that depended on the timing of its
administration. We were not able to show regression of already established colorectal
liver metastases when endostatin treatment was initiated 7 days after tumor cell
injection.
The ability to optimize the timing of endostatin administration will largely depend
on its working mechanism. So far, endostatin is known to have anti-angiogenic
properties, i.e. its anti-tumor effects depend on inhibition of developing tumor vascu-
lature. This action has predominantly been ascribed to inhibition of apoptosis and
–migration of endothelial cells.7,8 Many studies point towards an effect of endostatin
on the adhesion of endothelial cells to other endothelial cells9: These inhibitory effects
may be mediated by direct blocking of specific integrins10,11, by disassembly of focal
adhesions and actin stress fibers12, and/or by antagonizing the Wnt pathway13. Based
on these studies we hypothesized that (anti-adhesive) anti-tumor properties of
endostatin could play a role even shortly after administration, before new vessel
formation is needed for progression of malignancy. 
In this study, we have investigated the influence of endostatin on the early spatio-
temporal fate of murine colon carcinoma cells metastasizing to the liver. We show
that 2-hr pretreatment in vivo with rh-E resulted in reduced intrahepatic tumor growth,
mainly due to early (<15 minutes) inhibition of tumor cell seeding in the liver; and
induced a two fold decrease of tumor cell adhesion to endothelial cells under flow
conditions. 
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Materials and Methods
Endostatin.  Human recombinant endostatin was produced in Pichia pastoris (Courtesy
of Entremed, Rockville, USA). In mice, 500 µg was administered by daily subcuta-
neous (SC) injection of 100 µl. Control animals received the equal amount of solvent
citrate buffer (17 mM citric acid, 59 mM NaCl, 66 mM Na2PO4, pH 6.2). For the in
vitro experiments, three equivalent dosages of endostatin and its control were used,
i.e. 400 µg/ml, 200 µg/ml and 100 µg/ml.
Tumor Cell Culture. The murine colon carcinoma cell line C26 was routinely cultured in
dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % heat-inactivated
fetal calf serum (FCS), 100 units/ml penicillin and 100 microgram/ml streptomycin in a
10% C02 environment. Cell viability was determined by trypan blue staining. Confluent
cultures were harvested by brief trypsinization (0.05 trypsin in 0.02% EDTA), and
resuspended in Phosphate Buffered Saline (PBS) to a final concentration of 106 x 1.0
cells/ml (unless stated otherwise).
Endothelial cell Culture. Human vascular endothelial cells (HUVEC) were isolated from
human umbilical veins. Cells were cultured in endothelial basal medium (EBM)
containing EGM-2 medium (Clonetics, Bio Whitaker) supplemented with 5% FBS,
gentamicin, amphothericin B, hydrocortisone, ascorbic acid, and the following growth
factors: VEGF, bFGF, hEGF, and IGF-1. Cells of passage two were seeded on fibronectin
coated glass coverslips and grown until confluency. 
In vivo Liver Metastases Model.  Balb/C male mice, aged 10 weeks, purchased from
Harlan (Leicestershire, Great Britain), were housed under standard conditions and
allowed food and water ad libitum. Colorectal liver metastases were induced in all
mice as follows5. Mice were anaesthetized intraperitoneally with fentanyl citrate/flua-
isone (0.3 mg/mouse; Janssen-Cilag, Brussels, Belgium) and midazolamchloride (12.5
mg/mouse; Roche, Brussels, Belgium). Through a left lateral flank incision C26
colorectal carcinoma cells were injected into the spleen parenchyma. In case mice
were allowed to survive 24 hours, the spleen was removed after 10 minutes to avoid
intrasplenic tumor growth.  All experiments were performed in accordance with the
guidelines of the Animal Welfare Committee of the UMC Utrecht, The Netherlands.
Histological Analysis.  To determine the effects on tumor load of different schemes of
endostatin administration, mice (n=24) were randomly assigned to the following
experimental groups: endostatin treatment starting 2 hours before tumor cell
injection, 8 hours after tumor cell injection, 4 and 7 days after tumor cell injection.
The treatment was discontinued on day 4, day 12. Lower concentrations of tumor cells
were used for treatment groups until day 19 (105 x 1.0 /ml). For histological analysis
of tumor burden, the mice were sacrificed on day 7, day 12 or day 19 (n=3 per
group). The livers were harvested, formaldehyde fixed, and embedded in paraffin.
Intrahepatic tumor load was scored as the hepatic replacement area (HRA), the
percentage of hepatic tissue having been taken up by metastatic tumor cells. HRA
was assessed on non-sequential haematoxylin and Eosin stained sections by semi-
automated stereology (Leica-Q-Prodit system, Leica Microsystems, Rijswijk, The
Netherlands) using a four points grid overlaid on 100 fields per slide at a magnifi-
cation of 40x. 
Intrahepatic Detection of Radiolabeled Tumor Cells.  To determine the spatiotemporal
fate of tumor cells metastasizing to the liver we used radiolabeled tumor cells. To
prepare labeled cells for intrasplenic injection, C26 tumor cells were co-cultured with 1
mCi/ml [125I] iododeoxyuridine (Amersham Biosciences, Weert, the Netherlands) in
DMEM containing 5% FCS for 72 hours at 37°C in 10% CO2 environment. The cells
were washed in PBS, detached with trypsin-EDTA, washed with serum-containing
media and twice with PBS and resuspended to a final concentration of 106 x 5.3
cells/ml in PBS.
Intrasplenic injection of [125I] iododeoxyuridine-labeled tumor cells was followed by
hepatectomy at t=15 minutes and t=1 hour, respectively (n=5 per group per time-
point per experiment).  The resected livers were rinsed in 70% ethanol. Radioisotope
levels were measured by a gamma counter and expressed as percentage of the input
dose (Cpma). The input dose was determined by measuring two 100-ml aliquots of
PBS containing [125I] iododeoxyuridine-labeled tumor cells in parallel with the liver
samples (100 %).
In Vivo Microscopy.  To examine the fate of tumor cells in the liver after intrasplenic
injection by in vivo microscopy, C26 cells were labeled with a fluorescent probe,
carboxyfluorescein succinyl ester (CFSE, Molecular Probes, Leiden, the Netherlands).
Tumor cells were incubated for 15 minutes at 37ºC with 20 mL of 4% CFSE in
phosphate buffered saline containing 0.1% bovine serum albumin (BSA). Cells were
centrifuged, resuspended in DMEM and incubated for 30 minutes at 37ºC. Cells were
then centrifuged and resuspended for intrasplenic injection. A fraction of tumor cells
was cultured in parallel to confirm fluorescence in 99% of the cells.
At 15 minutes and 1 hour after intrasplenic injection of C26 tumor cells intravital
fluorescence microscopy was performed using a Nikon TE-300 inverted microscope
(Uvikon, The Netherlands) equipped with a filter set for fluorescein (excitation 450-
490 nm, emission >515 nm.). Images were registered with a charge coupled device
camera (Exwave HAD, Sony, the Netherlands) and recorded with a s-VHS VCR
(Panasonic). Using a high magnification 40x lens, 10-15 randomly selected fields were
chosen in each animal (n=20 mice); images were recorded for one minute and were
analyzed off-line. At indicated time points, the extent of metastasis was measured as
number of tumor cells per high power field (hpf ). 
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Tumor Cell Migration Assay.  The C26 tumor cells were grown to 75-90% confluency.
After washing, the cells were trypsinized, pelleted and resuspended in DMEM / 0.1%
BSA. The cells were labeled in situ with 10 µM Calcein-AM in DMEM for 15 minutes at
37°C and subsequently added to 8 µm FALCON® HTS FluoroBlok™ Cell Culture Insert
(Becton, Dickinson and Company, Franklin Lakes, NJ, USA), at a density of 100.000
cells/insert. DMEM supplemented with 10% FCS was used as a chemoattractant in the
lower wells, while DMEM/0.1% BSA was added to the control wells. Different concen-
trations of endostatin (100mg/ml and 400mg/ml) or equal concentrations of control
buffer were added. The inserts were incubated for 15 minutes, 1 hour, 4 hours and 24
hours at 37°C. The number of migrated cells was measured using a PE Biosystems
CytoFluor 4000 plate reader at a gain setting of 54. 
Tumor Cell Death Assay. Tumor cells were exposed to different concentrations of
endostatin  (400 µg/ml, 200 µg/ml and 100 µg/ml) in culture medium for 24 hours.
The total pool of adherent and detached cells was obtained by collecting the
detached cells. The remaining adherent cells were trypsinized and added to the
detached cells in the medium. One half of the cells was stained with 0.02% Trypan
blue and the percentage dead (Trypan blue-positive) cells was assessed using a
Bürker glass counter chamber. Duplicate samples were analyzed. In addition, the other
half of the cells was fixed in the culture medium using 3.7% formaldehyde and
analyzed.
Tumor Cell Adhesion Assay under Flow Conditions.  The effects of endostatin on the
in vitro adhesion of C26 tumor cells to stimulated HUVEC’s were assessed under flow
conditions. The HUVEC’s were stimulated with TNF-alpha (PeproTech, London, England)
at a concentration of 10 Ng/ml for three hours before tumor cell perfusion. Two hours
before perfusion, the stimulated HUVEC’s were incubated with endostatin in a concen-
tration of 400 µg/ml, an equal concentration of BSA or citrate buffer only.  
First, the adhesion of C26 colon carcinoma cells (106 x 4.0 cells/ml, 1% FCS, 25mM
Hepes buffer) to endostatin (n=7) versus citrate buffer (n=8) treated TNF-alpha stimu-
lated HUVEC’s was investigated using a modified form of a transparent perfusion
chamber (14). Data from two independent experiments was pooled. The microchamber
has a slit height of 0.2 mm and width of 2 mm and contains a plug on which a
coverslip (18 mm x 18 mm) with confluent HUVEC was mounted.  C26 colon carcinoma
cells were aspirated from a reservoir through the perfusion chamber with a Harvard
syringe pump (Harvard Apparatus, South Natic, MA). In this way, the flow rate through
the chamber could be controlled precisely. The wall shear stress (t) was 50mPa.
During the perfusion, the flow chamber was mounted on a microscope stage (DM
RXE, Leica, Wetzlar, Germany), equipped with a B/W CCD-video camera (Sanyo, Osaka,
Japan) connected to a VHS video recorder. Perfusion experiments were recorded real-
time on videotape. Video images were analyzed off-line for the number of adherent
C26 colon carcinoma cells with a Quantimet 570C image-analysis system (Leica
Cambridge, Cambridge, UK). The number of surface-adherent C26 cells per mm2 was
measured after 5 minutes of perfusion at a minimum of 25 fields  (total surface 1.0
mm2) using custom made software developed in Optimas 6.1 (Media Cybernetics
Systems, Silverspring, MD, USA). 
Second, adhesion of C26 colon carcinoma cells to HUVEC was determined in
whole blood.15 The HUVEC’s were seeded on glass coverslips sized 60x24 mm and
grown to confluency. They were perfused in a small parallel-plate perfusion chamber
with a slit height of 0.1 mm and a slit width of 2 mm corresponding with flow rates
of 15 µL/min (shear rate 10s). Fresh blood from healthy donors was anticoagulated
with 1/10 volume of 150 U/mL Orgaran (a low molecular weight heparinoid [LMWH];
Organon, Oss, the Netherlands). Blood was prewarmed at 37°C for 10 minutes and
was then drawn through the perfusion chamber by a Harvard infusion pump (pump
22, model 2400-004;Natick, MA). Tumor cells (106 x 6.0 /ml) were incubated with 200
µg/ml dihydroethidium (3,8-Diamino-5,6-dihydro-5-ethyl-6-phenylphenanthridine 2,7-
Diamino-10-ethyl-9-phenyl-9,10-dihydrophenanthridine Hydroethidine, Sigma-Aldrich,
Inc). Aliquots of 15 ml tumor cells in 150 ml blood were used per perfusion. Real-time
images were recorded using a VCR system and were analyzed off-line and the number
of adhered tumor cells per mm2 confluent HUVEC layer was calculated. After perfusion,
full blood perfused coverslips were fixed in a mixture of 2% paraformaldehyde and
0.2% glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.4). Staining of cytoskeletal
actin was done by Phalloidin-TRITC. Hoechst 33342 was used for blue nuclear
staining, and anti-fibrinogen was stained green (primary antibody Rabbit anti-human
anti-Fibrinogen). The coverslips were mounted by fluorescence medium, FluorSaveTM
(Calbiochem 345789, La Jolla, CA, USA). The stained cover slips were analyzed using
Multi-photon laser scanning microscopy. 
Statistical analysis. For comparison of the endostatin treatment and the controls, the
independent sample t test was used. Data was given as mean ± SEM and was consi-
dered significant when p <0.05.
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Figure 1A. Hepatic replacement area (HRA) for all different treatment groups. To determine the
anti-tumor effects of different schemes of endostatin administration we examined the intra-
hepatic tumor load (i.e. HRA) after tumor cell injection in the spleen. Endostatin was most
effective when administered early, even if only continued until day 4 (as measured by hepatic
tumor volume replacement on day 12, 15 ± 3.5 %, vs. 60 ± 2.9. in the citrate buffer treated
controls, p=0.001). Endostatin did not inhibit tumor growth when administered later than 4
days after tumor injection.  Data is plotted as mean ± SEM. 
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Results
Histological Analysis of Liver Metastases.  Intra-hepatic arrest and outgrowth of circu-
lating tumor cells is a multi-step process. Mice were injected with C26 tumor cells in
the spleen to induce liver metastases and treated with endostatin at different time
points. After 12 days, livers were removed and analyzed for the extent of replacement
of liver tissue by tumor cells (HRA). On day 12, the HRA of the controls (buffer
treated) was 60 ± 2.9 (figure 1A). The HRA in mice that were treated with endostatin
from 2 hours prior to tumor cell injection until sacrifice was the lowest: 19 ± 2.1 %
(p<0.001). When treatment was started 2 hours before tumor cell injection and
replaced by citrate buffer from day 4 until day 12, the HRA was still significantly
decreased (15 ± 3.5 %, p=0.001).  When treatment was started 8 hours after tumor
cell injection and continued until day 12, there was a significant anti-tumor effect as
well (HRA 32 ± 3.4 %, p=0.002). However, initiation of the treatment on day 4 or
later after tumor cell injection did not result in anti-tumor efficacy as reflected by HRA
(36.7 ± 10.1 %, p=0.139). Treatment from day 7 until day 19 did not reduce tumor
load and resulted in a HRA of 38.3 ± 7.3 % vs. 41 ± 10 % in the citrate buffer treated
controls (p=0.8) (figure 1A and 1B.).  Intrahepatic Detection of Radiolabeled Tumor Cells.  The above results suggest that
endostatin acts at a very early stage of metastasis formation. To investigate the initial
arrest of circulating C26 tumor cells in the liver of endostatin-pretreated mice, we
measured radiolabeled tumor cells after injection into the spleen. Livers were
collected at 15 and 60 minutes after tumor cell injection and the radioactivity was
subsequently determined. Data from two independent experiments was pooled. Fifty
percent of the intrasplenic injected tumor cells was arrested in the liver during the
first 15 minutes, as measured by radioactivity. Endostatin pre-treatment reduced the
percentage of injected dose in the liver to 34.4 ± 5.6 % at 15 minutes after tumor cell
injection vs. 57.4 ± 2.5 % in the controls (figure 2, p=0.001). ). When radiolabeled
cells in the liver were measured after 1 hour, these percentages had not significantly
changed (54.8 ± 3.2 % vs. 37.6 ± 5.2 %).
In Vivo Microscopy.  Initial tumor cell arrest in the liver was studied in more detail by
in vivo microscopy. C26 tumor cells were fluorescently labeled with calcein and
injected into the spleens of recipient mice. Tumor cells reaching the liver were easily
discernable from the hepatic tissue (figure 3). Two independent experiments were
pooled (n=20). Fifteen minutes after injection of tumor cells into the spleen, the
control mice showed a mean of 7.3 ± 0.6 fluorescent tumor cells per high power field
(figure 3A) whereas in the mice that were treated with endostatin 2 hours prior to
injection less arrested intrahepatic cells (3.2 ± 0.5 cells / hpf ) were counted
(p<0.001)(figure 3B.). When images were made one hour after tumor cell injection, this
reduction was unchanged (endostatin treated livers 2.7 ± 0.3 arrested cells / hpf vs.
controls 7.4 ± 0.7 cells /hpf, p<0.001). No differences were observed within either
Figure 1B. (see color appendix)
Effects of endostatin on already established tumors in the liver, measured by histological
hepatic replacement area (HRA) (H&E staining). Fig. 1B-a shows three small intrahepatic tumor
lesions (dark nodules) 7 days after intrasplenic injection of tumor cells. Fig. 1B-b. Tumor-bearing
livers 19 days after tumor cell injection. Endostatin was administered daily from day 7-day 19.
The tumors continued to grow under endostatin treatment. Fig 1B-c. No significant anti-tumor
effect was achieved as compared with the citrate buffer treated control (HRA 38.3 ± 7.3 % vs.
41 ± 10 %, p=0.8).
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treatment group between the two time-points 15 minutes and 1 hour after tumor cell
injection (controls 15 minutes vs. 1 hour p=0.93; endostatin 15 minutes vs. 1 hour
p=0.39). 
Tumor Cell Assay.  Significant Calcein-AM labeled C26 chemotaxis was not detected
until 2 hours of incubation. The migration of endostatin-treated as compared to the
control tumor cells was similar at all time-points measured. At the time of maximal
migration -at 4 hours- the lowest concentration endostatin resulted in a fluorescent
signal of the migrated cells of 6165 ± 926 vs. 5620 ± 765 in the controls (p=0.6). The
highest concentration of endostatin did not influence the migration of tumor cells
either (5562 ± 1018 vs. 5268 ± 623 in the controls, p=0.8). There was no direct effect
of endostatin on cell death of C26 murine colon carcinoma cells (data not shown). 
Tumor Cell Adhesion Assay under Flow Conditions.  Since endostatin treatment
decreased early intrahepatic tumor cell arrest and did not directly influence tumor cell
death or migration, we investigated tumor cell- endothelial cell interactions.
Fluorescent-labeled tumor cells were perfused over a confluent layer of endothelial
cells. Two hours pre-treatment with endostatin of stimulated HUVEC led to a more
Figure 3A. (see color appendix)
Intravital microscopy images recorded 15 minutes after injection of fluorescent tumor cells into
the spleen of (a) Control liver and (b) liver after 2 hour endostatin pre-treatment. The control
mice showed a mean of 7.3 ± 0.6 fluorescent tumor cells per high power field whereas mice
treated with endostatin 2 hours prior to injection showed a lower number of arrested
fluorescent cells in the liver (3.2 ± 0.5 cells / per high power field, p<0.001).
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Figure 3B.
Number of fluorescent tumor cells that are present in the liver per high power field as measured
by intravital microscopy 15 minutes and 1 hour after intrasplenic injection. No differences were
observed within either treatment group between the two time-points (controls 15 minutes vs. 1
hour p=0.93; endostatin 15 minutes vs. 1 hour p=0.39). 
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Figure 2.
Radioactive labeled tumor cells in the liver, 15 minutes and 1 hour after intrasplenic injection, as
measured by gamma counter and represented as percentage of injected (125I) iododeoxyuridine-
labeled tumor cells. Fifteen minutes after tumor cell injection in the spleen, the percentage of
injected dose in the liver was 34.4 ± 5.6 % in the mice that were treated with endostatin 2 hours
prior to tumor cell injection, vs. 57.4 ± 2.5 % in the controls (p=0.001). After 1 hour, these percen-
tages had not significantly changed.
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Discussion
Several mechanisms have been proposed that might explain the anti-angiogenic
activity of endostatin.7-13 However, it is unclear whether and to what extend these
activities contribute to early anti-angiogenic- and anti-metastatic effects. Undisturbed
early tumor cell metastasis is a multi-step process that requires both intravascular
arrest of tumor cells, as well as their adhesion to endothelial cells, followed by trans-
endothelial migration. All of these aforementioned steps -in theory- can be potential
targets by which early metastasis is inhibited. 
In this study we show that early treatment with endostatin enhanced anti-tumor
efficacy, in conjunction with an inhibition of the number of arrested tumor cells in the
liver, as soon as within 15 minutes after intra-splenic tumor cell injection. In vitro,
endostatin did neither affect the migration nor cause cell death of the tumor cells.
There was, however, a strong inhibitory effect of endostatin pre-treatment on the
adhesion of tumor cells to endothelial cells under flow conditions. This data cannot
be explained by classical "anti-angiogenesis". Therefore, our studies provide evidence
for a novel working mechanism of endostatin, in addition to direct effects on angioge-
nesis and endothelial cells.   
In vitro experiments mainly focused on endostatin and endothelial cell-cell
adhesion revealed an integrin dependent interaction.10,11 Possibly our findings demon-
strating that endostatin inhibits adhesion of tumor cells to endothelial cells and
diminishes intra-hepatic tumor cell arrest are integrin mediated. This explanation is
supported by the findings of Rehn et al10, who demonstrated that endostatin interacts
with a5β1, avβ3, and avβ5 integrins on the surface of HUVEC. Others found that
endostatin activity is mediated by an integrin dependent inhibition of adhesion of
endothelial cells to collagen I.11 Interestingly, in a study on the mapping of endostatin
binding sites in intact human tissues, endostatin was predominantly found to bind to
blood vessels.16 Inhibitory effects of tumor cell adhesion to HUVEC by endostatin are
not likely to be explained by a direct effect of endostatin on TNF-alpha up-regulation,
since this pathway was observed not to be influenced by endostatin17.
Furthermore, the ability of endostatin to bind to the proteoglycan heparin2 points
to a possible involvement of heparin sulfate proteoglycans (HSPG’s) in endostatin
activity. HSPG’s are expressed on the cell surface or present in the extracellular matrix
(ECM) and mediate the adhesion of cells to other cells or ECM.18,19 Indeed, heparin and
heparan sulphate can inhibit experimental tumor metastasis (reviewed in20).  
On the other hand, one can not rule out that alternative steps to adhesion could
be of importance in early metastasis. Intra-vascular tumor cell arrest, through direct
interactions of tumor cells with components of the blood, can mediate dissemination.
Tumor cell arrest can be affected by fibrin deposition21, as well as platelets-tumor cell
interaction22.  We could speculate that the binding of platelets to the tumor cells is
inhibited, possibly mediated by integrins as well. The relative contribution of fibri-
nogen-, platelet- and endothelial cell-mediated interactions with tumor cells will have
Figure 4. (see color appendix)
Immunohistochemistry and multi-photon laser scanning microscopy visualized tumor cell
adhesion to HUVEC. After perfusion with tumor cells in full blood, the coverslips were fixed and
stained. The number of adhered tumor cells to cover slips of stimulated HUVEC after two hours
pre-treatment with endostatin (b) was less than to those pre-treated with citrate buffer control
(a). Platelets are indicated by arrows, the green colors represent anti-fibrinogen.
than two-fold decrease of tumor cell adhesion under flow conditions (103 ± 18
adhered cells/mm2) as compared to pre-treatment with control buffer (180 ± 15
adhered cells/mm2, p=0.007). Shear forces did not induce rolling of the C26 cells, but
rather a direct tethering, followed by firm tumor cell adhesion under both control and
endostatin conditions. BSA did not inhibit adhesion of tumor cells to HUVEC (data not
shown). In concordance, after perfusion with full blood, the adhesion of C26 cells to
HUVEC was inhibited with endostatin pre-treatment (143 ± 20 adhered cells/mm2) vs.
controls (239 ± 41 adhered cells/mm2)(p=0.0231). Multi Photon Laser Scanning
Microscopy visualized the adhesion of tumor cells to endothelial cells (figure 4). 
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to be elucidated, in in vivo experiments using mice that lack components of the fybri-
nolytic system.
As in a previous study, we found that endostatin is effective against colorectal
liver metastases.5 Solaun et al. showed that the antiangiogenic mechanism (i.e.
endothelial cell apoptosis) was selective for sinusoidal-type metastases, in which the
neovasculature originating from sinusoidal endothelium cells was targeted by
endostatin.6 Differences in the tumor’s microenvironment are known to determine anti-
tumor efficacy of the treatment.23,24 The precursor of endostatin, the long form of
collagen XVIII, is almost exclusively found in the liver25 and mainly expressed by
hepatocytes26,27. Continuous capillaries contain both XV and XVIII collagen, but
fenestrated capillaries (e.g. liver sinusoids, glomeruli, lung alveoli, and splenic
sinusoids) express only type XVIII.28 In our hands, endostatin had no effect on subcu-
taneous tumors (data not shown). We could speculate that this is mediated by
dominant negative competition with its precursor. Such insights on organ-specificity
might be useful in the design of future clinical trials. Furthermore, since we found
optimal anti-tumor effects even as early as within 15 minutes after intrasplenic tumor
cell injection, endostatin prophylaxis might prove very promising to augment surgical
treatment of colorectal carcinoma and liver metastases. Even in no-touch surgery,
preventing metastatic seeding and combined with mesenterical vessel ligation, 12.5%
of patients have detectable tumor spill in the circulation.29 Overall, as many as 75% of
colorectal cancer patients develop liver metastases.30 Others also found that the
efficacy of endostatin improved when administered before tumor cell injection, as
measured by tumor load 21 days following tumor cell injection.6 Bergers et al. corres-
pondingly showed that endostatin, amongst others, was capable of treating early
stages of cancer.31 In vitro studies provide evidence to support an early effect of
endostatin: disassembly of focal adhesions and actin stress fibers in endothelial cells
in vitro was described to be already visible 1 hour after endostatin administration.12 In
addition, early response genes responsible for cell-matrix interactions were down-
regulated rapidly after endostatin treatment.32 
In conclusion, 2-hr pretreatment in vivo with endostatin inhibits intra-hepatic
tumor growth, mainly due to early (<15 minutes) inhibition of tumor cell seeding in
the liver. It also induces a two fold decrease of tumor cell adhesion to endothelial
cells under flow conditions. This appears a novel working mechanism of endostatin,
non-angiogenesis related, possibly mediated by integrin dependent adhesion of tumor
cells to endothelial cells. These data can be helpful in the design of trials to augment
surgical treatment of colorectal carcinoma and liver metastases. 
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Anti-angiogenic agents are promising new drugs in the fight against cancer. They
might improve anti-tumor efficacy of current treatment in patients with (disseminated)
colorectal cancer. Keeping in mind it is a highly idealistic prospective, optimization of
therapy requires rationale and knowledge of 1) selection of suitable patients with 2)
sensitive tumor types, 3) the mechanistic background of the drug(s) used, 4) the
appropriate timing of administration, and 5) a safe combination with surgery. To
understand the interactions of anti-angiogenic agents and surgery, we have studied
the effects of surgery on angiogenesis in tumor growth and during wound healing. 
Antiangiogenic cancer therapy is likely to be administered long term for sustained
suppression of tumor outgrowth. Surgeons will encounter more patients undergoing
such therapy. Therefore, it is essential to know the effects of antiangiogenic agents on
physiological angiogenesis, as occurs during the healing of colonic anastomoses. As
shown in chapter 3, angiostatin impairs anastomotic healing in mice. Histological
examination revealed a decreased number of newly formed vessels in the wound and
abundant granulation tissue as a result of the impaired healing (chapter 4). However,
on discontinuation of antiangiogenic therapy, normal anastomotic healing is promptly
restored.
Plasmin and other components of the plasminogen activation system play an
important role in tissue repair by regulating extracellular matrix remodeling, including
fibrin degradation. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a procarboxy-
peptidase that, after activation, can attenuate plasmin-mediated fibrin degradation by
removing C-terminal lysine residues from fibrin. These C-terminal lysines play a role in
the binding and activation of plasminogen. To test the hypothesis that TAFI is an
important determinant in the control of tissue repair we investigated the effect of TAFI
deficiency on the healing of cutaneous wounds and colonic anastomoses in chapter 5.
Histological examination revealed inappropriate organization of skin wound closure in
the TAFI knockout mice, including an altered pattern of epithelial migration. The time
required to overall heal the cutaneous wounds was slightly delayed in TAFI deficient
mice. Healing of colonic anastomoses was also impaired, as was reflected by a
decreased strength of the tissue at the site of the suture as well as by bleeding
complications in 3 out of 14 animals. Together, these abnormalities resulted in
increased mortality in TAFI deficient mice after colonic anastomoses. Although our
study shows that tissue repair, including re-epithelialization and scar formation, can
ultimately proceed in some TAFI deficient mice, TAFI appears to be important for
appropriate organization of the healing process.
Surgical treatment of colorectal liver metastases (CLM) is becoming increasingly
important. Routinely, temporary occlusion of the inflow of the liver by clamping of the
portal triad, i.e. Pringle maneuver (PM), is predominantly used to reduce intra-
operative blood loss. In case of local destruction of liver metastases by
Radiofrequency Ablation (RFA) the additive purpose of PM is an increase in destructed
tumor volume, resulting in larger lesions. In chapter 6, we hypothesized that PM
unfavorably affects the prognosis of cancer patients, by inducing temporary hypoxia
with upregulation of Hypoxia Inducible Factor-1alpha (HIF1a), increase in Vascular
Endothelial Growth Factor (VEGF) levels, and subsequent angiogenesis and growth of
residual tumor. We evaluated the effects of PM on 1) tumor recurrence in patients
following resection of CLM; 2) intrahepatic HIF1a expression and systemic VEGF-levels
in patients undergoing RFA, and 3) outgrowth of experimental CLM.
Vascular clamping of the liver’s inflow during hepatic surgery for CLM is associated
with increased expression of HIF1a and VEGF, increased residual tumor growth and
decreased survival. Therefore, Pringle maneuver should be avoided whenever
possible. Experimental studies on therapeutical application of VEGF-antibodies or
receptor-blockers perioperatively whenever Pringle maneuver is inevitable are
indicated.
In our study we show that new drugs directed against tumor vasculature (anti-
angiogenic therapy) provide us with promising combination strategies in the fight
against cancer. The currently available treatment for intestinal cancer that has spread
to the liver consists of surgery and is restricted to selected patients only.
Chemotherapy is used a.o. to increase the number of patients eligible for resection.
Strategies that target both tumor cells and vasculature have not been investigated in
models of early metastatic colorectal disease. The efficacy of a combination of
conventional chemotherapy with a potent angiogenesis inhibitor (endostatin or angio-
statin) in a murine model of early colorectal liver metastasis was studied in chapter 7.
We descibed that after twelve days of treatment, the liver metastases were signifi-
cantly decreased in the mice that had received combination strategies. The addition
of angiostatin or endostatin to conventional chemotherapy enhanced anti-tumoral
efficacy in a murine model of early colorectal liver metastasis. Since this is an experi-
mental study, the outcome of the combination of anti-angiogenic therapy with surgery
and conventional chemotherapy in upcoming clinical trials in patients must be
awaited.
Endostatin (rh-E), a carboxyterminal fragment of collagen XVIII, potently inhibits
angiogenesis and tumor growth, presumably through induction of apoptosis in
endothelial cells and/or inhibition of their migration. Inhibitory effects on endothelial
cell adhesion play a role in this context. Reports on the in vivo effects of rh-E,
however, have been contradictory. As we describe in chapter 8, we have observed
different biological activities of rh-E depending on the timing of administration.
Consequently, we hypothesized that part of the in vivo tumor inhibition of rh-E takes
place during the initial phase of metastasizing, by inhibiting tumor cell arrest in the
Chapter 10
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liver and tumor-endothelial cell interaction. Two-hr pretreatment of mice or HUVEC
with rh-E enhanced anti-tumor efficacy; resulted in early (<15 minutes) effects on
tumor cell arrest in the liver; and induced a two fold decrease of tumor cell adhesion
to stimulated HUVEC’s under flow conditions. Possible mechanisms include inhibition
of integrin dependent adhesion of tumor cells to endothelial cells or hampered intra-
vascular arrest, in addition to anti-angiogenesis. Potential clinical application might be
endostatin prophylaxis in preventing microscopic metastasis in patients subjected to
surgery for colorectal carcinoma. 
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Administration of anti-angiogenic agents in a safe combination with surgery might
improve anti-tumor efficacy of (disseminated) colorectal cancer. We have investigated
whether the antiangiogenic agent angiostatin affects physiological angiogenesis, in
addition to the already known effects on tumor endothelium. Since surgeons will
encounter more patients undergoing such therapy, knowledge about the effects of
anti-angiogenic therapy on physiological angiogenesis in wound healing is essential.
No data existed on angiostatin in wound-healing assays. It was assumed that it would
specifically affect activated, proliferating, and migrating endothelial cells and thus
would lack any major side effects during treatment. Indeed, endostatin, another
strong inhibitor of angiogenesis, was reported to have no adverse effects on physiolo-
gical angiogenesis in cutaneous wound healing1,2. In mice, Bloch et.al. observed
reduced connective tissue density in early and late wounds. They concluded that
endostatin treatment even improved the quality of the healed wound. According to
the authors an indirect effect based on the reduced number of functional blood
vessels, supposedly caused these effects. Furthermore, the authors suggested that the
large number of newly formed functional vessels in the wound is not required for
healing under normal circumstances and that endostatin administration might be safe
to combine with surgery. However, these wounds were created in cutaneous tissue. In
contrast to the healing of cutaneous wounds, we considered the healing of colonic
anastomoses far more dependent on angiogenesis and less dependent on diffusion of
oxygen through pre-existing vasculature. Thus, our model could be more sensitive to
angiogenesis-directed interventions compared with cutaneous wound healing. Indeed,
short-term administration of two mildly angiosuppressive agents seem to suggest
possible adverse effects during the early phase of wound healing3,4 This healing of
colonic anastomoses therefore served as a model for physiologically critical angioge-
nesis in chapter 35. Strong evidence is provided here that angiostatin impairs anasto-
motic healing in mice when administered continuously during the phase of postoper-
ative repair. Although the exact working mechanism of angiostatin has not been eluci-
dated, it was recently shown to have a direct effect on endothelial cells.6 Our
immunohistochemical evaluation in chapter 4 showed a reduction in the number of
newly formed vessels in the granulation tissue surrounding the anastomotic line. On
the basis of this data, we speculate that the formation of new vessels at the site of
the anastomosis is impaired by angiostatin. This in turn may lead to a decrease in
delivery of oxygen and nutrients to the healing colon. The adverse effects of angio-
statin on physiological angiogenesis suggest mutual underlying mechanisms for
tumor-induced and physiological angiogenesis. This assumption is supported by the
knowledge that many other factors involved in angiogenesis, such as vascular
endothelial growth factor, do indeed affect both physiological and pathologic angioge-
nesis.7 We could speculate that the anti-tumor effect and the effects on physiological
angiogenesis of angiostatin are both mediated through a direct effect on endothelial
cells.
Angiostatin did not impose toxicity on any organ besides the anastomosis.
However, mice with peritoneal leakage were severely ill, and consequently their skin
wounds (laparotomy scar) showed impaired healing as well. Although we did not
study cutaneous wound healing under angiostatin treatment, we do feel that
administration of anti-angiogenic agents to patients following major surgery (colonic
anastomosis) should be done with caution.
In addition, in chapter 5 we showed that mice lacking TAFI have impaired wound
healing in two different models of tissue repair. End-to-end anastomosis of the
ascending colon in those mice resulted in a decreased strength of the anastomosis
upon sacrifice at day seven postoperatively as compared with the wild-type controls.
Cutaneous wound healing was different in TAFI deficient mice as well. It appeared that
re-epithelialization by keratinocytes in TAFI-/- mice is delayed and furthermore did not
follow the normal pattern of migration. In normal secondary wound healing keratino-
cytes migrate from one wound edge towards the opposing edge. For undisturbed
migration the cells need contact with intact ECM over which they migrate.8 However,
in TAFI -/- mice the direction of keratinocyte migration was mostly directed down into
the dermal layer, indicating a disruption of functioning ECM. Nevertheless, in both
control and TAFI-/- mice cutaneous wound closure had ultimately been completed in
all mice within 15 days. Interestingly, fibrinogen deficient mice showed a remarkably
similar pattern of cutaneous wound healing9 as compared with the TAFI deficient mice
described in chapter 5. Another remarkable result of our study, was that at autopsy a
mesenterial thrombosis was suspected in combination with diffuse bleeding from
inflicted littermate’s bites. These findings were in critically ill mice with impaired
colonic healing, colonic dehiscence and subsequent peritoneal leakage This clinical
manifestation in the TAFI deficient mice could very well be a result of diffuse intravas-
cular coagulation (DIC).  In concordance with the phenotype described by others10,
mice in whom components of the fibrinolytic system are disrupted, e.g. antiplasmin 11,
PAI-112, and PAI-213, had normal bleeding phenotypes. Probably, the coagulation system
adequately functions under circumstances where the fibrinolytic system is not dramati-
cally challenged. The suspected DIC in the TAFI deficient mice after impaired colonic
anastomotic healing might be a result of a critically challenged fibrinolytic system,
where other mechanisms insufficiently compensate for the lack of TAFI.
Proper control of proteolytic degradation of the ECM and ECM remodeling is
necessary for secondary wound healing as well as anastomotic healing. Based on the
impaired healing in mice lacking TAFI and the observed alteration in keratinocyte
migration we could speculate that TAFI might be a player in this delicately regulated
process. Further studies should address the molecular and cellular mechanisms that
lead to TAFI activation. A possibility is that TAFI may control angiogenesis, a key
process in many (patho) physiological processes, in which the fibrinolytic system
plays an important role.
When is it presumed safe to administer anti-angiogenic agents to patients peri-
operatively when they are subjected to major surgery? In an attempt to answer this
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question, we have examined the kinetics of the adverse effects of angiostatin on the
healing of colonic anastomoses (chapter 3). This was undertaken by administering the
agent before surgery and discontinuing the treatment on the same day as the surgical
procedure. Administration of angiostatin immediately before surgery had no negative
effect on the healing of the anastomoses. These results in mice suggest that surgical
patients who are treated with angiostatin can safely be operated on as soon as the
treatment is discontinued. Assuming that antiangiogenic treatment is used periopera-
tively in patients undergoing colonic resection, it should preferentially be discontinued
as briefly as possible, in an attempt to keep any metastatic tumor cell deposits in a
state of dormancy. Because levels of circulating endogenous antiangiogenic agents
produced by the primary tumor diminish after resection of the primary, this leads to
accelerated metastatic outgrowth6,14. Considering the short half-life of angiostatin (4 to
6 hours), one might speculate that brief discontinuation of angiostatin treatment and
resuming its administration shortly after anastomotic healing could circumvent the risk
of anastomotic leakage while still effectively suppressing metastatic outgrowth. 
Resuming administration "as soon as possible" implies that the surgeon should
wait until anastomotic integrity is restored. When will that be? In wound healing the
inflammation phase starts directly after wounding and continues until approximately
the seventh day. The angiogenesis takes place during the proliferation phase, which
begins with the appearance of fibroblasts. After 3 weeks the fibroblast and macro-
phages disappear, while remodeling and maturation of the ECM are the most predom-
inant features of the healing process. The mucosa of the colon is healed within
several days following anastomosis. The strength of the healed colon, however, is not
dependent on mucosal healing but dependent on submucosal healing with fibroblast
infiltration, ECM remodeling and smooth muscle cells8. In animal models, the strength
of the colon is restored approximately one week following anastomosis5,15. In
individual patients sub-clinical leakage can occur as late as two to three weeks after
surgery.  Moreover, it depends on the sort of agent used which process in the wound
healing is potentially influenced. In our study, angiostatin did not cause increased
endothelial cell apoptosis in mice at sacrifice one week after intestinal wounding
(chapter 4). MMP-inhibitors might affect the healing process even unto a much later
stage, since they are potentially influencing ECM remodeling in the maturation phase
of wound healing. In daily practice, for every individual patient, the surgeon will
decide on the postoperative clinical course when the anastomosis may be considered
clinically healed and administration of the anti-angiogenic agents can be safely
resumed. 
What about the administration of anti-angiogenic therapy during pregnancy and
embryogenesis? Similar to effects on wound healing, possible adverse effects on
embryogenesis should be excluded before pregnancy could even be considered in
disease-free patients undergoing prolonged exposure to anti-angiogenic agents.
Endothelial cells and the formation of vessel structures are important features in the
formation of chorionic villi in the development of a human placenta. As we showed by
immunohistochemistry, in the majority of early abortions, especially the vessel
formation was hampered, indicating a prerequisite for normal villous development.16
The relative safety of pregnancy in cancer patients receiving anti-angiogenic agents
will have to be investigated for every compound used and/or pathway intervened.
In the second part of this thesis, the interactions between surgery and angioge-
nesis is addressed. Surgery may cause selective tissue hypoxia, but it is not known
whether this hypoxia leads to subsequent tumor angiogenesis. 
Temporary occlusion of the liver’s inflow, i.e. Pringle maneuver, first described by
H. Pringle in the Annals of Surgery in 1909, is applied worldwide as a routine
procedure during liver surgery. It’s purpose is to reduce intraoperative blood loss
during hepatectomy and to increase lesion size during local ablation techniques by
preventing heat transport by the flowing of blood17-19. In chapter 6 we show that
Pringle maneuver is associated with increased metastatic recurrence and decreased
survival. Further, we provide evidence that this may well be due to "Pringle-induced"
hepatic hypoxia that results in upregulation of HIF-1α in different types of liver cells.
This could lead to the observed increase in plasma VEGF levels and outgrowth of
micrometastases through induction of angiogenesis. Based on these considerations
and results, we suggest that Pringle maneuver should be omitted in patients where it
is not obligatory. Also, we believe that it should be included as an independent
prognostic factor in the design of future clinical trials. In addition, this outcome
warrants a prospective study on this matter. 
On the other hand, prospective studies on the effects of Pringle maneuver to
increase lesion size during local ablation of liver tumors have recently opened for
accrual. Local ablative techniques are a relatively new surgical interventions that are
used to locally destroy (secondary colorectal) hepatic malignancies.20-25 These
techniques are restricted to those patients not eligible for standard surgical resection,
with metastases confined to the liver. On interim analysis these studies show an
increase in lesion size and a short-term decrease in local recurrence of the ablated
lesion (unpublished data).  Data on long-term effects on distant recurrence or intrahe-
patic new lesions as well as survival, however, is not available yet. In studies on the
effects of vascular occlusion on enhanced lesion size during local ablation, the contri-
bution of vascular occlusion of the hepatic artery was significantly less than the
effects of venous clamping.26,27 Some authors even claimed that the occlusion of the
artery alone did not significantly increase lesion size in rabbits.28 It might very well be
that the effects of vascular clamping on intrahepatic hypoxia are predominantly
caused by clamping of the hepatic artery instead of the portal vein. We would like to
emphasize that studies, experimental and/or clinical, on clamping of the hepatic artery
versus portal vein or both and intrahepatic hypoxia are indicated before Pringle
maneuver is implicated as a standard measure during local ablation of liver tumors to
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increase local control. We would like to postulate that Pringle maneuver used to
increase lesions during the local ablative techniques should exclusively be applied to
the portal vein. In this way, larger lesions are obtained, local recurrence controlled,
without long-term adverse effects of clamping on recurrence and survival. 
Although we provide the first firm evidence for the disadvantageous effects of
Pringle-induced hypoxia, other studies have reported indirect clues to support this. In
a retrospective study comparing various forms of vascular clamping, Buell et al found
the lowest rate of recurrence in patients undergoing hepatic resection for metastatic
cancer when no form of vascular clamping was applied.29 In ventricular biopsies from
patients with coronary ischemia, angiogenic factors such as HIF-1α and VEGF were
shown to be increased, as a first adaptation mechanism of human myocardium to
deprivation of blood.30 However, no correlation between (surgery-induced) hypoxia,
angiogenic growth factors and tumor growth has been described so far. It is tempting
to speculate that other surgical interventions that hamper oxygen distribution can
provide a similar physiologically relevant HIF-1α upregulation and subsequent pro-
angiogenic response. For instance, partial bladder outlet obstruction increased angio-
genic response in bladder tissue in rats.31 In addition, during pneumoperitoneum in
laparoscopic surgery a decrease in microcirculation in intra-abdominal tissues was
observed32-34, and the consequent hypoxia was a cofactor in adhesion formation32.
Experimental studies on surgery-induced hypoxia and subsequent HIF-1α upregulation
might be worthwhile to pursue.
We have shown an increase in HIF-1α in the major cell types in liver biopsies
taken after Pringle maneuver, as proven by immunohistochemistry. The elevated
plasma levels of VEGF are indicative of a direct effect of HIF-1α upregulation on VEGF
production. Although liver endothelial and Kupffer cells showed the most outspoken
HIF-1α upregulation, circulating platelets, activated as a result of the stasis induced
by Pringle maneuver, may also contribute to the VEGF release35. In mice, we found
systemic outgrowth of experimental micro-metastases, even though the plasma VEGF
levels in patients were only elevated for several hours. HIF-1α was shown to prolong
the half-life of VEGF in vitro, up to 3 hours, through the stabilization of VEGF mRNA.36
The survival curves, however, showed a negative effect of the Pringle maneuver for as
long as years after surgery. It is not known whether these effects are the result of
several hours of VEGF upregulation, or that short-term intrahepatic hypoxia induced
other events leading to enhanced carcinogenesis. 
The adverse effects of "surgery-induced" hypoxia on tumor growth, recurrence and
survival, as described in chapter 6, might theoretically be overcome if HIF-1α is
blocked completely. Further experimental studies on therapeutical application of VEGF-
antibodies or receptor-blockers perioperatively are indicated to test whether VEGF
inhibition can overcome the enhanced tumor growth after Pringle maneuver.
In the first part of this thesis we have studied the interaction between surgery and
(anti) angiogenesis. Knowing that physiological angiogenesis can be affected as well,
and that certain types of surgical interventions can stimulate angiogenesis, ultimately,
the ultimate goal is optimal use of antiangiogenic agents in the treatment of cancer.
Surgical treatment is the only curative option for patients with colorectal liver
metastases. Studies on the treatment of patients prior or post liver resection for
secondary malignant disease with conventional chemotherapy, have produced contra-
dictory results37-39. More and more studies are being published on increased resecta-
bility rates of previously unresectable colorectal liver metastases, be it all by the
same group38,40-42. Overall, it seems that nearly one third of the patients with previ-
ously unresectable colorectal liver metastases can be converted to resectable disease
with preoperative chemotherapy. Nevertheless, alternative treatment modalities for
colorectal liver metastases are still warranted. This was investigated in the latter part
of this thesis.
Combining conventional chemotherapy with anti-angiogenic compounds might lead
to improved anti-tumor efficacy by targeting both tumor cell- and endothelial cell-
compartments. In concordance with this hypothesis, co-administration of angiogenesis
inhibitors with other drugs in cancer treatment is briefly mentioned and advised in
many reviews.43-47 The rationale of such combination strategies is supported by our
study described in chapter 748. We showed that, compared with monotherapy chemo-
therapeutic regimens, the anti-tumor effect of combined chemotherapeutic and anti-
angiogenic agents was even multiplicative. In apparent contrast to these findings,
some authors have speculated that treatment that targets vasculature could hamper
other blood-borne therapeutics in reaching tumor cells.49,30 Many in fact questioned:
"how chemotherapeutics may reach the tumor when anti-angiogenic therapy has
destroyed the transporting vascular structures." Recent unpublished data show that
the EGFR-receptor blocker "Iressa" in combination with conventional chemotherapy
does not prolong survival in patients compared with chemotherapy alone. On the
other hand, a combination of tumor necrosis factor a and melphalan was shown to
generate a higher intra-tumoral concentration of the cytotoxic agent than chemo-
therapy alone.50 An explanation for the beneficial effects of combination strategies was
given by Jain, who recently suggested that antiangiogenic therapy might lead to
`normalization' of tumor vasculature before its destruction.51a The effect of chemo-
therapy during the normalization phase might be enhanced, rather than being
inhibited at a later stage once vasculature has been destroyed. In large tumors
inhibition of angiogenesis could kill the center of the tumor, while the rim of the
tumor remains viable through co-option of the preexistent vessels. Under those
circumstances, chemotherapy could act as a cytotoxic agent for the peripheral part of
the tumor. 
An additional advantage of combination strategies might be a dose reduction of
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the individual drugs involved, without impairing anti-tumor efficacy. Treatment with
low-dose angiostatin combined with relatively low doses of conventional chemo-
therapy was effective, and the mice displayed only minor toxicity throughout the
treatment period. Antiangiogenic scheduling of treatment by lowering the dose with
increased frequency of administration has also proved effective.51 
So, whilst several animal studies show beneficial effects of combination strategies,
clinical evaluation remains to be awaited. Our study employed an experimental model
that resembles the most suitable patient category (early metastatic disease). This is
important because most angiogenesis inhibitors that are currently in clinical trials are
being administered to patients with bulky end-stage tumors as is true for the combi-
nation strategies currently under study. Few or no anti-tumor effects may be antici-
pated in bulky disease, and the selection of suitable patient categories is required
before efficacy can be established. Furthermore, as we showed in chapter 7 for high
dose angiostatin a multiplicative effect of a particular drug is difficult to prove when
the effect of that particular single drug is already very significantly high. In the deter-
mination of efficacy of combination regimens, this implies a statistical problem. 
The timing of administration is another important issue to be addressed in this
respect. What comes first, chemotherapy of anti-angiogenic therapy? If indeed anti-
angiogenic therapy normalizes the tortuous and leaky tumor vasculature, than it
should perhaps proceed chemotherapy. Other arguments in favor off that order might
be that anti-angiogenic therapy, as we stated above, is more effective in early
disease. 
What if anti-angiogenic agents are to be administered as adjuvant of neo-adjuvant
therapy, i.e. in combination with surgery? In chapter 8, we showed that pre-treatment
with endostatin inhibits hematogenic tumor cell seeding and adhesion to the liver.
Endostatin prophylaxis could prove very promising in the treatment of patients under-
going colorectal surgery of the primary tumor. Even in no-touch colorectal surgery,
with mesenterical vessel ligation, 12.5% of patients have tumor spill in the
circulation.52 Indeed, overall, as many as 75% of the patients develop liver
metastases. Given the half-life of endostatin (8 hours) adverse effects on colonic
healing are not to be expected when endostatin is administered perioperatively. As we
showed in chapter 8, even within 15 minutes tumor cell adhesion in the liver is dimin-
ished. Furthermore, anti-VEGF might prevent the outgrowth of micrometastases after
partial liver resection with inevitable clamping of the portal triad (chapter 6). The
results of chapter 7 on experimental  early colorectal liver metastases indicate that
anti-angiogenic therapy may also be highly attractive for peri-operative treatment
schedules (minor residual disease (R1 resections)). 
Differences in anti-tumor efficacy of anti-angiogenic compounds also depend on
the tumor’s microenvironment.53 Paget developed the "seed and soil" theory in 1889.
He stated that some tumor cells find certain organs more fertile an environment for
metastatic growth. In addition, the organ environment is capable of modulating the
tumor cell response to chemotherapy.54 Orthotopic tumors behave different from
ectopic tumors, with respect to production and receptors of angiogenic growth
factors.55,56 Hence, anti-angiogenic therapy may produce a different response at
different sites.57 Even more specific, anti-angiogenic therapy may produce a different
response at the same site for different tumor cells.58 In that study it was suggested
that the tumor cells altered the endothelial cell phenotype, mediating sensitivity to
anti-angiogenic therapy. 
In chapter 8 we showed that endostatin works mainly on the initial phase of
metastasis, i.e. seeding of tumor cells and adhesion to the vessel wall, and does not
regress already established tumors in our models. Maybe this is also true for other
agents called anti-angiogenic agents. It has been speculated that the in vivo target of
angiostatin is not the mature endothelial cell, but the circulating endothelial
progenitor cells (EPC’s).59 The growth of EPC’s isolated from human subjects were, in
contrast to mature endothelial cells, exquisitely sensitive to angiostatin. These results
suggested that angiostatin may exert its biological effects by inhibiting the contri-
bution of EPC’s to angiogenesis and not by altering the growth of mature endothelial
cells. Again, this favors for treatment with anti-angiogenic compounds in a very early
phase of cancer, or even maybe prophylactic.
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Conclusions
The combination of angiogenesis with surgery emerges when surgery induces physio-
logical angiogenesis (wound healing), induces hypoxia with subsequent angiogenesis, or
when anti-angiogenic therapy is added to the treatment of surgical patients. More and
more frequently this will be the case. We must attempt to understand the molecular
biological mechanisms behind the efficacy of anti-angiogenic agents, their intervention in
early metastatic disease, as well as their safety in combination with surgery. However,
the more insight we have gained regarding anti-angiogenic treatment, the more compli-
cated it seems to get. "Anti-angiogenic" therapy comprises a very heterogeneous group
of agents. It can also affect physiological angiogenesis. Currently, properties that have
been attributed to anti-angiogenic therapy now include amongst others: regression of
already established tumors by attacking putative targets as endothelial cells, or ECM;
prevention of outgrowth of microscopic tumor deposits by inhibition of tumor cells
adhesion to endothelial cells; and normalizing tumor vessels in order to make the tumor
more susceptible for chemotherapy.
Anti-angiogenic therapy is, or should we perhaps say, "was" considered one of the
most promising new developments in cancer treatment. At first, the media claimed that
Judah Folkman was going to cure cancer within ten years. The results of the current
treatments with respect to anti-tumor efficacy did, however, not live up to our expecta-
tions. "Angiogenesis" as such is often oversimplified. Translation of the experimental
models to the clinic proved to be difficult. Clinical trials will eventually answer important
questions as to selection of suitable patients, drugs, and timing of administration.
The following conclusions may be drawn from the work presented here:
• Anti-angiogenic agents can affect physiological angiogenesis. The administration of
anti-angiogenic agents to patients following major surgery (colonic anastomosis)
should be done with caution. 
• Extra cellular matrix remodeling in secondary wound healing and skin wound healing
is disturbed in mice lacking Thrombin-activatable fibrinolysis inhibitor, resulting in
impaired wound healing.
• Surgically induced hypoxia by clamping of blood flow can be associated with
increased expression of HIF1α and VEGF, increased residual tumor growth and
decreased survival. Therefore, Pringle maneuver should be avoided whenever
possible. VEGF might be a potentially interesting therapeutical target in this respect.
• Antiangiogenic therapy is most likely to be maximally effective in patients with early
metastatic or minor residual disease. The combination of conventional chemotherapy
and anti-angiogenic therapy is more effective against colorectal liver metastases than
the sum of effects of either monotherapies.
• Endostatin, in addition to its effects on the developing tumor vasculature, also
affects tumor cell adhesion in the very early phases of metastasis formation. Anti-
tumor efficacy could be improved by preventing microscopic liver metastasis during
colorectal surgery.
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Anti-angiogene therapie is een veelbelovende nieuwe ontwikkeling in de behan-
deling van kanker. De middelen uit deze categorie medicijnen zijn gericht tegen de
bloedvat-nieuwvorming (angiogenese) van kanker gezwellen, ofwel tumoren. De
klassieke theorie van de anti-angiogene therapie, gesteld door Dr. J. Folkman, is als
volgt. Door langdurige behandeling met anti-angiogene medicijnen wordt een tumor
verhinderd om groter te groeien en via de bloedbaan uit te zaaien (metastaseren)
naar andere organen. In de westerse wereld komt kanker van de dikke darm, colon
kanker, veel voor. Curatieve behandeling van colon kanker of uitzaaiingen daarvan in
de lever, lever metastasen, is  primair chirurgisch.  Het uiteindelijke streven, zij het
idealistisch, is het nog beter behandelen van de individuele patiënt met kanker. Dit
kan bijvoorbeeld door gebruik te maken van een combinatie van (nieuwe) behande-
lingsstrategieën. We hebben hiervoor meer kennis nodig over onder andere het
volgende: Welke patiënten komen in aanmerking voor anti-angiogene therapie; welke
tumor typen; hoe werken die middelen het beste; op welk tijdstip in de behandeling
kunnen ze het beste toegediend worden; en kunnen ze veilig gecombineerd worden
met chirurgische behandeling?
In het eerste gedeelte van het proefschrift wordt aandacht besteed aan de
veiligheid van de combinatie chirurgie en anti-angiogene therapie. In hoofdstuk 3
werden muizen geopereerd als hadden ze colon kanker. Ze werden bovendien gelijk-
tijdig behandeld met angiostatine, een krachtig anti-angiogeen middel. Het bleek dat
de genezing van de darmnaden slechter verliep in die muizen die angiostatine kregen
gedurende het genezingsproces. In hoofdstuk 4 werden de weesfels van die muizen
onderzocht of we een aanwijzing konden vinden waarom angiostatine de genezing
negatief beïnvloedde. Het bleek dat het aantal nieuwgevormde bloedvaten, dat in de
darm speciaal van belang is voor het genezingsproces, minder was. Andere werkings-
mechanismen van angiostatine die in de literatuur beschreven zijn konden we niet in
onze weefsels terug vinden.
Wondgenezing is een complex proces, waarbij ook componenten van de stolling
(fibrinolyse) en het steunweefsel (ECM) tussen de cellen een belangrijke rol spelen.
Ook hierbij is angiogenese van belang. Een eiwit dat onderdeel uitmaakt van zowel
de fibrinolyse als de ECM is Thrombin-activatable fibrinolysis inhibitor (TAFI). We
weten nog niet waarvoor TAFI in het menselijk lichaam belangrijk is. Om dit te onder-
zoeken werden in hoofdstuk 5 muizen gemaakt zonder TAFI (TAFI knock-outs). Bij die
muizen werden zowel huidwonden als darmnaden gemaakt. Het bleek dat TAFI een rol
speelt bij het wondgenezingsproces, aangezien de muizen zonder TAFI slechter
genazen. Gedetailleerd onderzoek onder de microscoop (histologie) liet een vertraging
van de genezing in de huid zien met een afwijkend patroon van migratie van de
oppervlakte bedekkende cellen (keratinocyten).
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In het tweede gedeelte van het proefschrift wordt aandacht besteed aan de inter-
actie tussen chirurgie en angiogenese. Indien een levermetastase is ontstaan is de
enige kans op genezing voor de patiënt om de laesie chirurgisch te laten verwijderen.
Wanneer die laesie technisch niet weggesneden kan worden, is er een nieuwe behan-
deling mogelijk middels locale ablatie met radiofrequente golven (RFA). Tijdens
operaties van de lever wordt veelal gebruik gemaakt van het afklemmen van de bloed
doorstroming van de lever. Dit wordt gedaan ten einde bloedverlies te beperken.
Bovendien  vergroot het de laesie die met RFA wordt gemaakt om de tumor te vernie-
tigen. In hoofdstuk 6 hebben we de hypothese opgesteld dat het afklemmen van de
lever doorstroming (Pringle manoeuvre) een vermindering van de zuurstof in de lever
veroorzaakt (hypoxie). Hypoxie geeft aanleiding tot angiogenese. Door angiogenese
vindt namelijk weer meer zuurstof transport plaats, zijnde een compensatie mecha-
nisme. Echter, angiogenese en verhoogde aanmaak van groeifactoren kan weer
aanleiding geven tot meer tumor groei. We hebben derhalve gekeken naar de effecten
van de Pringle manoeuvre op 1) tumor recidief bij patiënten na resectie van de lever
metastase(n) van colon kanker; 2) groeifactor waarden bij patiënten tijdens RFA; en 3)
de groei van lever metastasen in muizen. De Pringle manoeuvre bleek verhoogde
expressie te geven van de angiogene factoren Hypoxia Inducible Factor-1alpha (HIF1α)
en Vascular Endothelial Growth Factor (VEGF),  en gepaard te gaan met meer tumor
recidief en tumorgroei, alsmede met een slechtere overleving. Derhalve zijn wij van
mening dat de Pringle manoeuvre -indien mogelijk- dient te worden vermeden.
Verdere studies naar of anti-VEGF de negatieve gevolgen van de Pringle manoeuvre
kan tegen gaan dienen ons inziens te worden verricht.  Bovendien lijkt het raadzaam
de effecten van selectieve Pringle manoeuvre (alleen afklemmen van de ader, en niet
de slagader) nader te onderzoeken, aangezien de Pringle manoeuvre bij locale tumor
destructie veelvuldig wordt toegepast.
Optimaal gebruik van de anti-angiogene middelen is het onderwerp van het
laatste gedeelte van het proefschrift. In theorie is het zeer aantrekkelijk om twee
soorten medicijnen te combineren die op verschillende punten aangrijpen. Naast
chirurgische resectie van lever metastasen bij colon kanker wordt er steeds meer
gebruik gemaakt van chemotherapie. Die heeft onder andere geresulteerd in een
vergroting van het aantal patiënten dat na chemotherapie alsnog in aanmerking komt
voor resectie. De combinatie van chemotherapie -hoofdzakelijk gericht tegen de tumor
cellen- en anti-angiogene therapie -gericht tegen de bloedvaten van de tumor- werd
onderzocht in hoofdstuk 7. In de ideale situatie zal anti-angiogene therapie toege-
diend moeten worden wanneer de tumor niet groot (meer) is, inmiddels is wegge-
haald, en/of om metastasen te voorkomen. In een muizenmodel van de vroege lever
metastasen hebben wij chemotherapie gecombineerd met angiostatine of endostatine.
Na twaalf dagen behandelen met beider combinatie bleek dat er significant minder
van de lever ingenomen werd door tumor weefsel. Bovendien was de som van de
effectiviteit van de chemotherapie en de anti-angiogene therapie samen groter dan
van beiden apart. Mogelijk is dit gebaseerd op het normaliserende effect van de anti-
angiogene therapie op de tumorvaten, waardoor de chemotherapie beter wordt
opgenomen. Bij het combineren van anti-angiogene therapie met conventionele
middelen dient derhalve -afhankelijk van het werkingsmechanisme- de volgorde en
tijdschema van toedienen zorgvuldig te worden gekozen.
Endostatine is een van de potente anti-angiogene middelen. Het werkingsmecha-
nisme wordt voornamelijk toegeschreven aan de direct remmende werking op
bloedvat cellen (endotheel cellen). Endostatine remt met name de hechting van deze
endotheelcellen in kweek. In een levend organisme zoals de mens of de muis (in
vivo) is dat echter niet helemaal opgehelderd. Zoals we beschrijven in hoofdstuk 8
werkt endostatine bij de behandeling van kanker in de muis soms wel en soms niet,
hetgeen onder andere afhankelijk bleek van het moment van toedienen. Na verder
onderzoek vonden we dat endostatine in een hele vroege fase van de tumor groei en
metastasering het grootste deel van het remmende effect sorteerde. Dit in tegen-
stelling tot het klassieke concept van de anti-angiogene therapie waarbij de tumor
eerst groter moet worden om afhankelijk te zijn van bloedvaten. Bovendien remde
endostatine de vroege hechting van tumor cellen aan endotheel cellen, een proces
dat noodzakelijk is voor de metastasering. Het toedienen van endostatine voordat
tumor cellen losraken en in de bloedbaan komen, bijvoorbeeld tijdens chirurgische
manipulatie van dikke darmkanker, zou een belangrijke therapeutische aanvulling
kunnen zijn op de huidige behandeling van patiënten met colon kanker.         
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